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West Nile virus (WNV) is an emerging pathogen that has the potential to 
cause severe neuropathologies, including encephalitis, acute flaccid paralysis, 
and meningitis. The severity of WNV infection is highly strain dependent, ranging 
from avirulent to highly neuropathogenic. Here, we assessed both viral and host-
specific factors that contribute to WNV-mediated neuropathogenesis. We initially 
observed that despite inoculating equivalent levels of virus directly into the blood, 
mice inoculated with a nonvirulent strain of WNV, WNV-MAD78, exhibited 
increased survival compared to mice inoculated with a highly pathogenic strain, 
WNV-NY. Thus, one limitation for nonneuropathogenic WNV may exist at the 
blood-brain barrier (BBB). Therefore, we investigated the strain-specific 
contributions to establishing infection in the CNS by comparing the replication of 
WNV-MAD78 and WNV-NY in neurons, astrocytes, and microvascular 
endothelial cells, which comprise the neurovascular unit within the CNS. WNV-
MAD78 replicated in and traversed brain microvascular endothelial cells as 
 
  
efficiently as WNV-NY. Similar levels of replication for both strains were detected 
in neuronal cells. Thus, WNV-MAD78’s nonneuropathogenic phenotype is not 
due to an intrinsic inability to invade the CNS or replicate within neurons. In 
contrast, WNV-MAD78 replicated to lower levels than WNV-NY in astrocytes. 
Reduced susceptibility of astrocytes to WNV-MAD78 was a result of a delay in 
initiating viral replication and an interferon-independent reduction in cell-to-cell 
spread. Further characterization indicated that the restriction to WNV-MAD78 
cell-to-cell spread in astrocytes was due in part to the higher production of 
defective particles compared to WNV-NY infected astrocytes. To identify regions 
of the genome that contribute to this restriction, we generated recombinant 
viruses of WNV-NY and WNV-MAD78. While replication of a recombinant virus 
consisting of the structural proteins of WNV-NY and the nonstructural proteins of 
WNV-MAD78 was delayed in astrocytes, the virus reached peak viral titers 
similar to WNV-NY. In contrast, a recombinant virus comprised of the structural 
proteins from WNV-MAD78 and nonstructural proteins from WNV-NY replicated 
at a similar rate and level as WNV-MAD78 in astrocytes. Thus, protein 
composition of the virion is a determining factor in the level of WNV replication in 
astrocytes.   Therefore, viral processing pathways within astrocytes may be 
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Chapter 1: Introduction 
1.1 The Flaviviridae 
West Nile virus (WNV) is a member of the family Flaviviridae. The 
Flaviviridae are a family of enveloped, positive strand RNA viruses that replicate 
in the cytoplasm of host cells. Since many members of Flaviviridae cause 
significant disease in either humans or livestock, further research into disease 
mechanisms may lead to improved strategies for treating and preventing 
disease. The Flaviviridae family are comprised of three main genuses: 
hepaciviruses, pestiviruses, and flaviviruses (Figure 1). The hepaciviruses are 
comprised almost exclusively of hepatitis C virus (HCV) genotypes. HCV infects 
over 150 million people worldwide. HCV establishes chronic infections in the 
liver. Complications from HCV infections, such as cirrhosis of the liver or 
hepatocellular carcinoma, result in ~350,000 hepatitis C-related casualties yearly 
(19, 114). The closely related pestiviruses include several viruses, such as Borna 
disease virus (BDV), bovine viral diarrhea virus (BVDV), and classical swine 
fever virus (CSFV), that infect economically important livestock. Pestiviruses also 
establish chronic infections that cause diarrhea, hemorrhage, wasting disease, 
and spontaneous abortion (25, 278). In contrast to Hepaci- and Pestiviruses, 
Flaviviruses typically cause an acute infection. This genus includes multiple 
notable human pathogens such as West Nile virus (WNV), Yellow fever virus 
(YFV), Japanese encephalitis virus (JEV), Tick Born encephalitis virus (TBEV), 
and Dengue virus (DENV). Flaviviruses are further categorized into serogroups, 





Figure 1. Phylogenetic relationships within the Flaviviridae. Flaviviridae is 
comprised of hepaciviruses (green), pestiviruses (blue), and flaviviruses 
(orange). Distances between lines are representative of relatedness of groups 
(i.e. longer lines describe more distantly related groups than shorter lines), but 




Flaviviruses are transmitted through tick or mosquito vectors, although the 
vector for some flaviviruses remains to be determined. Flaviviruses can also be 
categorized as viscerotropic and neurotropic. Viscerotropic flaviviruses, such as 
DENV, replicate to high titers in the vasculature and induce pathology such as 
excessive bleeding, decreased blood pressure, and hemorrhagic fever (174). 
Neurotropic flaviviruses, such as JEV and WNV, cause severe disease as a 
result of neuronal damage from both viral replication and bystander cell death 
from the immune response (44, 122). For example, during WNV infection, a 
productive CD8+ T cell response is necessary for viral clearance from the CNS 
(248). However, without proper T cell maintenance and resolution of T cell 
infiltration into the CNS, CD8+ T cells can exacerbate pathology (212, 257). Thus, 
examining which cells within the CNS contribute to activation and resolution of 
the immune response is an essential step toward understanding the kinetics of 
immune responses in the CNS and for developing therapies that may aid in viral 
clearance.  
.  
1.2 WNV classification and lineages 
 WNV is divided into 5 lineages, although most WNV strains reside within 
2 main lineages (Figure 2). Within lineages, WNV sequences are >90% 
conserved at the nucleotide level, and >99% conserved at the amino acid level 
(141). Despite the high level of similarity at the amino acid level, there is 
substantial variation in pathogenicity among strains. Moreover, experiments in 




Figure 2. Diagram of the two main lineages of WNV. The select strains of 
WNV displayed are common experimental strains.  Underlined strains have been 
shown to be highly neuropathogenic.  JEV is the common outlier to all strains, 
residing within the same serogroup as WNV. Colored strains (NY 2000 and 
Madagascar 1978) are strains used throughout the following experiments. Length 
of lines qualitatively represents relatedness between strains, but was not 




genetic variances among strains that vary greatly in their observed pathology is 
an effective and necessary approach to identify viral motifs that contribute to 
WNV neuropathogenesis.  
 
1.3  WNV transmission cycle 
In nature, WNV is maintained in a transmission cycle between arthropods, 
including mosquitoes, and migratory birds.  Culex mosquitoes are the primary 
vector of WNV, but other mosquito species can harbor infectious virus (17, 110). 
In mosquitoes, WNV replicates to high titers without causing pathology (91). 
Although mosquitoes transmit WNV to a wide range of species, including various 
mammalian species, migratory birds and reptiles are the only species in which 
WNV replicates to high enough levels to perpetuate the transmission cycle (132).  
Because mosquitoes are the transmission vector for WNV, the seasonal 
emergence of human WNV infections corresponds to mosquito populations and 
activity. Thus, the overwintering of mosquito populations due to climate change 
will elongate the WNV season.  
 
1.4 West Nile virus (WNV) clinical presentation 
WNV was first identified in sub-Saharan Africa in 1937, with symptoms 
presenting as a mild, febrile illness, although most cases were asymptomatic 
(258).  Throughout the 1950s and 1960s, WNV evolved and spread from the 
African continent into the Mediterranean, continuing to cause only mild febrile 




Figure 3. Map of WNV distribution worldwide. Map includes both 
chronological spread (green=prior to 1990s, yellow=post 1990s ) and specific 
strains of interest (stars). Blue stars indicate noneuropathogenic strains of WNV, 
purple low neuropathogenic strains of WNV, and red highly neuropathogenic 




emerged in Eastern and Western Europe and the Western hemisphere in the 
1990s, prevalent strains caused a higher incidence of neurological disease (200, 
201). Currently in the US, about 80% of WNV cases are asymptomatic, but 
severe neurological disease, including WNV-induced acute flaccid paralysis, 
meningitis, and encephalitis, occurs in ~5% of cases, about 10% of which are 
lethal (12, 37, 197). Recovery from WNV neurological disease takes several 
months to years. In some cases patients never fully recover or experience further 
complications after resolution of the acute infection, including continuing 
headache and symptoms of encephalitis (145, 146, 189). Although considered an 
acute disease, recent evidence suggests that WNV can establish a chronic 
infection as well. WNV-specific antibodies and infectious RNA have been 
detected in humans in several distal locations (skin, urine, brain) months after the 
acute infection has been resolved (189, 204). Besides the initial symptoms, some 
patients and persistently infected rodent models display renal failure several 
months or years after acute infection.  In addition, WNV RNA has been detected 
in mice for several months after resolution of the acute infection (11, 242, 243). 
Persistence in the kidneys and CNS of non-human primates has also been 
documented (208). Active WNV replication has also been reported in a hamster 
model in CNS and renal tissues for up to 100 days after acute infection (255).  
The severe pathologies associated with WNV neuroinvasion highlight the 
importance of research aimed at understanding how host and viral factors 
contribute to neurological pathology. Currently, no vaccines or specific antiviral 
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therapies exist for WNV in humans, and developing novel therapeutics to target 
WNV is of great public health interest.  
  
1.5 WNV dissemination pathway within the mammalian host 
WNV enters the body through the bite of a mosquito. While high levels of 
virus are deposited directly into the epidermal and dermal layers of the skin, 
studies in mice have demonstrated that low levels of virus are deposited directly 
into the bloodstream approximately 70% of the time (266). Virus replication within 
the epidermal and dermal cells attracts immune cells, such as Langerhan 
dendritic cells, to the site of infection (153). Langerhan dendritic cells are 
hypothesized to contribute to viral dissemination by trafficking the virus to lymph 
nodes and the spleen, where a second round of replication occurs (39, 123).  
High levels of virus in the blood stream then expose distal organs, such as the 
heart, liver, kidneys, and CNS, to WNV. Although this viral dissemination 
pathway is generally accepted within the WNV community, several steps of the 
pathway, such as replication in or uptake of virus by Langerhan cells, have yet to 
be experimentally confirmed . Additionally, the kinetics of WNV replication in vivo 
are not always consistent with the current model (266). Further analysis of the 
kinetics of viral replication within specific cell types may help to clarify the viral 
dissemination pathway, and aid in the development of new strategies to prevent 





1.6 WNV Life Cycle 
Although a unique, universal receptor remains to be identified, several 
known extracellular proteins and ultrastructural motifs mediate WNV attachment, 
including Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin (DC-SIGN), DC-SIGNR, lipid rafts, and αVβ3 integrin (50, 60, 176). Once 
attached to the cell surface, WNV particles are internalized by host cells through 
receptor-mediated endocytosis (Figure 4) (49, 97, 98). During transport through 
the endocytic pathway, endosomal acidification induces a conformational change 
in the envelope protein, facilitating fusion of the viral particle to the endosomal 
membrane and release of the viral core into the cytoplasm (8, 137). In the 
cytoplasm, the viral genome is directly translated into a single polyprotein that is 
co-translationally cleaved by both viral and cellular proteases into 3 structural 
and 7 nonstructural proteins (Figure 5) (42, 43, 303). The structural proteins 
capsid or core (C), preMatrix (prM) and envelope (E), together with the viral 
genome, form the WNV particle. The capsid binds and stabilizes genomic RNA 
within the viral particle (165). If expressed in trans within the CNS, the capsid 
itself induces neuropathology (282), although by an unknown mechanism. prM 
forms a heterodimer with E and is required for the proper folding of the E protein 
(135, 161). Envelope proteins coat the virion and are cotranslationally inserted 
into host cellular membranes derived from the ER (194).  Located downstream of 
the structural genes are genes coding for 7 nonstructural proteins: NS1, NS2a, 






Figure 4. West Nile virus life cycle. WNV enters the cell through 
receptor mediated endocytosis. Acidification of the endosome triggers fusion of 
the viral envelope with endosomal membranes and allow for release of the viral 
core in to the cytoplasm where translation and replication occur. Assembly of 
WNV particles occurs on ER membranes, and once assembled, viral particles 
translocate through the exocytic pathways to the trans-Golgi network, where they 
undergo maturation. Mature viral particles are then released from the cell by 





Figure 5. WNV genome. WNV is comprised of 3 structural proteins and 7 
nonstructural proteins. (A) WNV-MAD78 contains a single glycosylation site (*)  





Though few, the nonstructural proteins, along with usurped host proteins, 
execute all of the functions necessary for successful WNV propagation. NS1 
exists in monomeric, dimeric, and multimeric forms, and is present in the 
cytoplasm, on the surface of infected cells, and secreted in cell culture medium 
(166, 310, 311). Intracellular NS1 contributes to replication complex assembly, 
and may be responsible for initiation of negative strand synthesis (128, 154, 155, 
190). However, the functions of surface-bound and secreted NS1 remain unclear 
(168, 306). The NS1 gene also contains a pseudoknot that leads to the synthesis 
of an additional, truncated protein, NS1’ (180). NS1’ has been associated with 
WNV-induced neuropathology, although the mechanism by which NS1’ increases 
neuropathology is currently unknown. NS2a is a transmembrane protein involved 
in RNA processing and viral assembly. NS2a facilitates immune escape by 
antagonizing the type-1 interferon (IFN) response, which is known to limit WNV 
replication and spread within the host (157, 158).  NS2B is a cofactor for the 
ATP-dependent protease and helicase, NS3 (74, 76). In addition to cleaving the 
viral polyprotein and unwinding dsRNA intermediates, NS3 dephosphorylates 
viral RNA at the 5’ UTR to facilitate cap addition by NS5 (304, 305). NS4a and 4b 
are both small hydrophobic proteins essential for viral replication and assembly 
by an unknown mechanism. NS4B is also a type I IFN antagonist (188, 307). The 
final protein, NS5, is the viral replicase, containing enzymatic activities for both 
polymerization of RNA as well as the 2’O-methyl capping activity necessary to 
synthesize the viral 5’ RNA cap (78). Along with its necessary replication 
functions, NS5 also antagonizes type I IFN amplification by blocking 
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phosphorylation of JAK/STAT receptors (143). The capping function of NS5 also 
enables WNV to escape the antiviral activity of interferon-stimulated genes, such 
as interferon-induced protein with tetratricopeptide repeats 1 (Ifit1) (273) .  
Following initial viral protein synthesis, replication of the genomic RNA 
begins. Cleavage of the polyprotein by NS3 and host proteases generates the 
proteins that assemble into the viral replication complex (VRC), which initiates 
negative strand synthesis by binding directly to structures within the 3’ non-
translated region (NTR) of the genome. The 5’ and 3’ NTRs of the genome 
contain structures that circularize the viral genome and promote initiation of 
transcription and translation (69, 103). Following negative strand synthesis, 
positive strand, genomic RNA is generated from the nascent negative strand 
template. Several studies of RNA viruses suggest that the ratio of positive strand 
to negative strands synthesized ranges from 10:1 to 100:1. However, the 
mechanisms contributing to the switch from negative to positive strand synthesis 
and the disproportional synthesis of positive strand RNAs remain unknown.  
Although both the 5’ and 3’ WNV UTRs are predicted to be highly structured, the 
strain-dependent differences in the length of the 3’ NTR suggests that strains 
may deviate in the secondary and tertiary structures they form within the 3’ NTR, 
resulting in various efficiencies of viral replication.   
After the viral genomic RNA and structural proteins have been 
successfully synthesized, viral particles assemble in the ER (169).  Here, certain 
motifs in both the prM and envelope proteins are glycosylated before assembling 
within the ER membrane. Steric hindrance from assembly of the viral particle 
14 
  
within the ER membrane prevents more than one copy of the genome per 180 
envelope proteins from being incorporated into each viral particle. Once 
assembled, the viral particle traffics from the ER to the trans-Golgi to undergo 
processing. Initial carbohydrates added to proteins in the ER are further modified 
in the trans-Golgi.  Here, the glycosylated portion of the prM protein is cleaved 
during the processing of prM to the mature form of the protein by the cellular 
protease furin, causing a conformational change in the envelope protein (111). 
Conformational changes in the envelope protein result in the rearrangement of 
the global structure of the virion from a “spike” conformation to a flattened pattern 
with a 3-2-5 axes of symmetry  (Figure 6). The cleaved prM, containing the 
carbohydrate moiety, is released into the extracellular milieu in concert with the 
mature viral particle. The process of maturation is often inefficient, creating 
particles with heterogeneous maturation states (207). Although virion maturation 
was once thought to be required for generation of an infectious viral particle, 
recent evidence suggests partially mature virions are also infectious. Indeed, the 
presence of uncleaved prM may enhance binding of virions to attachment factors 
in some circumstances (60). Recent data suggests that DC-SIGN, a cell-surface 
protein that binds carbohydrate moieties, acts as an attachment factor and 
facilitates WNV entry into the cell (60). This suggests that carbohydrate moieties 
on the envelope protein and prM may play a role for viral attachment and 
dissemination within the host, depending on levels of attachment factors 
expressed on specific cell types. Details of maturation mechanisms and 




 Figure 6. WNV particles. Cryo EM images of immature (A) and mature (B) 
WNV particles. WNV particles are processed in the trans-Golgi network by the 
host protease, furin. Clevage of prM by furin induces a conformational change in 
the structure of the virion from a “spiked” to smooth surface. Images used with 
permission from protein data bank (PDB) as follows: (A) PDB#2OF6 (322)  (B) 





1.7 The Blood Brain Barrier (BBB) 
 The CNS is a highly developed system that regulates all physiological 
processes, both voluntary and involuntary.  As such, entry into the CNS is highly 
restricted by physical barriers to the brain, including the blood-cerebral-spinal 
fluid (CSF) barrier and the blood-brain barrier (BBB) (213).  The BBB is 
comprised of two main cell types: endothelial cells, which line the blood vessels, 
and astrocytes, which are the most populous cell type within the CNS (1, 118, 
129) (Figure 7). The endothelial cells within the CNS are highly specialized, 
forming tighter cell-to-cell junctions and exhibiting lower rates of endocytosis and 
pinocytosis than endothelial cells in the periphery. The endothelial cells are in 
direct contact with the foot processes of astrocytes that reside within the CNS. 
Astrocytes maintain the integrity of the endothelial cell layer as well as regulate 
aberrant neurotransmitter release. In addition to the BBB, the blood-CSF barrier 
is comprised of highly restrictive epithelial cells that secrete the cerebral spinal 
fluid that encompasses the brain, and endothelial cells that completely lack cell-
cell junctions to allow for free movement of small molecules to contact the 
specialized epithelial cells that secrete the CSF.  The blood-CSF barrier prevents 
infiltration by maintaining tight cell-to-cell junctions on the epithelial cells and 
specific ratios of transporters and receptors on the epithelial cell surface to 
maintain proper balance of nutrients in the CSF while preventing aberrant 
immune responses (214).  
17 
  
 Figure 7. The BBB and mechanisms of neuroinvasion. The blood-brain 
barrier is comprised of endothelial cells and astrocytes, as indicated. Neurons 
reside within the CNS, and are the final component of the neurovascular unit. 
Viral infections traverse the BBB by one of four possible mechanisms, including: 
1) replication in and traversal of the endothelial cell layer, 2) disruption of cell-to-
cell junctions and paracellular transport of virus across the endothelial cell layer, 
3) infected leukocyte attraction and extravasation through the endothelial cell 




Despite these physical defenses, pathogens across a variety of kingdoms 
(parasite, bacteria, virus) can successfully infiltrate the CNS. Pathogens enter the 
CNS through three main routes: retrograde transport from peripheral neurons, 
trafficking of infected cells into the CNS via a Trojan horse mechanism, or by 
directly crossing the blood-CSF or BBB (48, 129). Several viruses, such as 
herpesvirus and rabies virus, enter the CNS through retrograde transport in 
peripheral neurons (21, 66, 90, 279). After replicating in the epithelium, these 
viruses initiate replication in neighboring motor and sensory neurons. Within the 
neurons, the virus hijacks the microtubule transport pathway, attaching to either 
the kinesin or dynein motors required to move proteins directionally within the 
neuron (1).   After spreading among peripheral neurons through retrograde 
transport and axonal budding and release, the virus is transmitted to the spinal 
cord and disseminates throughout the CNS.  
  The Trojan-horse model for infiltration involves extravasation of virus-
infected leukocytes from the blood into the CNS. Several viruses, such as 
measles virus and human immunodeficiency virus (HIV) actively replicate within 
leukocytes (29, 196, 240). Another virus, Nipah virus, does not replicate in 
leukocytes, but attaches to lymphocytes in the periphery (175, 302). For Nipah 
virus, traversal of lymphocytes with attached virus across the BBB is reported to 
initiate infection in the CNS. With or without viral replication, traversal of 




Multiple viruses enter the CNS via direct infection of brain endothelial cells 
(67, 260). Viral replication in the endothelium during influenza virus infection, for 
example, is responsible for the cytokine storm induced during influenza infections 
(293), and Venezuelan and eastern equine encephalitis viruses disseminate to 
the CNS via the hematogenous route (286) . Certain flaviviruses, such as JEV, 
also enter the CNS via a hematogenous route (156). As the brain is a highly 
vascularized organ, replication in endothelial cells and traversal of the vascular 
cells is frequently utilized by viruses to enter into the CNS. 
 Although the blood-CSF barrier plays a significant role in the stability and 
maintenance of the CNS, very little has been reported about viral-induced 
disruption and entry into the CNS via this route. Overall, this mechanism of entry 
into the CNS appears to be minimal, and has not been found to play a role in 
WNV infection.   While one report documented retrograde transport of WNV 
within neurons (229), the kinetics of WNV replication in the CNS throughout 
infection suggests that WNV primarily utilizes a hematogenous route of entry. 
While WNV can replicate to low levels within leukocytes, infectious virus is 
detected in the CNS prior to infiltration of infected leukocytes (92, 267), 
suggesting that the Trojan-horse mechanism is not the initial route of incursion 
for WNV. Recent evidence demonstrated that WNV replicates in and traverses 
intact brain endothelial cell monolayers while maintaining the integrity of the 
monolayer (117, 285), suggesting that infection of brain endothelial cells may 
play a role in the incursion of WNV into the CNS.  Nonetheless, infiltrating 
leukocytes may contribute to WNV entry and dissemination as the infection 
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progresses (15, 26). In addition to enhancing viral entry through the infiltration of 
infected cells, leukocytes secrete matrix-metalloproteinases (MMPs), which 
actively break down cell-to-cell junctions at the BBB, thereby allowing the 
unrestricted entry of free virus present in the blood.  This suggests that trafficking 
of leukocytes into the CNS may exacerbate infection in the CNS and actively 
contribute to disruption of the BBB.   
Thus, viral replication within cell types of the BBB and the immune 
responses in these cell types has implications in CNS disease manifestations. 
Because this physiological barrier is unique in its ability to modulate immune 
responses and controls access to the CNS, various therapeutics target 
responses at the BBB and need to traverse the BBB during CNS infection.  
Further, therapeutics targeted at modulating immune responses at the BBB 
during WNV infection may alter neurological pathologies to be less severe early 
on during infection.  
 Studies examining immune responses at the BBB comparing 
nonpathogenic and pathogenic strains of WNV are limited. Modeling the BBB in 
vitro has provided many insights into CNS physiology and function as well as 
viral pathogenesis (309). Initial studies performed with pathogenic WNV 
demonstrated that WNV infects cells of the BBB in an in vitro model system (117, 
285). In addition, virus-like particles of a low pathogenic lineage 1 strain of WNV 
exhibited decreased traversal of an endothelial cell layer compared to a 
pathogenic strain (108). After crossing the BBB, WNV reaches highly susceptible 
neurons. Neurological symptoms during WNV infection are a result of neuronal 
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death caused by either active replication of virus or bystander immune 
responses. The specific contribution of neurons to the immune response to WNV 
has been well documented.  For example, WNV replication in neurons induces 
caspase-3 dependent apoptosis (228). Further, infected neurons secrete 
CXCL10 that attracts CD8+ T cells necessary for efficient clearance of WNV from 
the CNS (131). Mice deficient in IFNβ exhibit increased susceptibility to 
pathogenic WNV infection and increased viral replication in cortical neurons 
(144). Further, WNV replication is restricted in cortical neurons treated with 
exogenous IFNβ (144).  Yet how other cell types contribute to neuropathogenesis 
is widely unknown.  
In addition, viral genetic factors contributing to WNV neuropathogenesis 
remain elusive. For example, glycosylation on the envelope is associated with 
increased neuropathogenicity of WNV in mice (13, 24, 237), although the 
mechanism of increased neuropathogenicity remains unknown. Glycosylation on 
both prM and envelope proteins improves both entry and assembly (106), and 
carbohydrate-binding proteins function as attachment factors for WNV entry (60). 
Thus, glycosylation-dependent cell-to-cell spread within the CNS may contribute 
to the strain-dependent variation in neuropathology.   
 
1.8 The role of astrocytes in the CNS 
Non-neuronal cells, or glial cells, comprise over 90% of the cells in the 
CNS. This group includes resident tissue macrophages, or microglia, which 
comprise about 12% of the CNS, oligodendricytes, which are responsible for 
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enveloping the axons of neurons and increasing the velocity of action potentials 
in neurons, and astrocytes, which comprise over 50% of the cells within the CNS 
(130). Astrocytes are anatomically divided into two main groups based on 
morphology: fibrous astrocytes (or white matter astrocytes), which directly 
contact the nodes of Ranvier, and protoplasmic astrocytes (or grey matter 
astrocytes), which directly contact synapses. Astrocytes of both groups can 
contact blood vessels within the CNS (130). Once thought to serve merely a 
structural role, astrocytes are now recognized as cells that aid in development of 
the CNS, maintain homeostasis within the CNS, regulate blood flow, and resolve 
infection and trauma within the CNS (259). 
Recent studies have elucidated several roles for astrocytes during 
development of the CNS and maintenance of the CNS thereafter. Astrocytes 
express receptors for neurotransmitters, and their ability to communicate with 
and even phagocytose specific synapses at the developmental stage of the CNS 
provides a unique role in shaping the CNS. Although astrocytes express several 
ion channels similar to neurons, they lack the ability to initiate an action potential 
(191, 241). Further, expression of aquaporin and ion channels highlights 
astrocytes as regulators of the CNS, and at times one astrocyte may contact up 
to 100,000 neurons (38, 104). Astrocytes also provide nutrients essential for 
neuronal survival by transporting glucose from blood into the CNS (33). 
Moreover, astrocytes respond to neuronal cell death by secreting neuronal 
growth factors, which either stimulate regeneration of axons or dendrites from 
neighboring neurons, or occupy the space themselves (160). Early in the 
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developmental process, astrocytes may contribute to the establishment of the 
formation of the tight junctions of cerebral endothelial cells and therefore 
contribute to the establishment of the BBB (1, 16). In addition to the development 
of the BBB, astrocytes are capable of regulating blood flow by expressing soluble 
molecules, such as nitric oxide, that modulate vasodilation. During viral-induced 
encephalitis, activated astrocytes regulate infiltration of leukocytes from the blood 
by gathering around the perivascular space (259, 288). Experimental disruption 
of astrocytic perivascular cuffing demonstrated an increase in infiltration of 
lymphocytes, thereby exacerbating inflammation in the CNS. 
 Astrocytes also play an essential role in initiating the antiviral response 
within the CNS. Upon stimulation with IFN, astrocytes express complement 
receptors (18). In addition, astrocytes can secrete soluble inhibitors to 
components of the complement cascade, thereby preventing themselves from 
being opsonized (85). Thus, astrocytes may serve to initiate the opsonization of 
free viral particles as well as neighboring infected cells, thereby promoting viral 
clearance, and inhibit their own complement-induced cell death emphasizing 
their necessity for maintaining homeostasis within the CNS.  
Astrocytes express several pattern recognition receptors (PRRs), 
including TLRs, RLRs, and NLRs. TLR3 plays a central role in both shaping the 
developing CNS and responding to invading pathogens. In addition, astrocytes 
secrete several cytokines, chemokines, and growth factors upon stimulation with 
poly I:C (35, 36). Recognition of viral RNA by RLRs in astrocytes induces an 
immune response. Knock down of RIGI in virus-infected human astrocyte cell 
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cultures decreased proinflammatory cytokine expression and decreased 
neurotoxic factors secreted by virus-infected astrocytes (84). Although astrocyte 
stimulation triggers the expression of both cytokines and chemokines, astrocytes 
secrete higher levels of chemokines compared to proinflammatory cytokines, 
further emphasizing their importance in recruiting leukocytes to the CNS (234). In 
addition to PRR expression, astrocytes are also capable of expressing MHC I 
and MHC II molecules, as well as T-cell coreceptors CD40 and SOCS1, 
suggesting that astrocytes are important antigen presenting cells within the CNS, 
and may be imperative in modulating cytolytic and regulatory T cell responses 
(28).  In autopsies of patients with WNV-induced encephalitis, viral antigen was 
present in both neurons and glial cells (282). Further, ex vivo inoculation of rat 
astrocytes with pathogenic WNV induced neurotoxic factors, suggesting that 
astrocytes may play a significant role in WNV-induced neuropathologies. In 
addition, studies in human glial cultures demonstrated that replication of a 
pathogenic strain of WNV in astrocytes induces expression of monocyte- and T-
cell attractant chemokines, suggesting that infected astrocytes may function to 
initiate or exacerbate immune responses from the periphery (46). Therefore, 
comparing the replication and innate immune responses initiated by astrocytes 
infected with pathogenic and nonpathogenic strains of WNV may lead to a more 
detailed understanding of the progression and underlying mechanisms of WNV-






1.9 Immune response to WNV within the CNS      
 The immune response within the CNS also plays a significant role in the 
neuropathogenesis of WNV. The immune system consists of two branches, the 
innate and the adaptive, that work together to respond to viral infections. While 
the innate immune system initiates a non-specific response to viral pathogens 
and activates the adaptive response, the adaptive immune system provides 
lasting memory and specific action against pathogens.  
 
1.9.1 Cell intrinsic innate antiviral response 
Innate immune signaling 
The cell intrinsic immune response is established on a cellular level, 
where pattern recognition receptors (PRRs) recognize pathogen associated 
molecular patterns (PAMPs) (4, 276), and initiate signaling cascades that result 
in the transcription of genes required for host defense (Figure 8). These genes 
include secreted factors that amplify the antiviral response as well as factors that 
directly impede viral infection, thereby limiting spread. There are 4 main groups 
of PRRs: Toll-like receptors (TLRs), RIG-I like receptors (RLRs), Nod-like 
receptors (NLRs), and C-type lectin receptors (CLRs). Throughout viral infection, 
each class of receptor contributes to innate antiviral defense mechanisms. 
 TLRs are transmembrane receptors expressed either on the surface of the 
cell or within endosomes. Each TLR contains both an extracellular recognition 




Figure 8. The intracellular innate antiviral response. Pattern recognition 
receptors (PRRs) recognize pathogen associated molecular patterns (PAMPs) 
present on virions or produced during the course of viral replication. PRRs then 
signal through adaptor molecules, such as TRIF, MyD88, and MAVS, to activate 
signalling pathways, including the IRF, NFκB, and MAPK pathways. These 
signalling pathways result in the activation of transcription factors essential for 
promoting antiviral gene synthesis. In addition, NLRs function by activating  the 
inflammasome and cleaving inflammatory cytokines, such as pro-IL1β, to 




recognition domains contain leucine-rich repeats that recognize conserved  non-
self moieties, including viral elements such as single-stranded RNA (TLR8, TLR 
7), double-stranded RNA (TLR3), and DNA (TLR9). Recognition of non-self 
moieties induces conformational changes within the intracellular domain and 
results in exposure and autophosphorylation of key residues. This in turn results 
in the phosphorylation of adaptor molecules, such as myeloid differentiation 
primary response 88 (MyD88) and TIR-domain-containing adapter-inducing 
interferon β (TRIF), that contain Toll/Interleukin-1 receptor (TIR) domains (79, 
113, 198, 290, 313). In contrast, RLRs detect non-self ss- and ds-DNA and RNA 
in the cytosol (124, 317). RLRs contain an N-terminal caspase activation and 
recruitment domain (CARD), an internal ATP-ase driven helicase domain, and a 
C-terminal repressor domain. Binding of nucleic acid to the C-terminal repressor 
domain induces a conformational change in the repressor domain, liberating the 
CARD domain to interact with other CARD-containing proteins, such as the 
adaptor molecule mitochondrial activating viral sensor (MAVS, also referred to as 
IPS-1, VISA and CARDIF) (4, 276).  Activation of adaptor molecules by either 
TLRs or RLRs transmits signals through several downstream signaling cascades, 
including the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFkB) pathway, the interferon regulatory factor (IRF) dependent pathway, and 
the mitogen-activated kinase (MAPK) pathway (62, 80, 112, 181, 182, 275). Each 
of these pathways culminates in the activation of transcription factors that bind 
cognate promoters and mediate transcription of antiviral genes such as type-1 
interferon (IFN), innate antiviral effector proteins, and proinflammatory cytokines.  
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ssRNA and dsRNA from viral infections is also recognized by NLRs in the cytosol 
(107, 119). NLRs contain a recognition domain as well as several CARD 
domains that multimerize to form the inflammasome following activation by 
binding of a viral PAMP (125). Upon multimerization, several highly active 
proteases cleave either precursory proinflammatory cytokines, such as pro-IL-1β 
and pro-IL-18, or caspases, which in turn carry out apoptosis, and are essential 
for restricting WNV infection in the CNS (212). TLRs, RLRs, and NLRs are to 
essential the antiviral response to WNV infection within the CNS (54, 82, 212, 
280, 297). WNV infection in MAVS-/-, MyD88-/-, IRF3-/-, and IRF7-/- mice results in 
100% lethality, with mice exhibiting increased replication in the periphery as well 
as the CNS (55, 270, 272). TLR3 and TLR7 are also necessary for a productive 
antiviral response in neurons that leads to viral clearance (54, 280), and 
deficiencies in the activation of these pathways results in an increase in WNV 
neuropathology. More recent analyses indicated that NLRs also play a role in 
regulating the inflammatory response in the CNS after WNV infection and 
promote resolution of inflammation. Indeed, apoptosis-associated speck-like 
protein contacting CARD (ASC)-/- and IL1βR-/- mice infected with WNV exhibit 
increased levels of virus in the CNS as well as increased proinflammatory 
cytokine expression and increased levels of CD8+ T cells late in infection (139, 
212). Thus, the contribution of cell intrinsic immune pathways in the CNS is 
essential for both initiating to and resolving immune responses to WNV infection.  
 CLRs function at the cell surface or outside the cell, where they bind 
specific carbohydrate moieties (86). CLR signaling leads to the translocation of 
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additional transcription factors involved in initiating a proinflammatory cytokine 
response, thereby amplifying responses initiated by TLRs and RLRs (86). 
However, CLRs also function as viral attachment factors, which promote viral 
infection and dissemination within the host (20, 60, 133, 163).  The specific 
contribution of CLR activation to WNV neuropathogenesis has not yet been 
explored. However, several CLRs have been shown to enhance WNV 
attachment and entry (60). 
  
1.9.2 Amplification of the antiviral response 
The interferon response to WNV  
 Interferon (IFN) is a class of molecules highly expressed in response to 
viral infection, and is a product of PRR signaling (120, 121, 224).  IFNs are 
further classified into three subgoups: type I, type II, and type III IFNs. All IFNs 
are induced during viral infection and act in both an autocrine and paracrine 
manner by binding to receptors present on host cell membranes, which in turn 
signal to activate transcription of interferon-stimulated genes (ISGs). Although 
PRR signaling itself initiates transcription of a subset of ISGs, additional 
expression of antiviral effector proteins through the action of IFN facilitates 
amplification of the antiviral state.   
The first type of IFN discovered, type-1 IFN, is produced by most 
nucleated cells. After secretion from the infected cell, type-1 IFNs bind to the 
type-1 IFN receptor (Figure 9).  IFN binding to its cognate receptor induces a 




Figure 9. The IFN signal transduction pathway (the JAK/STAT pathway). IFN 
signalling to neighboring cells begins with binding of IFN to its cognate JAK 
receptor. Binding of IFN to its receptor triggers activation of the kinase function of 
receptor associated JAKs, which phosphorylate the IFN receptor. This leads to 
the recriutment and phosphorylation of signal transducers and activators of 
transcription (STATs). In the case of type-I IFN, STATs heterodimerize and 
associate with IRF9 to form the IFN-stimulated gene factor 3 (ISGF3) 
transcription factor, while STAT homodimers are formed in response to type-II 
IFN, forming the IFN-gamma activation factor (GAF). These transcription factors 
translocate to the nucleus, where they bind to either GAS elements (type-2 IFN) 
or the ISRE (type-1 IFN). These promoters lie upstream of a multitude of genes, 




Transducer and Activator of Transcription (STAT) pathway, which mediates 
transcription of antiviral genes.The type-1 IFN response is essential for survival 
of WNV infection in mice (127, 144, 226), and mice deficient in either the type-1 
IFN receptor or IFNβ are unable to clear virus from the CNS.  also known as 
interferon-stimulated genes (ISGs), that function to limit the spread of viral 
infection.    
The wide variety of genes upregulated in response to IFN has been 
termed the INTERFEROME (225). ISGs carry out a diverse array of functions 
including regulation of gene transcription and translation, amplification of the IFN 
response, activation of the adaptive immune response, and initiation of antiviral 
RNA interference pathways (203), among many others. Although a few of the 
ISGs have been well described, many mechanisms of ISGs are currently 
unknown.  Some ISGs, such as protein kinase R (PKR), disrupt translation (58, 
220, 221, 315). Another ISG that has been well characterized is the 2’-5’ 
oligoadenylate synthetase (OAS). OAS activity is stimulated by dsRNA. Once 
activated, OAS induces oligamerization of ATP to form 2’-5’ linked oligoadnylates 
(2-5A). 2-5As bind to and activate the cellular endoribonuclease RNAseL, which 
mediates the degradation of viral and cellular RNAs (52, 171-173).  Both PKR 
and RNAse L restrict WNV neuropathogenesis by limiting the spread of WNV 
from neuron to neuron (230). Moreover, a genetic variant in mice of the Oas1b 
gene that encodes a stop codon is associated with increased susceptibility to 
flavivirus infection (231, 232) and single nucleotide polymorphisms (SNP) that 
encode alternate splicing variants of the OAS1 gene in humans is associated 
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with increased susceptibility to WNV in humans and horses (150, 216). However, 
it should be noted that the Oas1b protein in mice is not a functional 2’-5’ 
oligoadenylate synthetase, suggesting that OAS1b may have additional antiviral 
activities outside of activation of RNAseL. Another ISG, Ifit1, also restricts the 
spread of WNV specifically in the CNS, although not specifically by limiting 
replication in neurons or brain endothelial cells. Instead, Ifit1 may play a role in 
regulating the cellular immune response to WNV infection within the CNS and 
limiting immune-mediated pathologies (273). Viperin, an ISG that is hypothesized 
to alter cholesterol levels and membrane formation in the ER, restricts WNV 
replication in the CNS in both neurons and non-neuronal cells (271).  
WNV has evolved several mechanisms to evade the cell intrinsic antiviral 
response. For example, WNV evades detection by PRRs at early times post-
infection, thereby delaying the initiation of the innate immune response (81). 
Additionally, the NS4B and NS5 proteins of WNV inhibit JAK/STAT activation and 
thus down regulate the production of ISGs in WNV-infected cells (102, 143, 188). 
Because of the extensive co-evolution between viruses and the innate immune 
response, it is essential to further examine immune response modulation during 
viral infections to better develop therapies to target specific viral escape 
mechanisms.     
 WNV infection also induces type-II IFN (59, 224) (also known as IFNγ). 
Type-II IFN signaling resembles that of type-1 IFNs, although the receptors are 
structurally and functionally unique to their respective IFN subtype. The type-II 
IFN receptor is comprised of two subunits that, upon binding type-II IFN, signal 
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through the JAK-STAT pathway to mediate transcription of Gamma-activated site 
(GAS) genes. GAS genes promote Th1 T cell development, upregulate binding 
factors on leukocytes, and upregulate synthesis of proteins required to 
synthesize reactive oxygen and nitrogen species (14, 206). Type-II IFN is 
secreted by T cells and natural killer (NK) cells and is essential for activating 
macrophages, modulating the adaptive response to infection, and clearing viral 
infection (2).  WNV infection in IFNγ-/- mice and IFNγ R-/- mice results in higher 
viral load in the lymphoid tissue and earlier incursion of WNV into the CNS (252).  
  
1.9.3 The proinflammatory cytokine response 
 PRR activation of the innate antiviral pathway also leads to the 
transcription of several proinflammatory cytokines (6). Proinflammatory cytokines 
are small proteins synthesized and secreted from the cell via the secretory 
pathway or secreted upon activation and cleavage by the inflammasome. 
Following secretion, cytokines bind to neighboring cells that express the cognate 
cytokine receptor. Receptor binding activates several intracellular pathways and 
either mediates the amplification of proinflammatory cytokines in a positive 
feedback mechanism, or increases production of anti-inflammatory cytokines and 
the repression of the proinflammatory cytokines in a negative feedback 
mechanism (195).  
The proinflammatory cytokine response to infection mobilizes the cellular 
immune system to the site of infection and modulates physiological responses 




 Figure 10. Proinflammatory cytokine synthesis and signalling. 1)Viral 
infected cells induce PRR-triggered pathways that result in the transcription of 
proinflammatory cytokines. 2) These cytokines function to activate and mobilize 
cellular responses, both innate and adaptive, to the site of infection by binding 
receptors present on leukocytes. Further cytokine expression by leukocytes 
determines which type of cellular responses to activate. 3) Cellular responses 
may result in the direct killing of virus by reactive oxygen or nitrogen species 
within an infected leukocyte, secretion of antibodies to neutralize viral particles, 
induction of cell death of the infected cell, or resolution of the proinflammatory 




lymphoid cells), the ability to clear virus depends on the secretion of 
proinflammatory cytokines that attract and activate leukocytes to either directly 
lyse infected cells or aid in viral clearance. Indeed, non-immune cells secrete 
proinflammatory cytokines at the onset of infection (136). Leukocytes are also  
primary producers of cytokines. Secretion of cytokines by leukocytes activates 
the adaptive immune response and controls specific types of antiviral responses.   
When activated, leukocytes secrete significantly higher levels of cytokines than 
non-immune cells (Figure 10). The effect of the proinflammatory response on 
viral infection depends on several variables, including the cell types that are 
recruited and the kinetics of activation (136).  
 Many cytokines, such as interleukin (IL)-6, tumor necrosis factor α (TNFα), 
IL-12, and pro-IL-1β, actively disrupt homeostasis of several physiological 
systems. For example, once in the blood, these cytokines initiate production of 
prostaglandins in the hypothalamus, or activate cells of the hypothalamus itself, 
causing fever (193).  Unregulated proinflammatory cytokine responses lead to 
several harmful consequences, including toxic shock, colitis, and rheumatoid 
arthritis (134, 136, 184).   
Several proinflammatory cytokines play a role in WNV neuropathogenesis. 
For example, IL23-/- mice exhibit increased mortality during WNV infection due to 
an inability to attract monocytes to the CNS (280). TNFα expression in the CNS 
is also essential for attracting CD8+ T cells and monocytes to help clear WNV 
infection in the CNS (253). However, during WNV infection in IL22-/- mice, 
survival was increased compared to wild type mice due to a decrease in CD45+ 
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cell accumulation and a decrease in viral load in the CNS (291).   The 
proinflammatory responses specific to physiological sites of WNV replication, and 
the kinetics of the innate response at these sites, remains an active area of 
research.  
  A subset of chemoattractant cytokines, known as chemokines, functions 
by forming a gradient to attract cells that express their cognate receptor.  While 
some chemokines bind multiple different receptors, other chemokine:receptor 
pairs are unique (7).  Chemokine receptors are G-protein coupled receptors that 
signal through several intracellular pathways. Chemokines mobilize and activate 
leukocytes that express high levels of the receptor on their surface (7). Several 
chemokines and chemokine receptors play a role in WNV neuropathogenesis. 
For example, CCR5-/- mice are unable to efficiently traffic leukocytes to the CNS, 
resulting in increased mortality compared to wild type mice (92). In addition, 
humans who do not express a functional CCR5 are more likely to develop 
neurological disease from WNV infection (93). Further, mice deficient in CCR2 
cannot effectively clear WNV from the CNS and have lower accumulation of 
leukocytes in the CNS compared to wild type mice (152). Certain chemokines 
have been shown to play a detrimental role during WNV infection.  CXCR2-/- and 
mice depleted of neutrophils after initial WNV infection experience a delay in 
lethality, and presumably, WNV entry into the CNS (15). The cell types within the 
CNS that directly contribute to chemokine secretion in response to WNV infection 




 Figure 11. The extravasation process. 1) Activated endothelial cells express 
increased levels of selectin molecules that bind to glycoproteins on leukocytes, 
such as sialyl-Lewis-X, facilitating loose attachement. 2) Chemokines secreted 
by and/or bound to endothelial cells bind to chemokine receptors on leukocytes. 
3) Chemokine:receptor binding triggers a conformational change in integrins 
within leukocytes. 4) Once activated, integrins bind to cellular adhesion 
molecules either on the endothelium or within cells residing on the basal side of 
the endothelium. 5) Diapedisis of activated leukocytes is then directed by 
continuous chemokine gradients throughout the endothelial layer and within 




In addition to attracting leukocytes to the site of infection, several 
proinflammatory cytokines mediate the process of leukocyte extravasation (148) 
(Figure 11). Extravasation involves the traversal of leukocytes across the 
endothelial barrier and into infected tissue, and is characterized by 3 events: 
rolling, attachment, and transmigration of leukocytes through the endothelial cell 
layer (261, 301). Activation of endothelial cells by proinflammatory cytokines 
results in the increased levels of selectin molecules, which bind carbohydrate 
moieties, such as sialyl-Lewis X, present on leukocytes during the initial rolling 
phase of extravasation (126). Firm attachment is then facilitated by chemokines 
that are secreted or present as immobilized chemokine gradients on the 
endothelial cell surface. Binding of chemokines to their cognate receptors 
activates intracellular signaling events within leukocytes that induce 
conformational changes in integrins present on their surface  (142, 210). 
Activated integrins in turn bind to cellular adhesion molecules (CAMs), such as 
intercellular adhesion molecule  (ICAM) and vascular cellular adhesion molecule 
(VCAM), present on activated endothelial cells, strengthening the 
leukocyte:endothelial attachment (40, 41, 318). The process of establishing a 
chemokine gradient, binding and attaching of leukocytes, and leukocytes 
transmigrating through the endothelial cell layer, is known as diapedisis (40, 41). 
Further chemotaxis induced by cells on the basolateral side of the endothelium 
enhances extravasation events (9, 183, 294).  Through this initial cross-talk event 
between the innate activation of the endothelium and the binding of leukocytes, 
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the branches of the immune system work together to distribute the appropriate 
immune cell for clearing the viral infection. If leukocyte extravasation is the 
mechanism of neuroinvasion for a virus, a decrease in extravasation events may 
delay neurological pathologies. Indeed, in WNV-infected ICAM-/- mice, viral loads 
and proinflammatory cytokine expression were decreased compared to wild type 
mice (57).  
 Unsurprisingly, several viruses have evolved strategies, such as 
synthesizing cytokine mimics, to disrupt chemotactic events and thus, cellular 
response to viral infection (6). Further studies are needed to assess the initial 
chemokine response to WNV in the CNS, and how to maintain a proper response 
to prevent neurological injury.  Determining how chemokine gradients are 
induced during WNV infection, including which cells contribute to secretion and 
binding of chemokines at the site of infection, will further the understanding of 
WNV disease progression. Additionally, further examination of the 
proinflammatory response may provide insight into determining whether a 
chemokine response contributes to neuropathology or viral clearance. 
WNV neuropathogenesis as a result of the immune response is a current 
topic of active research and controversy. Several singular host factors in mice 
have been shown to either increase or decrease neuropathogenesis in mice 
(Table 1), depending on experimental design. Specifically, the interferon 
response is required for host survival (127, 144, 226), as well as an active 
adaptive immune response (63-65). Many components of the IFN, pro- and anti-
inflammatory cytokine pathways, such as IL-23, TLRs, IFNγ, TNFα, and IL-1β, 
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are necessary for viral clearance and maintaining a regulated immune response 
to WNV infection (212, 252, 253, 280, 291, 297). Additionally, several factors 
contributing to the trafficking of immune cells to the CNS, such as CCR2, CCR5, 
CXCR3, and CXCL10, are essential for successful viral clearance from the CNS 
(15, 57, 131, 151, 152).  
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NY 1999 (I) 40 No Δ in lethality (92) 
CX3CR1
-/- 
NY 1999 (I) 40 No Δ in lethality (92) 
CXCR2
-/- 
CT2741 (I) 90 Delayed lethality (15) 
IFNβ
-/- 
NY 2000 (I) 95 V: ↑ in CNS 
I: ↓ CD8
+





NY 2000 (I) 100 V: ↑in all tissues (226) 
Sema7a
-/- 
CT2741 (I) 35 V: ↓ in CNS 
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CT2741 (I) 40 No Δ in lethality (280) 
IRF7
-/- 
NY 2000 (I) 100 V: ↑ in CNS 
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CNS entry, ↑ in 
persistent virus 
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NY 2000 (I) 70 V: ↑ in brainstem 





TX02 (I) 100 V: ↑CNS, early entry 
I: ↑activated immune 
cells  
(270) 





NY 2000 (I) 90 V: early CNS entry (230) 
Viperin
-/- 
NY 2000 (I) 85 V: ↑ in CNS (271) 














 Sarafend (II) 18 No Δ in lethality (300) 
CD8α chain 
-/- 
NY 2000 (I) 84 V: ↑ in CNS, early 
CNS infection, 
persistent virus in 
brain 
(249) 
TCR β chain 
-/- 
CT2741 (I) 90 V: ↑ in CNS (299) 
β2 microglobulin
-/- 





NY 2000 (I) 88 V: persistent in CNS (249) 
Granzyme A and 
B
-/- 




granzyme A and B 
-/- 
Sarafend (II) 50 V: ↑ in CNS (300) 
Fas
-/- 
Sarafend (II) 32 No Δ in lethality (300) 
Gld(FasL
-/-












Sarafend (II) 62 V: ↑ in CNS (300) 
MHCII
-/- 
NY 2000 (I) 100 V: persistent in CNS 
I: ↑ CD8
+




NY 2000 (I) 100 V: persistent in CNS 
I: ↑ CD8
+


















clear virus from CNS 
(250) 






TX02 (I) 60 No data reported (212) 
Nlrp3
-/- 
TX02 (I) 60 No data reported (212) 
Nlrc
-/- 
TX02 (I) 30 No data reported (212) 
ASC
-/- 
NY 1999 (I) 95 V: ↑ in CNS 
I: ↑ cytokine 
expression in CNS 
(139) 





CT2741 (I) 55 V: ↓ in CNS 





CT2741 (I) 35 V: ↓ in CNS 







CT2741 (I) 40 V: ↓ in CNS 





     




NK cells NY 2000 (I) 35 No Δ in lethality (248) 
CD8
+ 
T cells Sarafend (II) 70 V: ↑ in CNS (299) 
CD4
+ 
T cells NY 2000 (I) 100 V: persistent in CNS (257) 
Neutrophils prior 
to infection 
CT2741 (I) 100 No data reported (15) 
Neutrophils after 
infection 
CT2741 (I) 45 No data reported (15) 








However, several studies report contrasting observations; while some studies 
suggest recruitment of T cells and monocytes to the CNS is beneficial to the 
host, others suggest that infected leukocytes initiate infection in the CNS (291, 
292, 295, 297).  Thus, examining neuroinvasion and pathogenesis at a more in-
depth, cellular level may provide additional insights into the progression of WNV 
neuropathogenesis.  
 
1.9.4 Adaptive immune response to WNV in the CNS  
The cellular immune response is comprised of all leukocyte subtypes, both 
innate and adaptive. Trafficking of innate immune cells to the site of infection, 
including macrophages, monocytes, dendritic cells and neutrophils, serves two 
main purposes: the direct killing of viruses by production of reactive oxygen or 
nitrogen species (ROS or RNS), and presentation of antigen to adaptive immune 
cells, such as B and T cells, that mature in the lymphoid tissues. The innate 
immune response also promotes trafficking of lymphoid cells, such as cytotoxic 
cells (T-cells), T-helper cells, and antibody-producing cells (B-cells), into infected 
tissues to both kill infected cells and neutralize viral particles (287). Importantly, 
the T- and B-cell responses to viral infection are specific and lead to lasting 
immunity to viral infection. T cells recognize infected cells upon binding of their T-
cell receptor to major histocompatibility complex (MHC) molecules containing 
viral antigen on an infected cell (202, 215) (Figure 12). T cell activation also 
requires binding of cytokines and additional ligands synthesized by an infected 




Figure 12- Recognition of a WNV-infected neuron by a CD8+ T cell. WNV-
infected neurons present antigen via MHCI to CD8+ T cells and express 
increased levels of Fas, CD40 and DR5. In addition, WNV-infected neurons 
secrete CCL5 and CXCL10 to recruit CD8+ T cells to the CNS. Upon recognition 
of antigen, CD8+ T cells secrete IFN γ and release granules containing perforin 
and granzymes. FasL and TRAIL expressed on the surface of CD8+ T cells binds 
to Fas and DR5, respectively, on neurons, and induce caspase-3 dependent 




infection, antigen presentation and recognition by activated T cells is essential for 
complete viral clearance, resolving immune responses, and maintenance of the 
immune system through long term immunity. In contrast, B cells recognize 
exogenous antigens directly. Recognition of antigen by B cells is also essential 
for generating and maintaining an active antibody response to neutralize viral 
particles and maintain immune recognition of infection. In order to escape the 
effects of the adaptive immune response, many viruses have co-evolved 
strategies to escape T or B cell activation within permissive hosts (316). 
T-cells are classified into several subgroups according to the type of T cell 
receptor they express.  All T cell subtypes respond to WNV infection and play a 
role in viral clearance and maintenance of a regulated adaptive immune 
response (247, 248, 250, 251, 256, 257, 296, 298, 299). CD8-bearing T cells are 
cytolytic, whereas CD4-bearing T cells either regulate immune responses (Tregs) 
or activate B cells to produce antibodies. The class of MHC molecule presented 
by an infected cell will determine whether a CD4+ or CD8+ T-cell response will be 
initiated. After engagement of the MHC molecule and costimulation by additional 
cell surface receptors, T cells carry out their distinctive functions. Activated 
CD8+T cells express high levels of Fas Ligand, which upon engaging Fas 
receptors on infected cells leads to apoptosis in the infected cell. CD8+ T cells 
also secrete perforin, a pore-forming molecule, and granzymes, which are serine 
proteases, that enter into and induce apoptosis in infected cells.  Depending on 
the cytokine environment they encounter after maturation, activated CD4+ cells 
further develop into subsets of helper T cells, which stimulate B cells, repress the 
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innate immune system, or regulate the immune response during viral clearance. 
Thus, both CD4+ and CD8+T cell responses are essential components of the 
immune response to viral infections (233), and necessary for successful viral 
clearance. Indeed, a productive adaptive immune response to WNV infection is 
essential for host survival. Although evidence suggests certain T-cell activities 
have both pathogenic and protective roles during WNV infection (248) (298), it is 
clear that productive and regulated T- and B-cell-specific responses to WNV 
infection are essential for host survival (64). Early B cell activation during WNV 
infection is dependent on IFN signaling and essential for survival (211), and the 
production of WNV-specific antibodies is necessary for lasting immunity to WNV. 
However, the production of antibody to immature viral particles may contribute to 
antibody-dependent enhancement of WNV (192).  Antibody-dependent 
enhancement is a process where antibodies with lower affinities to the viral 
antigen do not neutralize the viral particle, and instead facilitate viral entry into 
cells expressing Fc receptors. Since the particle is not neutralized, it remains 
infectious, entering cells via an indirect method. This phenomenon is primarily 
responsible for the increasing severity of subsequent dengue virus infections of 
different strains, and has also been observed in WNV infections in mice (192). 
Thus, instead of being anti-viral in nature, lower affinity antibodies permit viral 
particles to enter cells that may not express the cognate receptor for the virus. 
 The T-cell response to WNV infection in the CNS occurs in three stages: 
attraction to the site of infection, recognition of infected cells, and killing of 
infected cells. T cell infiltration into the CNS of WNV-infected mice is dependent 
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on inflammatory cytokines produced by infected cells of the CNS. For example, 
once infected, neurons secrete CXCL10, which binds to the cognate receptor on 
T cells, CXCR3.  Expression of this chemokine:receptor pair is necessary for an 
effective T cell response and clearance of virus from neurons during WNV 
infection (131). Additionally, WNV upregulates expression of CCL3, 4 and 5 in 
the CNS, all of which bind to the cognate CCR5 receptor (92).  Deletion of CCR5 
is associated with decreased trafficking of T cells to the CNS, leading to 
increased morbidity (92).  In addition, the trafficking of T-cells into the CNS and 
transmigration across the BBB is dependent on CD40-CD40L and TNFα-TNFαR 
interactions (253, 256).  
After infiltrating the CNS, CD8+ T cells recognize infected cells by the 
upregulation of MHCI on neurons (47).  Upon recognition, activated CD8+ T cells 
secrete chemokines to promote viral clearance, such as IFNγ, which are 
necessary for controlling WNV infection (87). Besides MHC molecules, WNV-
infected neurons express increased levels of death receptor 5 (DR5) and Fas, 
which bind Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and 
Fas ligand (FasL) on T cells respectively (247, 250).  Binding of both DR5 and 
Fas to their receptors induces a conformational change in their cytoplasmic 
regions, and leads to induction of apoptosis within the infected neuron. Finally, 
increased viral loads in the CNS of perforin-/- mice suggest that perforin leads to 
CD8+-induced viral clearance during WNV infection (251).  
Although T-cell development is essential for clearance and preventing 
persistence in the CNS, an overreactive response can contribute to 
49 
  
pathogenesis. Depletion of CD8+ T-cells in mice and rag-/- mice exhibited 
increased survival when inoculated with attenuated strains of WNV (298, 299). 
This suggests that, as with several other aspects of WNV infection, the adaptive 
immune response can be either harmful or helpful depending on the context. 
Further research into how different strains of WNV initiate adaptive responses 
and the kinetics of the adaptive response will help to determine how a regulated, 
protective response to WNV infection is initiated and sustained.  
  
1.10 Significance of PhD Dissertation Research 
 Neuroinvasive viruses are a severe public health threat. Many arboviral 
vectors, including mosquitoes and ticks, that spread neuroinvasive viruses 
continue to increase in population and global distribution. Likewise, climate 
change facilitates overwintering of infected arboviral vectors, potentially 
prolonging the life cycles of vectors and increasing encounters with hosts. 
Moreover, many viral infections, including WNV, once considered acute 
infections, may be persistent in the CNS and cause downstream neurological 
complications (186, 263). Neuropathology is also observed in many latent viral 
infections, such as HIV (10). Prevention and treatment of CNS pathologies must 
consider both viral and host factors. Examining contributions from both the 
kinetics of the host immune response and the viral replication kinetics at specific 
sites within the CNS is necessary for developing appropriate preventative 
treatments and therapies for multiple stages of infection. The CNS is increasingly 
recognized as a distinct immunological system, with unique responses to 
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infections (213). The consequences of disturbing the regulation of the immune 
system in the CNS are not completely understood. In several models of both 
acute and chronic disease, CNS disease pathologies resulted from aberrant or 
unregulated immune responses in the CNS (92, 94, 95). Thus, understanding 
how this unique and significant system is regulated is necessary for combating 
neuroinvasive disease.  
 Animal models have provided information linking ultimate neurological 
pathology to certain unique host and viral factors (See table 1). However, the 
contributions of the kinetics of the immune response in the CNS and viral 
replication in the various cell types within the CNS to neuropathology remain 
unclear. To address these questions, I examined, in vitro, various cell types at 
the interface of the BBB to assess cell-type specific antiviral responses to WNV, 
and host and viral responses within interacting cell types in the neurovascular 
unit (NVU). Along with a distinctive BBB model, I used WNV strains of both high 
pathogenicity (WNV-NY) and low pathogenicity (WNV-MAD78) to identify host 
antiviral responses and strain-specific factors that may contribute to their 
naturally occurring differential abilities to induce neuropathogenicity (23). 
 Initially, replication kinetics and spread were examined for each strain in 
each cell type of the NVU.  Replication of WNV-NY and WNV-MAD78 was 
equivalent in both neurons and endothelial cells. Additionally, both strains 
exhibited a similar capacity to traverse an endothelial cell layer grown in a 
suspended transwell, and an equivalent number of astrocytes were initially 
infected when they were added to the bottom well of the transwell model system. 
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However, in astrocytes, WNV-MAD78 replication was delayed compared to 
WNV-NY. Additionally, in astrocytes WNV-MAD78 was restricted in cell-to-cell 
spread compared to WNV-NY, and this restriction was independent of type-1 
IFN. Together, these data suggest that astrocytes are a potential site for 
regulation of WNV neuropathology.  
Because I demonstrated that astrocytes play a role in limiting 
nonneuropathogenic WNV replication, a more critical analysis on both cellular 
factors in astrocytes and potential genetic virulence factors was undertaken. 
While a differential expression of secreted antiviral molecules did not account for 
the restriction in WNV-MAD78 spread in astrocytes, furin activity and expression 
was increased in astrocytes compared to other cell types. In addition, the 
infectivity of WNV-MAD78 particles derived in astrocytes was restricted 
compared to the infectivity of WNV-NY particles derived in astrocytes. Therefore, 
novel viral chimeras were constructed and infectious particle production and viral 
replication in astrocytes were examined. The restriction of WNV infectious 
particle production in astrocytes was highly attributed to the composition of 
structural genes. These data provide support of a novel mechanism for restricting 
infectious particle production within astrocytes independent of the innate antiviral 
response 
 The innate immune responses in the cell types of the BBB were also 
examined individually and in concert in vitro. WNV-MAD78-infected endothelial 
cells exhibited increased chemokine expression and distribution across an 
endothelial cell layer compared to WNV-NY-infected endothelial cells. However, 
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WNV-NY-infected astrocytes displayed increased chemokine expression 
compared to WNV-MAD78-infected astrocytes. Moreover, when astrocytes were 
added to the bottom layer of a transwell containing endothelial cells, the 
distribution of chemokines within the endothelial layer was disrupted. 
Additionally, WNV-NY-infected astrocytes secreted higher levels of chemokines 
compared to WNV-MAD78-infected astrocytes. The addition of astrocytes to the 
BBB model displayed that the immune response to WNV in the CNS is a 
dynamic process that is modified as infection progresses through the BBB.  
To provide additional insight into the physiological relevance of the in vitro 
studies undertaken, preliminary animal experiments were performed. Initial 
experiments demonstrated that there is an additional restriction for WNV-MAD78 
entry into the CNS compared to WNV-NY. Viral RNA and neutralizing antibodies 
were detected in the serum and spleen prior to initiation of a proinflammatory 
antiviral response at any of these sites. A lack of cytokine and chemokine 
response in the serum, spleen and brain at early times post infection suggests 
that chemokine responses are a result of WNV infection in the brain, and do not 
precede viral incursion into the CNS.  Together with the in vitro data, these data 
led to a more complete model for the differences in replication and the immune 
responses at the BBB between neuropathogenic and nonneuropathogenic 




Chapter 2- Materials and Methods 
 
Cells and viruses. Previously characterized human brain microvascular 
endothelial cells (HBMECs) were obtained from K.S. Kim (Baltimore, MD) (312). 
HBMECs were isolated from individuals with seizure disorders and transformed 
by stably transfecting cells with the SV-40 large T antigen.  HBMECs were grown 
in RPMI 1640 supplemented with 10% FBS, antibiotic/antimycotic, nonessential 
amino acids, MEM vitamins, 5 U/mL Heparin, NuSerum (10%), 2mM L-
glutamine, 1 mM sodium pyuruvate, and 150 µg/ml endothelial growth 
supplement. All HBMEC experiments were performed with cells passaged no 
more than 12 times.  Donor matched primary human brain cortical astrocytes 
(HBCAs) (ABRI371) and human brain microvascular endothelial cells 
(HBMVECs) (ABRI401) derived from normal human tissue were purchased from 
CellSystems (Kirkland, WA).  Both cell types were maintained according to the 
manufacturer’s instructions. All experiments with HBMVECs and HBCAs were 
performed on cells passaged no more than 14 times. Primary cortical neurons 
were prepared from day 15 C57BL/6 mouse embryos as previously described 
(131). Cortical neuron experiments were performed using neurons that were 
cultured for 3 to 4 days in neurobasal medium containing B27 and L-Glutamine 
(Invitrogen). Neuro2A and Vero cells were maintained in DMEM supplemented 
with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, antibiotic/antimicotic 
solution and non-essential amino acids (complete DMEM). Neuro2A cells were 
differentiated 3 days prior to infection by reducing the FBS concentration to 0.5% 
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and were maintained in differentiation media throughout the course of the 
experiment.  
 Working stocks of WNV-NY strain 3356 were generated from an 
infectious clone pFL-WNV (245). Briefly, infectious particles were recovered as 
previously described (245), passaged once in 293 cells at a low multiplicity of 
infection (MOI), and subsequently passaged in Vero cells. WNV-MAD78 was 
obtained from the World Reference Center of Emerging Viruses and Arboviruses 
(Galveston, TX). Lyophilized virus was resuspended in complete DMEM 
supplemented with 20% FBS, amplified once in Vero cells and plaque purified.  
Viral stocks were amplified once in 293 cells at a low MOI and working stocks 
were generated by passaging once in Vero cells.  All viral stocks were aliquotted 
and stored at –80oC.   
Growth curves. Cell cultures were infected with WNV-NY or WNV-
MAD78 at the indicated MOI for 1 hour at 37oC. Unless otherwise stated, the 
amount of virus added to cultures to achieve the indicated MOI was calculated 
using the titer of the viral stock on the respective cell line. The inoculum was 
removed and complete media was added.  Culture supernatants were recovered 
at the indicated times and clarified by low speed centrifugation for 5 minutes.  
Supernatants were transferred to new tubes and stored at –80oC. Viral titers 
were determined by plaque assay on Vero cells.  
Virus titration by plaque assay. Monolayers of Vero cells in 6 well plates 
were washed once with PBS prior to the addition of serial dilutions of viral 




rocking, the inocula removed and complete DMEM solution with 0.9% low melt 
agarose (Fisher) was overlaid. VSV plaques were counted 24 hours post-
infection. For WNV titration, cell monolayers were incubated for 48 hours and a 
second overlay of agarose-containing complete DMEM supplemented with 
0.003% neutral red (Sigma) was added. The plates were incubated for an 
additional 48 (WNV-NY) to 96 hours (WNV-MAD78) prior to counting plaques. All 
titers were performed in duplicate. 
Viral translocation assay. HBMECs or HBMVEs (4 x 104 cells) were 
plated on the luminal side of a fibronectin-coated cell culture insert with a pore 
size of 3 µm pores (BD Biosciences) and incubated for 5 days at 37oC in a 5% 
CO2 incubator. The widely accepted methods of transendothelial electrical 
resistance (TEER) and translocation of FITC-labeled dextran were used to 
assess the integrity of the endothelial monolayers  (264) (285). As previously 
reported, monolayers reaching TEER values between 250 to 300 ohms/cm2 were 
largely impermeable to FITC-labeled dextran (285). Therefore, monolayers were 
considered confluent once a minimum TEER value of 250 ohms/cm2 was 
achieved.  Confluent cultures were infected at an MOI of 0.1 by adding virus to 
the upper, luminal chamber. Inoculum was removed after incubating for 1 hour at 
37oC and 500 μl of appropriate complete medium was added to both chambers.  
Medium was collected from both the chambers at indicated times and the level of 
infectious virus was determined by plaque assay.  
In vitro BBB model. HBMECs (4 x 104 cells) and HBCAs (7.5 x 103 cells) 
were plated on the transewell insert and bottom chamber, respectively. The 
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transendothelial electrical resistance (TEER) of the HBMEC monolayer was 
measured 5 days after plating using a Millicell ERS. Cultures were considered 
confluent when a resistance of 250 to 300 ohms/cm2 was recorded. The HBMEC 
monolayer was infected at an MOI of 0.1 by adding virus to the luminal chamber. 
Inoculum was removed after incubating for 1 hour at 37oC and 500 μl of 
appropriate complete medium was added to both chambers.  Medium was 
collected from both the chambers at indicated times and the level of infectious 
virus determined by plaque assay.  
Indirect immunofluorescence analysis (IFA). At the indicated times 
post-infection, the HBCA or HBMEC monolayer was washed with PBS and fixed 
with 3% paraformaldehyde. Cell monolayers were permeabilized with a solution 
of PBS/0.2% Triton X100, blocked with PBS containing 10% normal goat serum, 
and incubated with the indicated primary antibodies from the following: WNV 
hyperimmune ascitic fluid (1:1000, World Reference Center of Emerging Viruses 
and Arboviruses),,rabbit anti-NFkB (1:500, Santa Cruz ab7151), followed by 
corresponding secondary antibodies as follows: goat anti-mouse IgG Dylight 
549nm-conjugated (1:800, Jackson ImmunoLaboratories) or goat anti-rabbit IgG 
Alexafluor 488nm-conjugated (1:500, Jackson ImmunoLaboratories). All 
monolayers included a nuclear Hoescht stain (0.1µg/mL). Cells were visualized 
with an Olympus IX51 microscope equipped with a digital camera.  
Flow cytometry. HBCA monolayers infected with WNV-NY or WNV-
MAD78 (MOI of 0.01) were removed from plates by trypsinization, washed 2 
times with PBS and fixed in 3% paraformaldehyde. Cells were permeabilized with 
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PBS/0.2% Triton X-100, blocked in PBS containing 0.5% heat-inactivated FBS 
and probed with WNV hyperimmune ascitic fluid (1:1000, World Reference 
Center of Emerging Viruses and Arboviruses) followed by goat anti-mouse IgG 
633nm Dylight conjugated antibody. For flow cytometry analysis, 100,000 single 
cell events were collected using a FACS Canto (BD Biosciences).  
Type-I Interferon Bioassay. A549s (7 x 104 cells) in 24-well plates were 
treated with 2-fold serial dilutions of human leukocyte IFNα (BEI Biosciences) or 
cell-free, UV-inactivated supernatants recovered from WNV-infected HBCAs.  
Pretreated cells were infected with VSV (MOI of 1) and supernatants collected at 
24 hours post-infection.  Viral titers were determined by plaque assay on Vero 
cells as described above. IFN concentrations were determined based on a 
standard curve generated from the titers recovered from samples treated with 
IFNα.  
Neutralization of type-I IFN. The antibody concentration necessary to 
neutralize the IFN present in supernatants recovered from WNV-infected HBCAs 
was determined by pretreating A549 cells for 24 hours with 160 IU/mL of IFNα or 
β in the presence of 10-fold dilutions of the antibodies to IFNα (BEI) or IFNβ 
(BEI).  Control wells consisted of cells treated with IFN only, no IFN or isotype 
matched antisera to IFNα or IFNβ. Pretreated cells were infected with VSV (MOI 
of 1) and supernatants collected at 24 hours post-infection.  Viral titers were 
determined by plaque assay on Vero cells.  For neutralization experiments, 
HBCAs were inoculated with WNV (MOI of 0.01) for 1 hour at 37oC. The 
inoculum was replaced with complete DMEM containing 2 times the amount of 
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antibody necessary to neutralize 160 IU/ml IFNα and/or IFNβ or the appropriate 
control sera.   
Quantitative Real-time PCR (qRT-PCR) Total RNA was extracted from 
HBCAs infected with WNV-MAD78 or WNV-NY (MOI=0.01) or from HBMECs 
mock-infected or infected with WNV-NY or WNV-MAD78 (MOI=0.1) using Trizol 
(Invitrogen Life Technologies, Inc.) and treated with TurboDNAse (Applied 
Biosystems). Spleen and brains were harvested from mice and homogenized in 
1mL TRIZOL-LS treated with TurboDNase (Applied Biosystems). Where 
applicable, RNA was extracted from supernatants (Qiagen). Total viral RNA 
levels were determined by quantitative real-time PCR analysis on a Roche 
LC480 using Veriquest One-Step SYBR green MasterMix (Affymetrix 
Biosystems) with 50 ng of RNA, or One-Step SYBR green from Quanta 
Biosciences with 50 ng of RNA.  Primer efficiencies were determined and the fold 
change relative to mock-infected cells at 1 h post infection was calculated using 
the Paffl method. Primers used for qPCR are indicated in table 1. Two-step 
qPCR was used to determine strand-specific viral RNA levels.  cDNA was 
generated from 500 ng of RNA using Moloney murine leukemia reverse 
transcriptase (NEB Biosciences) and gene-specific primers. The resulting cDNA 
was used as template for qPCR with SYBR green 2x Veriquest MasterMix 
(Affymetrix). Primers used for 2-step qPCR were the primers for WNV-NY and 





Table 2. Primers used for qPCR and qRT-PCR.  
Primer name Sequence 
WNV-NY E (fwd) 5’- GGA CCT TGT AAA GTT CCT ATC TCG-3’ 
WNV-NY E (rev)  5’-AGG GTT GAC AGT GAC CAA TC-3’ 
WNV-MAD78 E (fwd) 5’-CTG TAA GGT GCC CAT TTC C-3’ 
WNV-MAD78 E (rev) 5’-CCT CTT CCC ACC ACA ATG TAG-3’ 
hGAPDH (fwd) 5’- CCA CTC CTC CAC CTT TGA C-3’ 
hGAPDH (rev) 5’- ACC CTG TTG CTG TAG CCA-3’ 
hCCL2 (fwd) 5’-TCT CTG CCG CCC TTC TGT G-3’ 
hCCL2 (rev) 5’-GCT TCT TTG GGA CAC TTG CTG CTG-3 
hCCL5 (fwd) 5’-CTC TGT GAC CAG GAA GGA AGT-3’ 
hCCL5 (rev) 5’-GGG TTG AGA CGG CGG AAG-3’ 
mGAPDH (fwd) 5’-AAG GTC GGT GTG AAC GGA TTT-3’ 
mGAPDH (rev) 5’-ATT TGC CGT GAG TGG AGT CAT AC-3’ 
mCCL2 (fwd) 5’-G CAC CAG CAC CAG CCA AC-3’ 
mCCL2 (rev) 5’-CCA GAA GCA TGA CAG GGA CC-3’ 
mCCL5 (fwd) 5’-CGC CAA GTG TGT GCC AAC-3’ 
mCCL5 (rev) 5’-ACC GAG TGG GAG TAG GGG A-3’ 
mCXCL2 (fwd) 5’-CCA CTC TCA AGG GCG GTC-3’ 





ELISAs. The concentration of hCCL2 and hCCL5 in the supernatants of 
mock and WNV-infected cells was determined by ELISA according to the 
manufacturers’ instructions (BD Biosciences and R&D systems, respectively). 
The concentration of TNFα, IL-12p40, and IL-6 in the serum of mock and WNV-
infected mice was determined by ELISA according to manufacturers’ instructions 
(BD Biosciences and R&D systems).  
Permeability assays. FITC-dextran (100 µl of 100μM, Sigma, 4kda) was 
added to the luminal chamber of a transwell plate and incubated for 1 h at 37o C 
in the dark. Media was recovered from the abluminal chamber and diluted 1:2 in 
2% Triton lysis buffer to inactivate virus. Fluorescence levels were quantitated 
using a FLUOstar Omega fluorescence microtiter plate reader (BMG LabTech).  
For positive control, monolayers were incubated in 5mM EDTA in PBS for 1 h 
prior to the addition of FITC-dextran. 
Confocal Microscopy. HBMEC monolayers grown on transwell inserts 
with or without HBCAs plated in the bottom chamber were infected as described 
above.  The luminal and abluminal sides of the transwell insert were washed with 
PBS at 48 (HBMEC alone) or 72 (coculture) hours post-infection, fixed with 4% 
paraformaldehyde, and permeabilized in 0.2% Triton-X100/PBS.  Cells were 
blocked with 10% Normal goat serum/PBS and incubated for 1 h in the presence 
of rabbit anti-CCL2 (1:10, Abcam), goat anti-CCL5 (1:15, R&D systems), and 
WNV hyperimmune ascitic fluid (1:1000, Arbovirus resource center). Cells were 
washed three times with PBS containing 0.5% Tween-20 and incubated with 
Dylight488 anti-rabbit IgG (1:100, JacksonImmunolabs) Dylight549 anti-mouse 
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IgG (1:800, JacksonImmunolabs), Alexafluro633 anti-goat IgG (1:200, Invitrogen) 
and Hoechst stain (0.1ug/mL).  The inserts were mounted on slides using Mowiol 
media (Calbiochem). Imaging and Z-stacks were captured using a Zeiss LSM 
710 Microscope at 40x objective. All quantification analysis was performed using 
ImageJ software (239). 
Type-1 IFN and TNFα treatments. HBMEC monolayers were either 
pretreated 24h before inoculation with either TNFα (5ng/mL Invivogen), Human 
leukocyte IFNα (BEI Resources), or recombinant human IFNβ (BEI Resources) 
or post-treated after inoculation with either WNV-NY or WNV-MAD78 (MOI=1). 
Monolayers that were pretreated were also post-treated with the same cytokine. 
At 24 and 48 h post inoculation, culture supernatants and cell lysates were 
collected for plaque assays and Western blot analysis, respectively. 
Western Blotting. Cell monolayers were washed twice with modified 
DPBS (Hyclone), and lysed with Ripa buffer (10 mM Tris pH 7.4, 150 mM NaCl, 
0.02% NaN3, 1% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl 
sulfate [SDS], and 1X protease inhibitors [Sigma]).  Lysates were subjected to 
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose 
membranes.  Nitrocellulose membranes were then blocked in 5% NFD milk 
diluted in Western wash buffer (PBS+0.1% Tritoxn-X) and incubated with the 
following primary antibodies: polyclonal rabbit anti-GAPDH (1:5000, Abcam; 
ab36845), polyclonal mouse anti-WNV (1:1000, Arbovirus Resource Center; 
T35570), rabbit anti-ISG15 (1:2500, gift from the Haas lab), rabbit anti-ISG56 
(1:2500, gift from Ganes Sen), mouse anti-VCAM (1:50, Santa Cruz ab 13160), 
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mouse anti-ICAM (1:50, Santa Cruz ab 18853). Following primary antibody 
incubation, anti-mouse or anti-rabbit antibodies conjugated to HRP were 
incubated with membranes and blots were visualized using ECL (GE 
Healthcare).  
Adhesion assay. HBMECs were either mock-infected, infected with either 
WNV-NY, WNV-MAD78 (MOI=0.1) for 48h, or treated with 100ng TNF for 24h 
as a positive control. THP-1 cells were labeled using CellTracker™ Green 
CMFDA (2uM, Invitrogen) and 2 x 106 labeled cells in 500µl complete THP-1 
media were added to each well after removal of supernatant.  Plates were rocked 
for 30 minutes at 37 degrees Celcius, 5% CO2 and washed vigorously 3 x with 
PBS to remove nonadherent cells. Cells were fixed using 3% paraformaldehyde 
and visualized on an Olympus microscope model IX51.   
Transmigration Assay. Cells were plated and inoculated as described 
above for the in vitro BBB. At 72h postinfection, THP-1 cells were labeled using 
CellTracker™ Green CMFDA (2µM, Invitrogen) and 2 x 106 labeled cells in 500µl 
complete THP-1 media were added to each well after removal of supernatant. 
Cultures were then incubated at 37ºC for 6 hours to allow for transmigration of 
labeled THP-1 cells through the endothelial monolayer. After incubation the total 
components in the abluminal chamber were lysed directly by adding 500µL 2x 
Triton-X lysis buffer (2% Triton-X 100,) directly to the 500µl of culture media. 
Lysed samples were removed and places into light-sensitive tubes prior to 
reading fluorescence of 150µl each sample in triplicate on an Omega FLUOstar 
(Absorbance 485nm, emission 520nm).  
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Ethics statement. All procedures with mice were done in accordance with 
the recommendations in the Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health.  The protocol was approved by the University of 
Maryland Institutional Animal Care and Use Committee (permit #: R0969).  
Animal Experiments. Four week old Swiss-webster female mice were 
purchased from Harlan Laboratories.  Animals were inoculated intravenously by 
injecting 100 µl containing 104 pfu of WNV-NY, WNV-MAD78 or PBS directly into 
the tail vein.  Animals were weighed and monitored for signs of morbidity daily. 
Viral stocks for animal experiments were generated by passaging WNV-NY and 
WNV-MAD78 one time in Vero cells. Blood was collected at 8, 24, 48, 96 and 
120 hours post inoculation via orbital bleed and serum separated via 
centrifugation (1000xg, 20 mins) and subjected to plaque assays. Spleen and 
brain were harvested at the same time points as blood after transcardial 
perfusion with 20mL PBS. Each organ was divided and subjected to either RNA 
extraction in TRIZOL or homogenized in 1mL PBS. Quantification of virus at 
these three sites within mice was performed using plaque assay, nested PCR, 
and/or integrated PCR.  
Nested PCR. RNA was extracted using TRIZOL reagent as described by 
manufacturers instructions. RNA was resuspended in 15 µl water, and 2µl was 
used as template in the RT-PCR reaction, consisting of SYBR Mastermix 
(Quanta biosciences), and external WNV primers (sense- 5’-TCC TTG ATT GGA 
CTG AAG -3’, antisense 5’-TGA GTG GCT CCA ACC TG -3’). Products were 
then buffer exchanged (Promega) and eluted in 40ul water. The following round 
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of PCR consisted of 1 ul of the eluted template and utilized internal WNV-NY 
primers (sense 5’- CAG ACA CAC GGA GAA ACG AC-3’, antisense 5’- TGA 
GTG GCT CCA ACC TG -3’) or WNV-MAD78 primers (sense 5’-CAT GGA CGT 
GGG ATA CCT CTG -3’, antisense 5’- TGA GTG GCT CCA ACC TG -3’). All 
reactions were run on 2% agarose gels and visualized using ethidium bromide.    
Integrated PCR. Supernatants of homogenized infected mouse organs 
were inoculated onto HBMEC monolayers. After 1 hour of inoculation, complete 
HBMEC media was added to the flasks. At 72 and 96 hours post inoculation, 
supernatants were collected and subjected to plaque assays. At 96 hours post 
inoculation, cells were washed 3x with PBS and lysed in 1mL Trizol. RNA 
extraction was subjected to RT-PCR with MMLV (NEB Biosciences) using 7µg of 
and random hexamers (10µM). PCR was carried out using primers for the E 
gene of either WNV-NY or WNV-MAD78 (See above table for primer) and Taq 
polymerase (NEB biosciences).  
Plaque Reduction Neutralization Test (PRNT). Serum collected from 
animal experiments was heat inactivated at 56ºC previous to incubation with 
appropriate parent virus (WNV-NY or WNV-MAD78, 1:1 ratios) for 30 minutes, 
and plaque assays performed on Vero cells as described above. Values are 
graphed as an inverse of the dilution where >50% of plaques were inhibited 
compared to control plaque assays. Serum for mock-infected animals were 
utilized as a negative control, and serum from animals from timepoints at 48, 96, 
and 120hpi were assessed.  
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RT- PCR amplification of products for synthesis of infectious clone. 
WNV-MAD78 RNA was isolated from infections in Vero cells using TRIzol (Life 
Techinologies). After extraction, 2-7µg of RNA was used for reverse transcription 
with murine leukemia reverse transcriptase (MMLV- RT, NEB) with either random 
hexamers or sequence-specific primers. To amplify all WNV-MAD78 products, 
5µl cDNA and a combination of the following Taq polymerase enzymes with their 
complementary buffers were utilized: Deep Vent Polymerase (NEB), Vent 
Polymerase (NEB), Phusion Polymerase (Finnzymes). Primers used to amplify 
specific fragments are described in the table below. PCR products were ligated 
into cloning vector pVL-blunt to amplify and confirm sequence.  









5’UTR/KpnISphI Mlu/T7/5’UTR: 5’-CAT 
ACG CGT TAA TAC 
GAC TCA CTA TAG 
AGT AGT TCG CCT 
GTG TGA GCT GA-3’ 
Fwd:5’-GGT ACC AGT 
AGT TCG CCT GTG 
TGA GCT GAC-3’ 
Rev: 5’-CCA TGG TTG 





XhoI (SphI)ClaI Fwd: 5’-GCT CGA GTG 
ATG GAA GCA G-3’ 
Rev: 5’-ATC GCA GGC 
CGC AAA TTC CTT CC-
3’ 
72 Phusion 
ClaIBamHI Fwd: 5’-CAA GAA CTC 
CGC TGT GGG AGT 
GGA G-3’ 
Rev: 5’-GTT CTC TTG 
GTT GGT CCA TCT 
CGC C-3’ 
 Phusion 
BamHIKpnI Fwd:5’-GTT CGC TGA 
GGC GAA CTC GG-3’ 
Rev: 5’-TTT GGT ACC 
GGA TAG GAA GTC 
CTC TC-3’ 
72 Phusion 
KpnI(XmnI)XhoI Fwd: 5’-CCG GTA CCA 
AAC CTC CGC-3’ 
Rev: 5’-ATC CTC AGA 
AAG CCC AAT TTG 
TGA GCG TT-3’ 
68 Phusion 
BamHI Fwd: 5’-GGG ATC CGA 50 Vent 
67 
  
(Nhe)(XmnI)XbaI GTG TAC TCA GAC C-3’ 
Rev: 5’-TTC TAG ACT 
GTT GTT GCG TTC C-3’ 
XmnIXbaI Fwd: 5’-CGG TGA GAA 
CTG TCA GGG AAG-3’ 
Rev: 5’-CCT GAC TTT 





XbaINotI Fwd: 5’-CGG GTA CAT 
CCT GAA GTC GGT 
TGG GGT GAG G-3’ 
Rev: 5’-AGC GGC CGC 
AGA TCC TGT GTT CTT 






Fwd: 5’-AGA TGA TGA 
AGA TGG AAG CAG C-
3’ 
Rev: 5’-CAA CCT GCG 
TGG AGT AGT TAC 







Fwd: 5’-GGT AAC TAC 







Rev: 5’-GTT CTC TTG 







Fwd: 5’-caa agg atc cta 
ata cga ctc act ata gAG 
TAG TTC GCC TGT 
GTG AGC TGA-3’ 
Rev: 5’-AAC CTG TGT 
AGG GTA GTT TCC 








Fwd: 5’-CGG AAA CTA 
CCC TAC ACA GGT 
TGG AGC CAC-3’ 
 
Rev:5’-CTC TAG ACA 






Assembly of infectious clones and in vitro transcription. After the sequence 
of each individual fragment was confirmed, WNV fragments were subcloned into 
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medium-copy vectors (peGFP, pBKSM), and further subcloned into low-copy 
vectors (pWSK29, pWSK129) as described in Figure 13. In addition, the BssHI 
site in the vector of pWSK29 was mutated for ligation of 5’-Mlu/T7/5’UTR of 
WNV-MAD78. For in vitro transcription, full-length constructs were sequenced 
prior to digestion with NotI (WNV-MAD 78) or XbaI (WNV-NY) (NEB). Digestions 
were treated with Proteinase K (5mg/mL), purified with phenol:chloroform 
extraction and ethanol precipitation, and 1µg of DNA was used for in vitro 
transcription (T7 Ampliscribe Max Cap kit Epicentre). RNA was purified as per 
manufacturer’s instructions and visualized on a non-denaturing agarose gel prior 
to electroporation. 
Glycosylation mutants and structural/nonstructural chimeras were 
synthesized using Gibson Assembly MasterMix as described in Figure 13. The 
two-plasmid system established takes advantage of a naturally occurring 
NgoMIV site within the 5’ end of WNV-NY NS1, and an engineered, silent 
mutation made in the same location of the WNV-MAD78 NS1. Thus, plasmid 1 
contains 5’ UTRE of either WNV-NY or WNV-MAD78, whereas plasmid 2 
contains NS13’ UTR, effectively separating the genome into structural and 
nonstructural proteins. The strategy utilized was similar to published clones of 
WNV-TX02/ WNV-MAD chimeras (269). Briefly, PCR fragments were generated 
utilizing the full length infectious clones as template, and primers containing any 
desired mutations. In addition, the vector plasmid for the Gibson reaction (i.e. p1 
of WNV-MAD78 for the two-plasmid system) was linearized using naturally 




Figure 13. Assembly of infectious clones. (A) Assembly of WNV-MAD78. RNA 
was isolated from infections in A549 cells and RT-PCR performed with the 
primers described in Table 3. Prior to assembly in medium copy vectors, each 
fragment was cloned in a high copy vector and the sequence verified. After 
cloning in medium copy vectors, fragments were combined in low copy vector 
pWSK29. (B) Assembly of chimeric viruses. Gibson assembly was performed in 
order to introduce mutations desired (89). After assembly into 2 separate 




 either end of the PCR products generated. The PCR product/s and the digested 
vector plasmid generated were then added at a 1:2 vector: PCR product ratio to 
a recombinase, ligase, and polymerase mastermix (NEB) and incubated for 60 
minutes at 50 ºC. The reaction was directly transformed into MDS42 E. coli, and 
single colonies were screened and sequenced prior to preparation. To generate 
template for in vitro transcription using the two-plasmid system, p1 of either virus 
was digested with BamHI (WNV-NY) or MluI (WNV-MAD78) and NgoMIV, and p2 
with NgoMIV and XbaI. DNA fragments were isolated and purified, and p1 and p2 
genomic fragments were combined in a 1:1 molar ratio (p1:p2) up to 10µg of total 
DNA. The combined DNA was then ethanol precipitated, resuspended, and 
ligated using T4 DNA ligase (NEB) overnight at 16ºC. The ligation was then 
treated with Proteinase K (5mg/mL), purified through phenol:chloroform 
extraction and ethanol precipitation, and 1µg of DNA was used for in vitro 
transcription (T7 Ampliscribe Max Cap kit Epicentre). RNA was purified as per 
manufacturer’s instructions and visualized on a non-denaturing agarose gel prior 
to electroporation.  
Electroporation and amplification of virus. Viral RNA (10-12µg) was 
electroporated (Neon-Invitrogen) into Vero cells (1x106) and cultured in DMEM 
(CellTech) supplemented with 10% FBS (Hyclone) for 7 days. Viral stocks were 
further amplified once in Vero cells and stored at -80 ºC. RNA was extracted 
using 1mL TRIzol (Life technologies) for each virus synthesized and RT-PCR 
performed to confirm viral mutations throughout amplification.   
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Furin activity assay. Cells were lysed in assay buffer (Triton-X100 0.5%, 
0.5mM CaCl2, 100mM HEPES pH 7.0), and a fluorogenic substrate (pERTKR-
AMC, R&D systems, 100µM) was added to equivalent amounts of HBMEC or 
HBCA cell lysates. Fluorescence was immediately read over a 10 minute period 
with readings taken every 20 seconds (excitation, 380nm; emission, 460nm). As 
a control, recombinant furin (R&D systems, 0.2µg/mL), was assayed.  
Inhibition of furin in HBCAs. In order to determine the necessary 
amount of inhibitor to use to inhibit furin activity in HBCAs, furin inhibitor (Dec-
RVKR-CMK diluted in PBS, 5mM stock concentration) was added at increasing 
concentrations to a set number HBCAs over a 48h period. After incubation with 
inhibitor for 48h, HBCA cell lysates were collected as described above and furin 
activity assays were performed. It was found that 50μM Dec-RVKR-CMK 
effectively inhibited the furin in HBCAs, and a second dosing at 24h was 
necessary to maintain the inhibition of furin. During infection, HBCAs were 
inoculated (MOI=0.01) with either WNV-NY or WNV-MAD78 and either PBS or 
furin inhibitor was added to media after inoculation (final concentration=50µM). At 
24h, an additional dose of furin inhibitor (final concentration=50µM) or PBS was 
added. Cell supernatants were clarified by low-speed centrifugation at 48h post 
infection and plaque assays performed in Vero cells as described above.  
Focus forming assay of HBCA supernatants on HBCAs. Prior to 
inoculation, supernatants from WNV-infected HBCAs were either treated with 
control antisera or antibodies to type-1 IFN (both α and β) at concentrations 
determined above (see type-1 IFN Bioassay and treatments) for 1h at 37ºC. 
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Antibody-treated supernatants or supernatants that were left untreated were then 
serially diluted and added to HBCA monolayers. Inoculum was then removed 
after 1h, complete media was added and HBCAs were incubated for 16h at 37ºC, 
5% CO2. At 16h, media was removed, cells washed 2x with PBS, and fixed in 3% 
paraformaldehyde. Cells were stained as described in indirect 
immunofluorescence assay section above with antisera to WNV and Hoescht 
nuclear stain. Individually stained cells were counted. The ratio of the titer found 
in HBCAs using the focus-forming assay was compared to that of the titer of the 
same supernatants using plaque assays in Vero cells. 
Secreted factor assays. HBCAs were either mock-infected or infected 
with WNV-NY or WNV-MAD78 (MOI=0.01). At 48hpi, culture supernatant was 
clarified and subjected to type-1 IFN bioassays. Supernatants were UV-
inactivated and diluted 1:1 in 2xDMEM supplemented with 20% FBS. 
Supernatants were either treated with control antisera to IFNα and IFNβ, or 
antisera to IFNα and IFNβ for 1h at 37°C. After incubation, treated or untreated 
supernatants were added to HBCA monolayers and incubated for 6h at 37ºC, 5% 
CO2. HBCAs were then washed 1x with serum free DMEM and inoculated with 
either WNV-NY or WNV-MAD78 (MOI=0.01). During inoculation, fresh 
supernatant was prepared as described above. After 1h, inoculum was removed 
and the corresponding supernatants were added to HBCAs. Infected monolayers 
were incubated for 24h. Culture supernatants were removed, clarified by low 
speed centrifugation, and subjected to plaque assays in Vero cells.  
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Statistical Analysis.  Graphpad Prism 5 was used to generate all 
statistical analyses.  Standard error and significance were determined using 
either one-way Anova with Bonferroni post-test correction or a two-tailed paired 





Chapter 3-Differential replication for Pathogenic and Nonpathogenic strains 
of WNV within Astrocytes  
Abstract 
The severity of West Nile virus (WNV) infection in immunocompetent 
animals is highly strain dependent, ranging from avirulent to highly 
neuropathogenic. Here, we investigate the nature of this strain-specific restriction 
by comparing the replication of avirulent (WNV-MAD78) and highly virulent 
(WNV-NY) strains in neurons, astrocytes, and microvascular endothelial cells, 
which comprise the neurovascular unit within the central nervous system (CNS). 
We demonstrate that WNV-MAD78 replicated in and traversed brain 
microvascular endothelial cells as efficiently as WNV-NY. Likewise, similar levels 
of replication were detected in neurons. Thus, WNV-MAD78’s non-
neuropathogenic phenotype is not due to an intrinsic inability to replicate in key 
target cells within the CNS. In contrast, replication of WNV-MAD78 was delayed 
and reduced compared to that of WNV-NY in astrocytes. The reduced 
susceptibility of astrocytes to WNV-MAD78 was due to a delay in viral genome 
replication and an interferon-independent reduction in cell-to-cell spread.  
Together, our data suggest that astrocytes may regulate WNV spread within the 







The Flaviviridae includes several globally important emerging arthropod-
borne viruses, such as yellow fever virus, dengue virus, Japanese encephalitis 
virus and West Nile virus (WNV). WNV has re-emerged as a pathogen that 
causes severe neurological disease. Prior to the 1990s, most WNV infections 
were asymptomatic or associated with a mild febrile illness known as West Nile 
fever. Since its introduction into the United States in 1999, annual outbreaks of 
WNV have resulted in ~16,000 reported cases with neurological complications, 
including meningitis, encephalitis, and acute flaccid paralysis.  These cases have 
resulted in greater than 1,500 deaths, making WNV the leading cause of 
mosquito-borne neuroinvasive disease in the United States  
(http://www.cdc.gov/ncidod/dvbid/westnile/index.htm). In addition, outbreaks 
have occurred in other parts of the world, including Eastern and Western Europe 
(199, 200). Nevertheless, the factors responsible for the increase in pathogenicity 
of WNV remain poorly understood.  
Many neuroinvasive viruses, including WNV, preferentially enter the CNS 
via the hematogenous route by crossing the blood-brain barrier (BBB). The BBB 
is comprised of specialized endothelial cells, which line the cerebral 
microvasculature, and the foot processes of astrocytes, which envelop >99% of 
the endothelium. Under normal physiological conditions, the BBB tightly 
regulates transport of molecules into and out of the CNS. The restrictive nature of 
the BBB is a consequence of the formation of complex cell-to-cell tight junctions 
and lower basal levels of pinocytosis and endocytosis (1, 129). Although 
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astrocytes were once thought to serve a structural role in the BBB, it is now clear 
that they play an important role in maintaining its functional integrity. In vitro, co-
cultures of brain endothelial cells and astrocytes establish a tighter barrier than 
endothelial cells alone, and secretion and activation of matrix metalloproteases 
(MMPs) by astrocytes result in disruption of the BBB during disease (101, 284). 
Astrocytes also modulate neuronal health and activity through the uptake of 
excess neurotransmitters and secretion of nutrients (96, 109, 217, 218). Thus, 
astrocytes serve as a structural and functional bridge between endothelial cells 
and neurons. Together, these three cell types form the neurovascular unit (NVU), 
which functions to regulate blood flow, the integrity of the BBB, and neuronal 
activity in response to environmental changes (118). Understanding how viruses 
replicate within the NVU may facilitate novel strategies for treating viral infection 
of the CNS.  
The neuroinvasive potential of WNV is strain dependent.  While most, if 
not all, strains of WNV are neurovirulent when mice are inoculated intracranially, 
only a subset of strains are neuroinvasive when inoculated via a peripheral route 
(23). The mechanistic basis for the increased neuroinvasiveness of some strains 
of WNV remains poorly understood. However, the observation that exogenous 
disruption of the BBB enables a non-neuropathogenic strain of WNV to enter the 
CNS (164) suggests that the capacity to traverse the BBB is a determining factor 
for neuropathogenicity. Here, we investigated the nature of the restriction at the 
BBB by comparing the ability of an avirulent lineage 2 African isolate, WNV-
MAD78 (258), and a highly virulent lineage 1 North American strain isolated in 
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2000, West Nile virus New York (WNV-NY), (23, 127, 253) to replicate in various 
cell types comprising the NVU. While both strains replicated efficiently in brain 
microvascular endothelial cells and neurons, WNV-MAD78 replication was 
restricted within astrocytes compared to WNV-NY.  WNV-MAD78 exhibited both 
a delay in viral genome synthesis and reduced cell-to-cell spread in astrocytes 
compared to WNV-NY.  Moreover, the restriction of WNV-MAD78 replication and 
spread in astrocytes was independent of type-I interferon (IFN). Together, our 
findings suggest that astrocytes may play an important role in controlling WNV 
dissemination within the CNS.    
 
Results 
WNV-NY and WNV-MAD78 replicate to similar levels in neuronal 
cells. Because neurons constitute a primary target of WNV infection in vivo (73), 
we compared WNV-MAD78 and WNV-NY replication in primary cortical neurons 
derived from wild type C57BL/6 mice and the mouse neuroblastoma cell line 
Neuro2A (Figure 14 A and B) at a multiplicity of infection (MOI) of 0.01 and 0.1, 
respectively.  WNV-NY and WNV-MAD78 reached similar peak titers in both cell 
types, although the kinetics of WNV-MAD78 replication were slightly delayed at 
24 hours in cortical neurons (9.2-fold, P = 0.03). Despite the slight growth delay, 
neuronal cells were highly permissive for WNV-MAD78 replication, suggesting 
that the non-neuropathogenic phenotype documented in mice (23, 127) is not 





Figure 14. WNV-NY and WNV-MAD78 replication in neuronal cells.  
Cortical neurons isolated from C57BL/6 mice (MOI of 0.01) (A) and differentiated 
Neuro2A cells (MOI of 0.1) (B) were infected with WNV-NY or WNV-MAD78. The 
MOI was calculated using the titer of the viral stocks on Vero cells. Culture 
supernatants were recovered at the indicated times and titers determined by 
plaque assay on Vero cells. Values represent the average number of plaque 
forming units (PFU) per mL (+/- standard error) of supernatant and are from at 
least two separate experiments. A student’s unpaired t-test was performed to 
determine statistical significance.  Asterisks indicate differences that are 




WNV-MAD78 efficiently infects and traverses human brain endothelial cells. 
Although many viruses achieve high levels of viremia, under normal conditions 
the BBB is highly effective at protecting the brain from circulating virus in the 
blood stream. However, neuroinvasive viruses have evolved a variety of 
mechanisms to breach the BBB and gain access to the CNS (129). Because 
replication in brain endothelial cells is sufficient for transport of neuroinvasive 
strains of WNV across brain microvascular endothelial cells (285), we 
hypothesized that the decreased neuropathogenicity of WNV-MAD78 was due in 
part to a deficiency in replication in brain endothelial cells.  Therefore, we 
monitored replication of WNV-NY and WNV-MAD78 in an established human 
brain microvascular endothelial cell line (HBMEC) that has been widely used as a 
model to study bacterial and parasitic neuroinvasion (100, 115, 264, 265, 312) 
and primary brain microvascular endothelial cells (HBMVECs) derived from 
normal brain cortex tissue (45, 285). WNV-NY and WNV-MAD78 replicated at 
similar rates and to equivalent levels in both cell types, reaching peak titers 
between 32 and 48 hours post-infection (Figure 15 A & B) without induction of 
CPE (data not shown). However, we did observe a statistically insignificant, 
decrease in WNV-MAD78 titers very late in infection. These data suggest that 
replication in endothelial cells is not responsible for the decreased 
neuropathogenicity of WNV-MAD78.  
It was recently reported that non-replicating virus-like particles (VLPs) 
generated from a lower virulence lineage 1 strain of WNV exhibited reduced 
transcellular migration across human umbilical vein endothelial cell monolayers  
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Figure 15. WNV-NY and WNV-MAD78 replication in human brain 
microvascular endothelial cells. Immortalized HBMECs (A) or primary 
HBMVECs (B) were infected with WNV-NY or WNV-MAD78 (MOI of 0.1). Culture 
supernatants were recovered at the indicated times and titers determined by 
plaque assay on Vero cells. Values represent the average number of plaque 
forming units (PFU) per mL (+/- standard error) of supernatant from at least two 
separate experiments. (C) Traversal of HBMVEC by WNV-NY and WNV-MAD78. 
Confluent monolayers of HBMVECs were cultured on transwell inserts and 
infected with WNV-NY or WNV-MAD78 (MOI of 0.1). Culture supernatants were 
collected from the luminal and abluminal chambers at the indicated times and 
titers determined by plaque assay on Vero cells. Values represent the average 
number of plaque forming units (PFU) per mL (+/- standard error) of supernatant 
from two separate experiments.  
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compared to those generated from a highly virulent strain (108). Thus, non-
neuropathogenic strains, such as WNV-MAD78, may have a reduced capacity to 
traverse the BBB despite replicating efficiently in brain microvascular endothelial 
cells. To test this, we infected HBMEC or HBMVEC monolayers grown on 
transwell supports and measured virus yields in both luminal (upper) and 
abluminal (lower) chambers. Equivalent levels of infectious particles were 
present in the luminal and abluminal chambers of WNV-NY- and WNV-MAD78-
infected HBMECs (data not shown) and HBMVECs (Figure 15C) at 24 and 48 
hours post-infection, demonstrating that both strains are capable of traversing the 
BBB at similar rates and levels. Therefore, the non-neuropathogenic phenotype 
of WNV-MAD78 does not correspond to a reduced capacity to replicate in or 
traverse brain microvascular endothelial cells. 
 
WNV-MAD78 replication is restricted in co-cultures of HBMECs and 
HBCAs. We next tested whether astrocytes, which constitute the peri-
parenchymal layer of the BBB, differentially limit WNV-MAD78 replication using 
an in vitro BBB model comprised of HBMECs cultured on transwell supports with 
primary human brain astrocytes derived from the cerebral cortex (HBCAs) in the 
bottom chamber.  As previously observed, both strains of WNV were detected in 
medium recovered from the abluminal chamber 24 hours after infection of the 
HBMEC monolayer (Figure 16A). However, viral protein expression was not 
detected in the HBCAs until approximately 48 hours after infection (Figure 16B, 




 Figure 16. WNV replication in an in vitro model of the BBB. (A and B) 
HBMECs cultured on transwell inserts with HBCAs plated in the abluminal 
chamber were infected with WNV-NY or WNV-MAD78 (MOI of 0.1). (A) Culture 
supernatants were recovered from the abluminal chamber of the transwell at 24 
hours post inoculation and viral titers determined by plaque assays on Vero cells. 
Values represent the average number of plaque forming units (PFU) per mL (+/- 
standard error) of supernatant from at least three separate experiments. (B) Viral 
replication in the HBCA layer of an in vitro BBB model. HBCAs were fixed with 
3% PFA at the indicated times and probed with WNV hyperimmune ascitic fluid 
and goat anti-mouse IgG 549nm-Dylight conjugated secondary antibody. Images 
are representative of at least three independent experiments. 
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WNV-NY- and WNV-MAD78-infected cultures (144±61, 109±63 WNV+ cells, 
respectively), suggesting that WNV-NY and WNV-MAD78 had similar capacities 
to establish an initial infection within the astrocyte monolayer. However, by 72 
hours post-infection, substantially more WNV-positive HBCAs were detected in 
WNV-NY-infected cultures compared to WNV-MAD78-infected cultures (Figure 
16B compare panels v & vi). Thus, WNV-MAD78 spread within the in vitro BBB 
model was constrained compared to that of WNV-NY.   
 
WNV-MAD78 replication within astrocytes is restricted at multiple 
steps in the virus life cycle. To further investigate the contribution of astrocytes 
in restricting WNV-MAD78 replication within the in vitro BBB, we examined WNV 
replication in HBCAs alone. In contrast to the donor matched HBMVECs utilized 
in Figure 2B and C, WNV-MAD78 infectious particle production in HBCAs was 
lower than that observed for WNV-NY throughout the course of infection (Figure 
17A).  At the point of peak viral production, WNV-MAD78 titers were reduced 
approximately 45-fold (P < 0.005) compared to WNV-NY.  Moreover, the latent 
period prior to the detection of extracellular infectious particles in WNV-MAD78-
infected cultures was prolonged compared to WNV-NY-infected cultures, 
suggesting that WNV-MAD78 replication is delayed in HBCAs.  A similar delay 
and reduction in WNV-MAD78 infectious particle production was observed when 
cultures were infected at an MOI of 2, which established a near synchronous 





Figure 17. WNV replication in HBCAs.  HBCAs were infected with WNV-
NY or WNV-MAD78 (MOI of 0.01). (A) WNV-NY and WNV-MAD78 infectious 
particle production in HBCAs. Culture supernatants were removed at the 
indicated times and titers determined by plaque assay on Vero cells. Values 
represent the average number PFU per mL (+/- standard error) of supernatant 
from at least three separate experiments. Asterisks indicate differences that are 
statistically significant (***p<0.005). (B-D) RNA synthesis of WNV-NY and WNV-
MAD78 in HBCAs. Total RNA was recovered from HBCAs infected as in (A). 
Total (B) and strand-specific (C, positive; D, negative) viral RNA levels were 
determined by qRT-PCR. Values represent the average (+/- standard error) of at 
least three independent experiments. A student’s unpaired t-test was performed 
to determine significance. Asterisks indicate differences that are statistically 
significant (*p<0.05, **p<0.01, ***p<0.005). 
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Accumulation of intracellular viral RNA also was delayed in WNV-MAD78-
infected HBCAs compared to WNV-NY-infected HBCAs (Figure 17B). Thus, the 
prolonged lag period prior to infectious particle production in the supernatants of 
WNV-MAD78-infected HBCAs may be due to a delay in viral RNA replication 
rather than assembly of virus particles. To better define the nature of the delay in 
WNV-MAD78 replication, we assessed the rate of accumulation of both positive 
and negative strand RNA at early times post-infection.  Synthesis of both positive 
and negative strand WNV-MAD78 RNA was delayed compared to that of WNV-
NY (Figure 17C and D), suggesting that WNV-MAD78 replication in astrocytes is 
restricted at an early step in the virus life cycle. 
The delay in synthesis of WNV-MAD78 viral RNA corresponded with a 
decrease in the number of extracellular infectious particles produced per infected 
cell compared to WNV-NY-infected cells at 24 hours post-infection (Figure 18A).  
However, by 48 hours post-infection, WNV-NY- and WNV-MAD78-infected 
HBCAs produced similar levels of infectious particles per cell.   In spite of this, 
the level of total infectious particles detected in WNV-MAD78-infected cultures 
remained substantially reduced compared to WNV-NY throughout the course of 
infection (see Figure 17A), suggesting that factors independent of viral RNA 
synthesis also are involved in restricting WNV-MAD78 replication within 
astrocytes. Indeed, visualization of WNV-infected astrocytes in the BBB co-
culture system indicated that WNV-MAD78 is also limited in cell-to-cell spread 
compared to WNV-NY (Figure 16B, compare panels v & vi).  To confirm these 




Figure 18.  Infectious virions released per cell and cell-to-cell spread in 
HBCAs. HBCAs were infected with WNV-NY or WNV-MAD78 (MOI of 0.01). 
Culture medium was removed at the indicated times and titers determined by 
plaque assay on Vero cells. The number of infected cells within the monolayer 
was determined by flow cytometry.  Cells were removed from the plate by 
trypsinization, fixed with 3% PFA, probed with WNV hyperimmnue serum 
followed by goat anti-mouse IgG 633nm Dylight conjugated antibody and 
subjected to flow cytometry. (A) Infectious particle production per infected cell.  
The number of infectious extracellular particles was determined by dividing viral 
titers by the number of infected cells.  Values represent the averages from three 
independent experiments. A student’s unpaired t-test was performed to 
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determine significance. Asterisks indicate differences that are statistically 
significant (*p<0.05) (B) WNV-positive cells per 105 cells from three independent 
experiments. Values represent the averages from three independent 
experiments. A student’s unpaired t-test was performed to determine 
significance. Asterisks indicate differences that are statistically significant 




infection using flow cytometry (Figure 18B). Low levels of WNV-positive cells 
were detected at 12 hours post-infection in WNV-NY infected cultures.  However, 
antigen-positive cells were not detected in WNV-MAD78-infected cultures until 16 
hours post-infection, which is consistent with the delay in viral replication.  
Importantly, the baseline number of WNV-NY-infected HBCAs at 12 hours post-
infection was comparable to the number of WNV-MAD78-infected HBCAs 
detected at 16 hours post-infection, confirming that both strains are capable of 
establishing an initial infection within the astrocyte monolayer. While the number 
of WNV-NY-positive cells continued to increase throughout the course of 
infection, the number of WNV-MAD78-positive cells remained unchanged.  By 48 
hours post-infection, there was a 15-fold (P < 0.01) increase in antigen-positive 
cells detected in WNV-NY-infected HBCAs compared to WNV-MAD78-infected 
HBCAs.  Overall, our data suggest that WNV-MAD78 is both delayed in initiation 
of viral synthesis in HBCAs and impaired in its ability to spread to neighboring 
cells compared to WNV-NY.  
 
The reduced susceptibility of HBCAs to WNV-MAD78 is independent 
of type-I interferon (IFN).  The restriction to WNV-MAD78 spread within 
astrocytes was suggestive of the paracrine protection of type-I IFNs (120, 121, 
205). Therefore, we examined supernatants recovered from WNV-infected 
HBCAs for the presence of type-I IFNs using a bioassay.  Measureable levels of 
IFN were first detected at 30 and 40 hours post-infection in supernatants 
recovered from WNV-NY and WNV-MAD78-infected HBCAs, respectively 
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(Figure 19A).  Furthermore, infection of HBCAs with WNV-NY induced 
significantly higher levels of IFN compared to WNV-MAD78 at all time points 
examined.  Therefore, the kinetics and amplitude of induction of secreted IFN did 
not correlate with WNV-MAD78’s diminished capacity to spread from cell to cell 
early in infection.  However, WNV-MAD78 is more sensitive to IFN treatment 
than pathogenic strains of WNV in other cell types (127) .  Thus, local levels of 
type-I IFNs surrounding the WNV-MAD78-infected cells may be sufficient to 
inhibit viral spread.  To assess this possibility, we examined viral spread and 
infectious particle production in HBCAs infected with WNV-NY or WNV-MAD78 in 
the presence or absence of neutralizing antibodies to IFN- Figure 19B-
D).  We consistently observed a significant increase in the number of WNV-NY-
infected cells in the presence of neutralizing antibodies to IFN- Figure 
19B).  Additionally, neutralizing antibodies to IFN- - anced 
infectious particle production in WNV-NY-infected HBCAs (Figure 19C & D).  In 
or infectious particle production in WNV-MAD78-infected cells (Figure 19B-D). 
This data suggests that IFN- -NY, but not WNV-





Figure 19. Role of type-I IFN in limited WNV replication and spread in 
HBCAs.  (A) Level of secreted type-I IFN secretion in supernatants recovered 
from WNV-infected HBCAs.  Culture supernatants were removed from HBCAs 
infected with WNV-NY or WNV-MAD78 (MOI of 0.01) at the indicated times post-
infection. IFN levels were determined using a VSV-based bioassay. Values 
represent the level of type-I IFN (IU/mL) (+/- standard error) from a minimum of 2 
independent experiments. A student’s unpaired t-test was performed to 
determine significance. Asterisks indicate differences that are statistically 
significant (**p<0.01, ***p<0.005).  (B-D) The effect of neutralization of type-I IFN 
on WNV spread and replication in HBCAs.  HBCAs were infected with WNV-NY 
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or WNV-MAD78 (MOI of 0.01) and the inoculum replaced with culture media 
containing control antisera or neutralizing antibodies to IFN- -
(B & C) or individually (D). (B) Cells were fixed at 48 hours post-infection with 3-
4% PFA, permeabilized, probed with WNV hyperimmnue serum followed by goat 
anti-mouse IgG 633nm Dylight conjugated antibody and subjected to flow 
cytometry. Values represent the average number of WNV-positive cells per 105 
cells (+/- standard error) from at least two independent experiments. A student’s 
unpaired t-test was performed to determine significance. Asterisks indicate 
differences that are statistically significant (*p<0.05). (C &D) Culture 
supernatants were recovered at 48 hours post-infection and viral titers 
determined by plaque assay on Vero cells.  Values represent the average 
number PFU per mL (+/- standard error) of supernatant from at least two 
separate experiments.  A student’s unpaired t-test was performed to determine 







The naturally occurring diversity in virulence among WNV strains provides 
an excellent model system to define the viral and host factors involved in 
pathogenesis.  To better understand the mechanistic basis for the differential 
neuropathogenicity between WNV strains, we compared the replication of 
pathogenic and nonpathogenic strains of WNV within the various cell types of the 
NVU. Consistent with reports that WNV-MAD78 is neurovirulent when mice are 
infected via intracranial inoculation (253), we observed that WNV-NY and WNV-
MAD78 replicate to equivalent levels in neuronal cells.  This suggests that WNV-
MAD78’s non-neuropathogenic phenotype is due to an inability to access highly 
susceptible neurons under peripheral infection conditions.  Indeed, the non-
neuropathogenic phenotype of some strains of WNV has been attributed to an 
inability to invade the CNS (23, 108, 164). Increasing evidence suggests that 
WNV entry into the CNS is a multistep process that can occur through one of 
several routes (15, 229, 285, 291, 297, 308). WNV entry into the CNS has been 
shown to precede disruption of the BBB and leukocyte infiltration (15, 88, 185, 
291), suggesting that WNV utilizes a direct mechanism to initially invade the 
CNS, such as basolateral secretion of virus particles from infected brain 
endothelial cells or transcytosis. Thus, the brain endothelium likely constitutes a 
primary barrier to WNV neuroinvasion. Using an established endothelial cell line 
that exhibits the physiological characteristics of the brain endothelium (99, 115, 
264, 265, 283, 312 ) and primary brain endothelial cells, we have demonstrated 
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that WNV-MAD78 can replicate in and traverse the brain endothelium as 
efficiently as WNV-NY. Our findings are consistent with reports that high and low 
neuropathogenic strains of Semliki Forest virus replicate to equivalent levels in 
endothelial cells (77, 260), suggesting that the capacity to cross the BBB is not 
always the determining factor for neuropathogenicity.  
The initial invasion of WNV into the CNS brings the virus into close 
proximity with the second component of the BBB, astrocytes.  Indeed, infected 
astrocytes have been detected in some fatal human cases of WNV encephalitis, 
suggesting that these cells are also targeted by WNV in vivo (282). We observed 
both a delay in the kinetics of WNV-MAD78 replication and a reduction in peak 
infectious particle production in astrocytes compared to WNV-NY.  Since the 
astrocyte and primary brain endothelial cells lines used in this study were 
recovered from the same donor, it is unlikely that the constrained replication of 
WNV-MAD78 in HBCAs was due to a donor-specific restriction.  Further 
comparison of the growth characteristics of WNV-NY and WNV-MAD78 in 
HBCAs indicated that both strains were capable of establishing an initial infection 
within this cell type.  However, accumulation of viral protein and RNA was 
delayed in WNV-MAD78-infected HBCAs compared to WNV-NY. Analysis of 
kinetics of accumulation of viral positive and negative strand RNA indicated that 
the delay in WNV-MAD78 replication was at, or prior to, the initiation of negative 
strand synthesis. However, it is unlikely that a delay in viral replication alone 
would result in the significant reduction in peak viral titers observed in WNV-
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MAD78-infected HBCAs, suggesting that an additional factor(s) is involved in 
restricting WNV-MAD78 accumulation in astrocytes.  
 The host innate antiviral response plays a pivotal role in controlling WNV 
replication in many cell types (56, 82, 127, 144, 230, 270).  This response 
consists of a direct IRF-3-dependent and an indirect IFN-dependent mechanism, 
which function to constrain viral replication within the infected cell and prevent 
viral spread to neighboring cells, respectively.    Measureable levels of type-I IFN 
were detected in supernatants recovered from both WNV-NY- and WNV-MAD78-
infected HBCAs.  However, significantly higher levels of IFN were detected in 
WNV-NY-infected HBCAs, which corresponded with the increased replication 
and spread of this strain within the monolayer.  Moreover, the high levels of IFN 
induced by WNV-NY, specifically IFN-
in astrocytes. In contrast, the low levels of IFN induced by WNV-MAD78 late in 
infection did not substantially restrict replication or spread within astrocytes.  
In addition, the observation that WNV-NY- and WNV-MAD78-infected 
HBCAs produced equivalent levels of infectious particles per cell at 48 hours 
post-infection suggests that the IRF-3-dependent arm of the host antiviral 
response does not differentially restrict WNV-NY and WNV-MAD78 replication 
within infected cells.  Furthermore, induction of the direct IRF-3 target proteins 
ISG15 and ISG56 in HBCAs corresponded with the rate of WNV-NY and WNV-
MAD78 replication (data not shown), indicating that WNV-MAD78 does not 
preferentially induce antiviral programs within the infected cell.  Combined, these 
data suggest that the restriction to WNV-MAD78 replication and spread in 
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astrocytes occurs prior to the induction of the host antiviral response. Therefore, 
the host antiviral response appears to play a minimal role in the reduced 
susceptibility of astrocytes to WNV-MAD78.  
Determining both the viral and host cell factors involved in constraining 
WNV-MAD78 replication in astrocytes will be necessary to fully elucidate the 
nature of the restriction of WNV-MAD78.  One possible viral factor is the 
presence of specific N-linked glycans on the envelope protein, which correlates 
with the ability to invade the CNS (23, 24, 31).  WNV-MAD78 lacks this 
glycosylation site; thus, our data suggest that glycosylation is not a determining 
factor in the initial infection of brain endothelial cells or subsequent replication in 
neurons. Consistent with this, WNV-MAD78 replicates efficiently in neurons when 
introduced directly into the brain by an intracranial route (253). Experiments are 
currently underway to determine whether glycosylation contributes to WNV 
replication and/or spread in astrocytes.  
We hypothesize that the constrained replication of WNV-MAD78 in 
astrocytes has several effects on WNV-mediated neuropathology. First, the 
restricted replication of WNV-MAD78 in astrocytes may minimize the initial 
amplification of virus and reduce the rate of spread within the CNS, thus allowing 
more time for the host innate and adaptive immune responses to clear the virus 
prior to widespread infection of highly susceptible neurons.  Second, as with 
other disease states, WNV infection induces astroctyes to release neurotoxic 
factors that exacerbate neuropathology (282).  Therefore, suppression of viral 
replication within astrocytes may reduce the extent of bystander cell death of 
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uninfected neurons. The combined effects of reduced replication in astrocytes 
and decreased production of neurotoxic molecules is consistent with reports that 
mortality is delayed and reduced in mice infected with WNV-MAD78 via 
intracranial inoculation (253).  
Studies with Icam1-/-, Mmp9-/- or Drak2-/- mice suggest that WNV 
undergoes a second round of entry and dissemination within the CNS as a result 
of recruitment of infected leukocytes and/or perturbation of the BBB (57, 292, 
295). There is circumstantial evidence that astrocytes contribute to the second 
wave of WNV neuroinvasion through the upregulation of MMPs, which disrupt the 
BBB, and proinflammatory cytokines, which recruit infected leukocytes (282, 
284). Indeed, propagation within astrocytes, neurons, and glial cells prior to the 
breakdown of the BBB is believed to be a common strategy of neuroinvasive 
viruses, including tick-borne encephalitis virus and HIV, to enhance 
dissemination within the CNS (75, 223). Therefore, the inability of WNV-MAD78 
to replicate in astrocytes may limit the capacity of the virus to undergo a second 
round of entry into the CNS (15, 291). Thus, astrocytes may play a central role in 
both the initial dissemination of WNV to the CNS as well as secondary waves of 
spread, which are likely to exacerbate WNV-mediated neuropathology. 
Overall, our data suggest that WNV-MAD78 is capable of invading the 
CNS. However, the inability to amplify and spread within astrocytes may block 
WNV-MAD78 dissemination to neurons. Furthermore, our findings suggest that 
astrocytes play an essential role in initiating and regulating WNV infection in the 
CNS, and may act as a critical determinant of differential WNV neuropathology.  
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Determining which astrocyte factors limit WNV infection may ultimately promote 












 Maturation of flaviviral particles is the final step prior to release from the 
cell. However, complete maturation of the viral particle does not need to occur for 
flaviviral particles to be infectious. Previously, we observed that a 
nonneuropathogenic strain of WNV, WNV-MAD78, was restricted in cell-to-cell 
spread in astrocytes compared to a neuropathogenic strain, WNV-NY. After 
determining that the restriction in infectious particle production for WNV-MAD78 
in astrocytes was not a result of a differentially-induced host factor, we 
investigated the role of maturation of WNV in astrocytes. When furin inhibitor was 
added during WNV-MAD78 infections in astrocytes to block viral particle 
maturation, an increase in infectious particles was observed. To examine the 
contribution of viral factors that contribute to the state of the mature virion, we 
constructed recombinant viruses containing the structural proteins from WNV-
MAD78 and nonstructural proteins from WNV-NY. Indeed, we observed a 
restriction in infectious particle production in astrocytes similar to that of WNV-
MAD78. Recombinant viruses constructed with the structural proteins from WNV-
NY and nonstructural proteins from WNV-MAD78 replicated to levels similar to 
that of WNV-NY in astrocytes. Thus, processing of the virion in astrocytes 
restricts infectious particle production for WNV-MAD78, and may play a role in 





West Nile virus (WNV) is a positive sense, RNA virus in the Flaviviridae 
family. All members of the Flaviviridae undergo viral particle modification and 
processing in the ER and trans-Golgi. Both prM and the envelope are 
glycosylated in the ER, and these carbohydrate moieties are further modified in 
the trans-Golgi. Final cleavage of prM by the cellular protease furin induces a 
conformational change in the envelope proteins and the global structure of the 
virion (262). While mature viral particles are considered more infectious than 
immature viral particles, processing of the virion in many cases is incomplete. 
Partially mature particles are capable of initiating infection (53, 192). Yet how 
cell-specific expression of enzymes that contribute to particle processing within 
permissive cells contributes to limiting cell-to-cell spread remains unknown.  
Since its introduction into the Western hemisphere in 1999, WNV has 
been the causative agent of over 15,000 cases of neurological disease 
{webpage,  #7067}. Neurological symptoms include meningitis, encephalitis, and 
poliomyelitis; all of these symptoms are caused by the death of neurons within 
the CNS. During WNV infection, neuronal cell death may be due to viral 
replication and/or bystander death due to the production of neurotoxic factors by 
other cells within the CNS. How some strains of WNV cause severe 
neuropathology and others do not is not fully understood.   
 WNV primarily enters the CNS via the hemaotgenous route by crossing 
the blood-brain barrier (BBB) (117, 285). The BBB is a highly restrictive barrier 
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that protects the CNS from aberrant immune responses and pathogens in the 
periphery. It is comprised of endothelial cells that line the cerebral vasculature 
and astrocytes in direct contact with endothelial cells within the CNS. Endothelial 
cells in the CNS contain cell-to-cell junctions that are tighter than their peripheral 
counterparts, while astrocytes act as physical supports for endothelial cells (1). In 
addition, astrocytes help to maintain homeostasis in the CNS by regulating the 
permeability of the BBB and by taking up excess neurotransmitters (118). 
Beyond the BBB lie sensitive neuronal cells that are responsible for controlling all 
physiological systems within the body.  
Responses to viral infection within astrocytes have been given much 
recent attention. Further, viral replication in astrocytes may have implications in 
physiological outcomes during viral infection of the CNS (5, 209).  Previously, we 
demonstrated that both a neuropathogenic strain, WNV-NY, and a 
nonneuropathogenic strain, WNV-MAD78, of WNV are capable of establishing a 
productive infection within astrocytes. However, WNV-MAD78 exhibited a delay 
in viral replication and an IFN-independent restriction in cell-to-cell spread within 
astrocytes.  
Here we explore the cellular and viral factors involved in restricting WNV-
MAD78 replication within astrocytes. Examination of the intrinsic immune 
response indicated that these classical antiviral pathways were not responsible 
for the differential replication of WNV-NY and WNV-MAD78 within astrocytes. An 
examination of WNV particles indicated that WNV-NY particles were significantly 
more infectious than WNV-MAD78 particles derived from astrocytes, suggesting 
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that the decreased viral spread in astrocytes may be due to the increased 
production of defective particles by WNV-MAD78. Examination of endogenous 
furin expression and activity in astrocytes indicated that this cell type expressed 
higher levels of furin than cell types where WNV-NY and WNV-MAD78 replicate 
to equivalent levels, suggesting that a decrease in viral maturation is not 
responsible for the reduced infectivity of WNV-MAD78.  
In order to identify the viral factors responsible for the cell type-specific 
restriction of WNV-MAD78, we assessed the replication of a series of 
recombinant viruses in astrocytes. While neither glycosylation of the envelope 
protein nor the entire nonstructural region were sufficient to reduce spread, 
replacement of the structural genes of WNV-NY with those of WNV-MAD78 was 
sufficient to restrict infectious particle production in astrocytes. The following 
study identifies novel mechanisms, both host and viral, by which 
nonneuropathogenic strains may be restricted in infectious particle production in 
astrocytes and, therefore, restricted in neuropathogenesis.   
 
Results 
WNV-MAD78 replication in astrocytes is not restricted by a secreted host 
factor 
 Since WNV-MAD78 replication and spread is delayed in astrocytes 
compared to WNV-NY, and the spread is type-1 IFN independent (117), we 
hypothesized that an additional host factor may restrict WNV-MAD78 replication 
and spread. Several secreted factors, including chemokines, cytokines, and 
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reactive nitrogen and oxygen species (RNS and ROS), as well as astrocyte-
specific activation, have previously been identified as host factors that restrict 
viral replication (179, 209). To further examine all secreted factors during WNV 
infection in astrocytes, astrocytes were pre- and post-treated with supernatants 
from previous infections at 48h, and infectious particle production was examined 
(Figure 20 A and B). Because type-1 IFN is secreted and restricts WNV-NY cell-
to-cell spread in astrocytes (117), antibodies to type-1 IFN were added to the 
supernatants with which the cells were treated to negate the effect of type-1 IFN. 
Still, no decrease in infectious particle production was observed for WNV-
MAD78-infected astrocytes, suggesting that the restriction to WNV-MAD78 
infectious particle production in astrocytes is not due to a preferentially induced 
antiviral state compared to WNV-NY-infected astrocytes.  
 
Astrocyte-derived WNV-MAD78 particles are less infectious than WNV-NY 
particles 
 Because the restriction for the infectious particle production of WNV-
MAD78 in astrocytes was not due to a preferentially induced antiviral state 
compared to WNV-NY-infected astrocytes, we examined infectivity of viral 
particles produced during infection in astrocytes. When the amount of viral RNA 
present in the supernatant (genome equivalent) was compared to the infectious 
particle production (plaque forming units) during WNV infection of astrocytes, 
WNV-NY had a significantly lower GE/PFU ratio compared to WNV-MAD78 




Figure 20. WNV-MAD78 replication in astrocytes is not restricted via 
canonical pathways. HBCAs were pretreated (6h) with supernatants from a 
previous infection in HBCAs (+/- antibodies to type-1 IFN) and infected with either 
(A) WNV-NY or (B) WNV-MAD78 (MOI=0.01). After inoculum was removed, cells 
were post-treated with supernatants (+/- antibodies to type-1 IFN) as described in 
materials and methods and 24hpi supernatants were collected and plaque 
assays were performed in Vero cells. Data presented is an average (+/- standard 
error) of 3 independent experiments.  
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 Figure 21. WNV-MAD78 particles derived from astrocytes are less 
infectious than WNV-NY particles derived in astroyctes. (A) HBCAs were 
inoculated with WNV-NY or WNV-MAD78 (MOI=0.01) and at 24 and 48hpi, 
supernatants were collected. Similarly, (B) HBMECs were inoculated with WNV-
NY or WNV-MAD78 (MOI=0.1) and at 24hpi and 48hpi, supernatants were 
collected. For both cell types, plaque assays were performed in Vero cells to 
determine infectious viral particle production (PFUs). RNA was isolated from the 
supernatant and subjected to qRT-PCR with primers specific for each virus 
(genomic equivalent, GE). The ratio of viral RNA present in the supernatant to 
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infectious viral particle is displayed. Data presented is an average (+/- standard 
error) of at least 3 independent experiments. (C) HBCAs were inoculated 
(MOI=0.01). At 48hpi, supernatants were collected, and the viral titer was 
determined in the supernatants both by plaque assay in Vero cells and focus 
forming assays in HBCAs. Data presented is the ratio of the viral titer on Vero 
cells to the viral titer on HBCAs, and is the average (+/- standard error) of 3 





in WNV-NY-infected astrocytes are more infectious and therefore more likely to 
infect neighboring cells than the particles produced in WNV-MAD78-infected 
astrocytes.  
 Previously we demonstrated that WNV infection of endothelial cells was 
equivalent for both neuropathogenic and nonneuropathogenic strains of WNV 
(117). To further assess the infectivity of WNV particles produced during 
astrocyte infection, we compared the infectivity (GE/PFU) of astrocyte and 
endothelial cell derived virus particles (Figure 21B). WNV-NY- and WNV-
MAD78-infected endothelial cells produced particles that were equivalently 
infectious. Further, particles produced in endothelial cells were more infectious 
than those produced during infection in astrocytes (Compare GE/PFU ratio on 
21A vs B), which may account for the lower overall peak viral titers in astrocytes 
compared to endothelial cells for both strains.    
 To further examine WNV-MAD78 particles derived in astrocytes, focus-
forming assays were performed on astrocytes to assess the ability of astrocyte-
derived virus to infect astrocytes. Because these supernatants are from a late 
time during infection (48h), the particles are exclusively derived from astrocytes. 
The viral titer of these supernatants on astrocytes was then compared to the viral 
titer of the supernatant on Vero cells, thus examining the cell-specific infectivity in 
astrocytes (Figure 21C). When the Vero titer:astrocyte titer ratio of WNV-MAD78 
particles was compared to WNV-NY particles treated in the same manner, we 
observed that WNV-MAD78 viral particles did not infect HBCAs as efficiently as 
108 
  
WNV-NY particles. Together with the particle:PFU ratio, these data suggest that 
WNV-MAD78 viral particles are less infectious in astrocytes compared to WNV-
NY particles, and may contribute to their inability to spread from cell to cell.  
  
WNV-MAD78 infectious particle production is partially limited by furin 
activity in astrocytes 
 Infectivity of viral particles is thought to be a function of viral maturation; 
immature viral particles are still infectious, but to a lesser degree than completely 
mature particles (53). Since there was a significant difference in the infectivity of 
the astrocyte-derived particles compared to endothelial cell-derived WNV 
particles, we hypothesized that there were cell-type dependent differences in the 
processing of WNV particles. Since furin is involved in maturation of the WNV 
particle, we examined the activity of furin in both endothelial cells and astrocytes 
(Figure 22A). Furin activity was greater in astrocytes compared to endothelial 
cells, suggesting that WNV maturation may be more efficient in astrocytes 
compared to endothelial cells.  Surprisingly, inhibition of furin in astrocytes led to 
increased infectious particle production for WNV-MAD78-infected astrocytes 
(Figure 22B), suggesting that higher levels of particle maturation in astrocytes 
may be detrimental to WNV-MAD78.  





Figure 22. Furin activity in astrocytes is greater than that in endothelial 
cells and plays a role in inhibiting WNV-MAD78 infectious particle 
production. (A) The same number of HBCAs and HBMECs were lysed in lysis 
buffer (Triton-X100 0.5%, 0.5mM CaCl2, 100mM HEPES pH 7.0) and along with 
recombinant furin, recombinant furin with inhibitor (5mM), or assay diluent alone, 
assayed for furin activity according to the process described in the materials and 
methods. Data is representative of activity assays performed at least twice. (B) 
HBCAs were inoculated with either WNV-NY or WNV-MAD78 and after 
inoculation, media with or without furin inhibitor (Dec-RVKR-CMK diluted in PBS, 
5mM).  For detailed materials and methods on inhibition of furin in astrocytes, 
please see materials and methods. At 48hpi, supernatants were collected and 
110 
  
subjected to plaque assays performed on Vero cells. Data presented is an 




WNV structural proteins contribute to infectious particle production in 
astrocytes  
 
One of the consequences of maturation of WNV particles is cleavage and 
release of prM. Several identified cellular attachment factors for WNV, such as 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin 
(DC-SIGN) and DC-SIGNR, specifically bind carbohydrate moieties (60). WNV-
MAD78 contains only one glycosylation site, in prM, while WNV-NY contains this 
same site and an additional glycosylation site in the envelope protein. However, 
the prM glycosylation site is cleaved off during maturation of the viral particle. 
Therefore, WNV-MAD78 particles in astrocytes may contain fewer carbohydrate 
moieties within the virion, and may be unable to bind attachment factors on 
neighboring cells.  We hypothesized that glycosylation of the envelope 
contributes to WNV spread within astrocytes, and therefore increased 
neurological disease associated with pathogenic strains of WNV. Recombinant 
viruses were generated that introduced the glycosylation site into the envelope 
protein for WNV-MAD78 and removed the site from WNV-NY (Figure 23A). 
Modifications to the glycosylation site did not increase WNV-MAD78 replication 
nor decrease WNV-NY replication in astrocytes.  Next, we examined 
recombinant viruses comprised of either WNV-MAD78 structural proteins and 
WNV-NY nonstructural proteins (WNV-MAD78 S/WNV-NY NS) or WNV-NY 
structural proteins and WNV-MAD78 nonstructural proteins (WNV-NY S/WNV-




Figure 23.  Structural proteins of WNV contribute to infectious particle 
production in astrocytes. HBCAs were infected with either WNV-NY, WNV-
MAD78 (displayed in all figures), WNV-NY S156P, WNV-MAD78P156S (A), 
WNV-MAD78/UTR NY (B), WNV-MAD S/WNV-NY NS, or WNV-NY S/WNV-
MAD78 NS (C) at an MOI=0.01. At the times indicated, viral supernatants were 
collected and plaque assays done in Vero cells. Data presented is an average 
(+/- standard error) of at least 3 independent experiments.  The (*) represents 
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data significantly different from WNV-NY, while the (Δ) represents data 




astrocytes (Figure 23 B). The production of infectious viral particles was delayed 
for both recombinant viruses.  However, WNV-NY S/WNV-MAD78 NS infectious 
particle production reached levels similar to WNV-NY at 24 hours post infection. 
In contrast, WNV-MAD78 S/WNV-NY NS remained restricted in infectious 
particle production compared to WNV-NY, although viral titers were higher than 
WNV-MAD78 at 48 hours post-infection. Together, these data suggest that the 
structural proteins contribute to the restriction in infectious particle production of 
WNV-MAD78 in astrocytes. In addition, these data support our hypothesis that 
viral particle processing and the components of the virion in astrocytes plays a 
role in the ability for pathogenic strains to spread from cell to cell.  
 
Discussion 
 The mechanistic basis for the differential neuropathology induced 
by various strains of WNV remains unknown. Our studies examine astrocyte-
specific host responses to strains of WNV that vary in their abilities to induce 
neuropathogenicity. We have previously shown that the restriction in cell-to-cell 
spread for WNV-MAD78 was independent of type 1 IFN (117). Although WNV-
MAD78 has been shown to be more sensitive to type-1 IFN than WNV-NY in vivo 
(127). However, WNV-MAD78 cell-to-cell spread in astrocytes is restricted prior 
to the activation of the antiviral response, suggesting that although type-1 IFN 
may restrict WNV-MAD78 replication in other cell types, WNV-MAD78 cell to cell 
spread in astroyctes is not efficient enough where type-1 IFN plays a role. In 
addition to type 1 IFN, other host immune responses, such as glial fibrillary acidic 
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protein (GFAP) activation and nitrous oxide production, were examined in 
astrocytes to assess if they were differentially regulated during WNV-MAD78 
infection in astrocytes (data not shown). GFAP expression is a classical indicator 
of highly responsive astrocytes (72), and increased expression of GFAP has 
been shown in astrocytes infected at a high MOI with a highly pathogenic strain 
of WNV (284). However, we failed to detect increased GFAP expression for 
WNV-infected cells. Further, WNV infection did not upregulate GFAP expression 
in astrocytes, suggesting that astrocyte activation does not play a role in 
restricting nonneuropathogenic WNV infection in astrocytes. Junin virus 
replication in astrocytes is restricted by reactive nitrogen species produced 
during infection (209). However, inhibition of inducible nitric oxide synthetase 
(iNOS) did not lead to increased cell-to-cell spread for WNV-MAD78 (data not 
shown). Further, restricted infectious particle production of WNV-MAD78 was 
independent of any secreted factor.  These data did not address the delay in 
initiation of replication for WNV-MAD78 compared to WNV-NY in astrocytes, 
where astrocytes may contribute a cell-specific component. It is very likely that 
astrocyte-specific intracellular components promote replication and contribute to 
the delay in initiating replication in WNV-MAD78-infected astrocytes compared to 
WNV-NY-infected astrocytes. More extensive studies can assess these factors 
and the delay for WNV-MAD78 in initiating replication in astrocytes.  Together, 
these data demonstrate that the restriction in cell-to-cell spread for WNV-MAD78 
compared to WNV-NY is likely independent of a differentially expressed host 
factor in astrocytes.  
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 Since host responses to WNV infection in astrocytes did not appear to 
contribute to the restriction in cell-to-cell spread for WNV-MAD78 in astrocytes, 
we examined the contribution of the viral particles produced during astrocyte 
infection and the ability to infect neighboring astrocytes. To assess whether there 
were deficiencies in astrocyte-derived viral particles, we examined both the 
particle:PFU ratio and compared the infectivity of astrocyte-derived particles on 
astrocytes and Vero cells. Both of these assays demonstrated that WNV-MAD78 
particles derived in astrocytes are less infectious compared to WNV-NY particles. 
Thus, the host response may not be restrictive to WNV-MAD78, but rather, the 
viral particle itself is less infectious. WNV processing in cells occurs in the ER 
and involves several glycosidases that glycosylate specific moieties on both prM 
and, in some cases, the envelope protein. In the trans-Golgi, these 
carbohydrates are further modified and the cellular protease furin, which cleaves 
off the glycosylated moiety in prM to be released in the extracellular milieu during 
maturation of the particle.  Only pathogenic strains of WNV are glycosylated at 
this envelope residue (13, 24, 237), leading us to hypothesize that it may play a 
role in restricting cell-to-cell spread in astrocytes.  Previous data suggests that 
mature particles are more infectious than immature particles (53). Surprisingly, 
furin activity in astrocytes was higher compared to activity in other cell types, 
such as endothelial cells, where there is no difference in infectious particle 
production between WNV-NY and WNV-MAD78 (117). When furin was inhibited 
throughout infection in astrocytes, we observed an increase in the number of 
infectious viral particles produced for WNV-MAD78 compared to infections 
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without inhibitor. However, WNV-NY titers were not affected. These data further 
suggested that enhanced viral processing may be detrimental to WNV-MAD78 
replication in astrocytes and may contribute to the inability for WNV-MAD78 to 
spread from cell to cell.  
While viral egress and release is an important step in WNV infection, 
subsequent binding to neighboring cells and entry into a naïve cell is necessary 
for perpetuation. Several viral attachment factors have been suggested to play a 
role in WNV entry (50, 60, 176). In particular, DC-SIGNR and DC-SIGN are 
capable of promoting WNV infection in some cell types. However, we did not find 
an increased expression of either of these two molecules in astrocytes compared 
to highly permissive cells (data not shown). Since these receptors bind 
carbohydrate moieties, we hypothesized that the glycosylation, and therefore 
maturation, state of the viral particle may play an important role in cell-to-cell 
spread in astrocytes. Glycosylation of the envelope during WNV infections has 
been found to improve viral assembly and egress, and contributes to increased 
neuropathogenesis in mouse models (106). However, equivalent total particle 
production was detected for WNV-NY and WNV-MAD78 in astrocytes, 
suggesting that the restricted cell-to-cell spread of WNV-MAD78 was due to the 
production of defective particles rather than a decrease in particle production. 
Since glycosylation of other types of viral particles, such as HIV (320), has been 
shown to affect viral entry and cell-to-cell spread, we constructed recombinant 
viruses that exchanged residues in the glycosylation motif between WNV-NY and 
WNV-MAD78. However, these recombinant viruses replicated similar to their 
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parental counterparts, and glycosylation did not alone account for the reduction 
in infectious particle production during infection of astrocytes. Yet at 72hpi, 
infectious particle production of the WNV-NY S156P recombinant virus 
decreased to levels similar to WNV-MAD78. Thus, while glycosylation may not 
play a role in cell-to-cell spread in astrocytes, it may contribute to the stability of 
the viral particle. In contrast, recombinant viruses containing the structural 
proteins from WNV-MAD78 and the nonstructural proteins from WNV-NY 
replicated similar to WNV-MAD78, suggesting that the structural components 
alone were sufficient to restrict infectious particle production in astrocytes. How 
the structural genes contribute to the restriction in spread is still left to be 
uncovered. It is likely that factors other than glycosylation on the envelope 
protein within the virion are able to bind to subsequent astrocytes, and therefore 
contribute to the restriction in cell-to-cell spread for WNV-MAD78. Further 
experiments are necessary to assess the contribution of individual proteins within 
the particle and specific residues contribute to the restriction of cell-to-cell spread 
for WNV-MAD78 in astrocytes.  
While the structural proteins appear to play a role in the restriction of cell-to-
cell spread in astrocytes, viral replication and capability to cause 
neuropathogenesis in vivo has yet to be described. Although preliminary studies 
have been done in mice with recombinant viruses similar to the ones synthesized 
in these studies (269), these studies did not examine neuropathology. Further 
studies in vivo will also clarify the contribution for viral replication in astrocytes in 
promoting or restricting WNV neuropathology. In addition, the host responses 
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elicited to the viral chimeras that may contribute to neuropathology also needs to 
be assessed. The recombinant viruses synthesized could be used as a tool to 
further assess viral factors that contribute to the astrocyte-specific delay in 
initiation in viral replication for WNV-MAD78. These recombinant viruses may 
aide in identifying the astrocyte-specific factors that inhibit viral replication 
compared to other cell types. Astrocyte-specific factors may therefore serve as 
novel therapeutic targets in limiting severe CNS neuropathologies. 
This study examined both host and viral determinants contributing to the 
restriction in WNV-MAD78 replication and spread within astrocytes. Previously, 
we hypothesized that all strains of WNV may be able to enter into the CNS. 
However, in astrocytes, WNV replication is restricted for nonneuropathogenic 
strains of WNV both at the level of initiating replication as well as cell-to-cell 
spread. Since differential host responses did not contribute to the restriction in 
infectious particle production for WNV-MAD78-infected astrocytes, we 
hypothesized a novel role for cellular processing specific to nonneuropathogenic 
viruses and in restricting cell-to-cell spread. Indeed, we observed that cellular 
processing by furin was sufficient to inhibit infectious viral particle production in 
astrocytes for nonneuropathogenic WNV, and when furin was inhibited, 
nonneuropathogenic strains produced increased amounts of infectious viral 
particles. In examining which viral components contributed to the restriction in 
infectious particle production, we observed that the strain that the structural 
genes are derived from determines the amount of infectious particles produced in 
astrocytes, suggesting that structure and processing of the virion may play a role 
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in inducing WNV neuropathogenesis. These novel insights provide both targets 
for development in therapeutics as well as possible candidate vaccines. Further 
research into what types of immune responses occur during infection in 
astrocytes with the recombinant viruses and how they likewise contribute to 
spread in other cell types of the CNS will expand the in vitro model for WNV 
infection of the CNS.  
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The neuroinflammatory response to West Nile virus (WNV) infection can 
be either protective or pathological depending on the context. Though several 
studies have examined chemokine profiles within brains of WNV-infected mice, 
little is known about how various cell types within the central nervous system 
(CNS) contribute to chemokine expression. Here, we assessed innate immune 
responses in cell types in brain microvascular endothelial cells and astrocytes, 
which comprise the major components of the blood-brain barrier (BBB), in 
response to avirulent (WNV-MAD78) and highly virulent (WNV-NY) strains of 
WNV. Intrinsic innate immune responses to both strains of WNV were activated 
with similar kinetics in both endothelial cells and astrocytes. While WNV-MAD78-
infected endothelial cells established a more pronounced chemokine gradient 
compared to WNV-NY-infected endothelial monolayers, the chemokine profile 
was disrupted when endothelial cells were co-cultured in the presence of 
astrocytes. WNV-NY-infected astrocytes also expressed higher levels of 
chemokines compared to WNV-MAD78-infected astrocytes. Chemokine 
expression was functional in both endothelial cell monolayers alone or cocultured 
with astrocytes, as increased monocyte adhesion was observed in WNV-MAD78-
infected endothelial cell layers, but WNV-NY infected cocultures exhibited 
increased transmigration of monocytes through the coculture model. Combined 
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these data suggest that cells comprising the BBB contribute to a dynamic 
proinflammatory response that evolves as WNV infection progresses.  
 
Introduction 
West Nile virus (WNV) is a positive-strand, RNA virus in the family 
Flaviviridae. Initially identified in sub-Saharan Africa in 1937, WNV infection 
typically resulted in a mild febrile disease, though rare neurological complications 
were reported.  In contrast, the emergence of WNV in the Western hemisphere in 
the 1990s has been associated with an increased rate of meningitis, encephalitis, 
and acute flaccid paralysis (http://www.cdc.gov/ncidod/dvbid/westnile/index.htm), 
making WNV the leading cause of mosquito-borne neuroinvasive disease in the 
United States.  Recent outbreaks have also occurred in other parts of the world, 
including Eastern and Western Europe (199, 200), suggesting that WNV 
continues to impact global health. Nevertheless, no WNV-specific antiviral 
therapies or vaccines exist for humans. A greater understanding of the 
mechanistic basis for the differential neuropathogenicity among WNV strains may 
provide insights into the development of new therapies for the treatment of WNV 
neuroinvasive disease.  In addition, assessment of the kinetics of the immune 
response to WNV strains that vary in pathogenicity within various cell types of the 
CNS may reveal additional mechanisms that contribute to neuropathology.  
 Recognition of viral moieties by pattern recognition receptors (PRRs) 
induces several signaling cascades that lead to the direct transcription of antiviral 
genes, proinflammatory cytokines and chemokines (4). Antiviral gene products 
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function in several ways, including directly cleavage of viral RNA, inhibition of 
protein synthesis, and amplification of the antiviral response However, TLR3-/- 
mice may experience decreased levels of WNV replication in the CNS compared 
to wild type mice, suggesting that not all antiviral responses to WNV infection are 
beneficial to the host (297).  How viral infections initiate an innate immune 
response within the CNS is just beginning to be uncovered. 
Recently it has been demonstrated that CNS immune responses differ 
from immune responses in the periphery (254). Under normal homeostatic 
conditions, the CNS is an immune specialized compartment with limited 
leukocyte infiltration.  This is due in large part to the restrictive nature of the 
blood-brain barrier (BBB). The BBB is comprised of specialized endothelial cells, 
which line the cerebral microvasculature, and the foot processes of astrocytes, 
which envelop >99% of the endothelium.  The complex intercellular tight 
junctions between endothelial cells at the BBB form 50-100x tighter seals 
compared to their peripheral counterparts, severely restricting paracellular 
movement of solutes and circulating immune cells (1). 
In addition to the innate intracellular immune response within cells of the 
BBB preventing spread of viral infection, cell types of the BBB are involved in 
mobilizing the cellular immune response. Proinflammatory cytokines mobilize the 
cellular immune response to the site of infection. The cellular response either 
leads to clearance of infected cells and free virus and serves as a perpetuator of 
long term-immunity. One specific class of antiviral cytokines, type-1 IFNs, amplify 
the antiviral response by acting in both an autocrine and paracrine fashion to 
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prevent viral cell-to-cell spread (120, 121). The innate intracellular antiviral 
response to WNV infection has been characterized in several cell types in vitro 
and in vivo (127, 144, 226, 230, 271). For example, IFNAR-/-.mice experience 
higher levels of replication of WNV in all tissues and have markedly decreased 
survival during WNV infection with either pathogenic or nonpathogenic strains 
compared to wild type mice. As with many neuroinvasive pathogens, WNV 
induces expression of additional proinflammatory cytokines within the CNS  (15, 
92, 131, 152, 246).Chemokines are another specialized class of cytokines that 
function by forming gradients to attract circulating leukocytes to the site of 
infection. WNV infection in the CNS induces chemokine expression (92). 
Moreover, chemokine expression was higher in the brains of mice inoculated with 
a neuropathogenic strain of WNV compared to mice inoculated with a 
nonneuropathogenic strain of WNV at late times during infection (246). Thus, 
chemokine expression leading to leukocyte infiltration may contribute to WNV-
mediated neuropathologies.  
Despite the restriction to pathogens and immune responses at the BBB, 
one of the hallmarks of WNV encephalitis is the infiltration of inflammatory 
leukocytes into the central nervous system (CNS) (197). The process of 
leukocyte infiltration into infected tissue is a highly regulated, multistep process 
mediated by a family of chemoattractant cytokines known as chemokines (40, 
183). Recruitment of leukocytes to the site of infection can be divided into two 
phases: the initial attraction and movement of immune cells across the 
endothelial layer and the subsequent migration within the infected tissue. The 
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first step in the recruitment of leukocytes, crossing the endothelial layer, is 
mediated by solid phase gradients formed by chemokines binding to anchored 
sugar residues or scavenger receptors on endothelial cell surfaces (183). 
Immobilized chemokines expressed on endothelial cells attract leukocytes, which 
initially undergo selectin-dependent tethering and rolling.  Binding of immobilized 
chemokines to their cognate receptors on leukocytes activates integrins on the 
surface of leukocytes. Integrins bind to cell adhesion molecules present either on 
endothelial cells or cells directly in contact with the endothelium in the basolateral 
surface, thereby promoting firm attachment to the endothelial cell layer. 
Chemokine gradients established within endothelial cells also direct migration of 
leukocytes across the endothelial monolayer (diapedesis) (40, 183).   While entry 
of circulating leukocytes into infected tissues or organs is critical for controlling an 
invading pathogen, aberrant or unregulated entry can have pathological 
consequences. 
Determining which cell types in the CNS initiate chemokine production in 
response to pathogenic and nonpathogenic strains of WNV may facilitate 
development of therapies to modulate the process of neuroinflammation. 
Therefore, we examined the antiviral response within cell types of the BBB, 
including induction of ISGs, cytokines, and chemokines that may modulate the 
cellular response to WNV infection in the CNS. Two strains of WNV that vary in 
their capacity to induce neuropathology, WNV-NY, a neuropathogenic strain, and 
WNV-MAD78, a nonneuropathogenic strain, were utilized to determine strain-
specific contributions to neuroinflammation. Treatment of human brain 
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microvascular endothelial cells (HBMECs), with TNFα during or prior to infection 
had no effect on WNV replication. In contrast, WNV replication was delayed in 
HBMECs treated with type-1 IFN.  Post treatment of type-1 IFN was less 
restrictive to viral replication for WNV-NY compared to WNV-MAD78 in HBMECs. 
When the innate intracellular antiviral response to WNV infection in astrocytes 
was compared to that in endothelial cells, astrocytes displayed a more robust 
innate antiviral response. We also assessed the chemokine response of WNV-
infected HBMECs and human brain cortical astrocytes (HBCAs). WNV-MAD78-
infected endothelial cell monolayers expressed higher levels of CCL5 compared 
to WNV-NY-infected monolayers.  In contrast, the chemokine profile observed 
when endothelial cells were co-cultured in a transwell system in the presence of 
astrocytes was less pronounced for both strains of WNV. Under these conditions, 
WNV-induced chemokine secretion and gradient formation did not affect the 
integrity of the endothelial cell monolayer, suggesting that the initial entry of 
leukocytes into the CNS in response to WNV is an active process. Additionally, 
we observed increased expression of cellular adhesion molecules (CAMs) in 
WNV-infected astrocytes compared to mock treated astrocytes. In contrast, no 
upregulation in expression of CAMs was observed in WNV-infected HBMECs.  
When fluorescently labeled monocytes were added to infected HBMEC 
monolayers, increased levels of monocytes attached to WNV-MAD78-infected 
cells compared to WNV-NY infected cells. However, when monocyte traversal 
was examined in a coculture model, increased levels of monocytes traversed 
cocultures inoculated with WNV-NY compared to cocultures inoculated with 
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WNV-MAD78. Combined this data suggests that, as with other neurotropic 
viruses (75, 162, 187), the cells comprising the BBB contribute to the 
proinflammatory response to WNV. 
 
Results 
Treatment with type-1 IFN but not TNFα inhibits WNV replication in 
HBMECs  
Neither TNFα nor type-1 IFNs are induced at detectable levels during 
WNV infection of HBMECs (data not shown), suggesting that effects in vivo from 
these cytokines at the BBB may be from cytokines produced in another cell type. 
In addition, treatment of HBMEC monolayers with exogenous TNFα did not 
increase the permeability of the monolayer (data not shown). However, studies in 
mice indicate that high levels of virus are detected in the blood prior to high levels 
in the CNS. In addition, replication in the periphery induces the secretion of 
several proinflammatory cytokines, such as TNFα and type-1 IFNs (226, 253). An 
initial study examining WNV neuroinvasion suggest that the incursion of WNV 
into the CNS is a result of the breakdown of the BBB from TLR-dependent 
induction of proinflammatory cytokines, such as TNFα (297). To examine the 
effects of proinflammatory cytokines on WNV replication in cells that comprise 
the BBB, human brain microvascular endothelial cells (HBMECs) were either 
mock-infected or infected with WNV-NY or WNV-MAD78 and either left 
untreated, pre- and post-treated, or post-treated with either type-1 IFN or TNFα. 
Although treatment of HBMECs with TNFα (Figure 24) did not alter WNV 
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replication in HBMECs, treatment with high levels of type-1 IFN reduced peak 
viral titers for both WNV-NY- and WNV-MAD78-infected HBMECs. Consistent 
with previous studies performed in other cell types (127), WNV-MAD78 
replication was more sensitive to type-1 IFN treatment compared to WNV-NY 
replication in HBMECs. Further, in HBMECs treated with TNFα, NFκB 
translocated to the nucleus, demonstrating that HBMECs are not deficient in 
these signal transduction pathways (Figure 25 A). In addition, HBMECs treated 
with exogenous type-1 IFN, expressed low levels of ISGs (Figure 25 B), 
suggesting that HBMECs can respond to exogenous treatment of both TNFα and 
type-1 IFNs. Together, these data suggest that endogenous expression of TNFα 
and type-1 IFN at the BBB are not induced by WNV.  Moreover, exposure to 
exogenous TNFα does not affect WNV replication in HBMECs. However, 
exogenous type-1 IFN treatment reduces WNV replication in HBMECs, possibly 
limiting the initial infection of HBMECs in vivo.      
 
WNV-MAD78 and WNV-NY initiate similar activation kinetics of the 
innate intracellular antiviral responses in HBMECs and HBCAs.   
 High levels of WNV can traverse endothelial monolayers and reach 
astrocytes at equivalent levels, and type-1 IFN is secreted during WNV infection 
in astrocytes (117). Thus, one additional restriction to WNV replication in 
astrocytes may be the initiation of the innate intracellular response. Therefore, 
we compared the innate antiviral response to WNV-NY and WNV-MAD78 in 
HBMECs and HBCAs.  To monitor the innate antiviral response in HBMECs, we 
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examined the steady state levels of the intracellular antiviral effector proteins 
ISG56, ISG20, Viperin, and ISG15, which have been previously shown to be 
induced in response to WNV-NY infection in other cell lines (83, 127, 236, 271).  
Expression of ISG56, ISG20 and Cig5 was not detected by western blot analysis 
in either mock- or WNV-infected HBMECs (data not shown).  In contrast, ISG15 
was constitutively expressed in both mock and WNV-infected cultures (Figure 
26) at equivalent levels.  ISG15 differs from other antiviral proteins; it must be 
conjugated to intracellular proteins, a process referred to as ISGylation, in order 
to mediate its antiviral activity (159, 323).  However, low levels of ISGylation were 
only observed in WNV-MAD78-infected cells at 48 hours post-infection.  This 
suggests that despite constitutive ISG15 expression in this cell line, it is not 
functionally activated in response to WNV until very late in infection.   The lack of 
induction of antiviral effector protein in response to WNV infection was not due to 
the disruption of the Jak/Stat signaling, as ISG56 expression and ISG15ylation 






Figure 24. Treatment of endothelial cells with proinflammatory cytokines. 
HBMEC monolayers were either left untreated, (A) pretreated with TNFα 
(5ng/mL) or pre- or post-treated with either (B and C) IFNα or (D and E) IFNβ and 
infected (MOI=1) with either WNV-NY or WNV-MAD78. Plaque assays were 
performed on supernatants collected at the indicated timepoints. Values 




Figure 25. HBMECs respond to exogenous proinflammatory cytokine 
expression. (A) HBMECs were treated with TNFα (5ng/mL) for 1 hour and fixed 
in 3% PFA. Cells were then probed using an anti-NFkB antibody. HMBEC 
monolayers were treated with TNFα (5ng/mL) and cell lysates were collected at 
the indicated timepoints. SDS-PAGE gels were run before probing with indicated 
antibodies. Data presented are representative of at least 2 independent 
experiments.  (B) HBMECs treated with 100IU IFNβ were lysed at times 
indicated. Lysates were run on SDS PAGE gels and transferred onto 
nitrocellulose as described in the materials and methods. Membranes were 
probed with antibodies to GAPDH and ISG56. Data presented is representative 
of at least 2 individual experiments.  
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Combined this data suggests that the antiviral response to WNV infection in 
HBMECs is extremely muted. Yet, it is possible that the muted antiviral response 
in HBMECs, a transformed cell line, is suppressed by expression of the large T 
antigen (3). Therefore, we examined human brain microvascular endothelial cells 
(HBMVEs) that are not transformed and donor matched to the astrocyte cell line 
used. In HBMVEs, the intrinsic innate immune response is initiated at similar 
timepoints for both WNV-NY and WNV-MAD78 (Figure 26 B). This further 
suggests that despite initiation of the antiviral response, both neuropathogenic 
and nonneuropathogenic strains replicate to high levels in the brain endothelium 
(117). Thus, the intrinsic innate immune response does not differentially limit 
infectious particle production for nonneuropathogenic strains of WNV in brain 
endothelial cells.    
However, HBCAs mounted an antiviral response.  The antiviral effector 
proteins ISG56 and ISG15 were up regulated in response to WNV-NY and WNV-
MAD78 infection (Figure 26 C) as well as other effector proteins including 
Viperin and ISG20 (data not shown). However, the initiation of the innate 
intracellular antiviral response in HBCAs in response to both WNV-NY and WNV-
MAD78 was similar in both kinetics and amplitude. Together, these data suggest 
that the restriction of WNV-MAD78 cell-to-cell spread in astrocytes is not due to a 
differentially activated intrinsic innate immune response. Further, despite the 
innate antiviral response in HBMECs and HBMVEs in response to WNV 
infection, replication occurs to high levels in endothelial cells for both WNV-NY 




Figure 26- Innate intracellular antiviral responses in HBMECs and 
HBCAs. (A) HBMECs were mock treated or inoculated (MOI=0.1) with either 
WNV-NY or WNV-MAD78. Cell lysates were collected at the time indicated, 
lysates run on denaturing SDS-PAGE gels, and blots probed with the indicated 
antibodies. Blots presented are representative of at least 2 independent 
experiments. (B) HBMVEs were mock treated or inoculated (MOI=0.1) with either 
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WNV-NY or WNV-MAD78. Cell lysates were collected at the time indicated, 
lysates run on denaturing SDS-PAGE gels, and blots probed with the indicated 
antibodies. Blots presented are representative of at least 2 independent 
experiments. (C) HBCAs were mock treated or inoculated (MOI=0.01) with either 
WNV-NY, or WNV-MAD78. Cell lysates were collected at the time indicated, 
lysates run on denaturing SDS-PAGE gels, and blots probed with the indicated 






CCL2 and CCL5 expression and localization in WNV-infected 
HBMECs. Previous studies propose that WNV replication in brain microvascular 
endothelial cells facilitates WNV entry into the CNS (117, 284, 285).  Thus, to 
determine if brain microvascular endothelial cells play an integral role in the early 
neuroinflammatory response to WNV, we examined the expression of CCL2 and 
CCL5, two chemokines highly upregulated in the brains of WNV-infected mice 
(92, 152, 246), in human brain microvascular endothelial cells (HBMECs) 
infected with WNV-NY or WNV-MAD78. Consistent with a previous report (51), 
CCL2 was expressed in mock-infected HBMECs (Figure 27A & B). Moreover, 
WNV infection did not significantly alter CCL2 mRNA or protein levels in 
HBMECs (P > 0.05), despite the fact that this cell line is equally permissive to 
both strains of WNV (117).  Because stimulation of endothelial cells induces the 
redistribution of constitutively expressed CCL2 to the cell surface (51), we also 
used a transwell model system to examine the localization of CCL2 throughout 
the endothelial cell layer during WNV infection. Examination of the cellular 
distribution of CCL2 by confocal microscopy revealed several differences in 
CCL2 staining patterns between mock-, WNV-NY- and WNV-MAD78-infected 
HBMECs (Figure 28 A & B). Notably, CCL2 expression shifted from a diffuse 
staining pattern in mock-infected cells to a punctate staining pattern in WNV-
infected cells. Thus, during WNV infection in endothelial cells, CCL2 chemokine 
gradients are established by the redistribution of CCL2 instead of upregulation of 





Figure 27. CCL2 expression in WNV-infected HBMECs. Total RNA (A) and 
culture supernatants (B) were recovered from mock-infected HBMECs or 
HBMECs infected with WNV-NY or WNV-MAD78 (MOI=0.1). (A) CCL2 mRNA 
levels in mock and WNV-infected HBMECs were determined by qRT-PCR.  
Values represent the average (+/- standard error) fold increase compared to 
mock-infected HBMECs at 1 h post-infection from at least 3 separate 
experiments. (B) Levels of CCL2 present in the HBMEC-infected supernatants 
were determined by ELISA.  Values represent the average (+/- standard error) 




Figure 28.  Localization and quantification of CCL2 within WNV-infected 
HBMECs. HBMECs cultured on transwell inserts were either mock-infected, or 
infected with WNV-NY or WNV-MAD78 (MOI=0.1).  Cell monolayers were fixed 
at 48 h post-infection and probed for CCL2 using CCL2 polyclonal antisera 
followed by a DyLight-488 conjugated secondary antibody (green). Nuclei were 
visualized using Hoechst stain (blue) and used as a reference point for location 
within the stack.   Z-stacks were captured using confocal microscopy and 
quantification of each stack was determined using ImageJ. Mean fluorescence 
intensity (MFI) quantification of Z-sections (A) and images of Z sections (B) are 





Unlike CCL2, CCL5 mRNA expression was upregulated ~6000-fold in both 
WNV-NY- and WNV-MAD78- infected HBMECs compared to mock-treated 
HBMECs (Figure 29A, P < 0.005). However, in WNV-MAD78-infected cultures, 
the level of secreted CCL5 was significantly higher (3.5-fold, P < 0.05) compared 
to WNV-NY-infected cultures (Figure 29B) and higher levels of CCL5 were 
detected throughout the WNV-MAD78-infected monolayer compared to WNV-NY 
(Figure 30A & B), suggesting that CCL5 is also regulated at the post-
transcriptional level within these cells. Together our findings suggest that 
neuropathogenic and nonneuropathogenic strains of WNV induce differential 
proinflammatory chemokine responses in brain endothelial cells.  
 
CCL5 and CCL2 expression in WNV-infected astrocytes. Astrocytes 
play a central role in mediating neuroinflammation in response to many viruses, 
including WNV (46, 75, 162, 209, 282).   Therefore, we also examined CCL2 and 
CCL5 expression in primary human brain cortical astrocytes (HBCAs). As 
observed in HBMECs, CCL2 was constitutively expressed in HBCAs and WNV 
infection did not alter the level of secreted CCL2 (Figure 31A). In contrast to 
HBMECs, HBCAs secreted significantly more CCL5 in response to WNV-NY 
than WNV-MAD78 (Figure 31B, P<0.005). As we have previously demonstrated 
that HBCAs are more  permissive to infection with WNV-NY compared to WNV-






Figure 29. CCL5 expression in WNV-infected HBMECs.  Total RNA (A) and 
culture supernatants (B) were recovered from mock-infected HBMECs or 
HBMECs infected with WNV-NY or WNV-MAD78 (MOI=0.1). (A) CCL5 mRNA 
levels in mock and WNV-infected HBMECs were determined by qRT-PCR.  
Values represent the average (+/- standard error) fold increase compared to 
mock-infected HBMECs at 1 h post-infection from at least 3 separate 
experiments. (B) Levels of CCL5 present in the HBMEC-infected supernatants 
were determined by ELISA.  Values represent the average (+/- standard error) 
from at least 3 separate experiments. One-way Anova was performed to 





Figure 30. Localization and quantification of CCL5 within WNV-infected 
HBMECs. HBMECs cultured on transwell inserts were either mock-infected or 
infected with WNV-NY or WNV-MAD78 (MOI=0.1).  Cell monolayers were fixed 
at 48 h post-infection and probed for CCL5 using CCL5 polyclonal antisera 
followed by an Alexafluor 633 conjugated secondary antibody (orange). Nuclei 
were visualized using Hoechst stain (blue) and used as a reference point for 
location within the stack.   Z-stacks were captured using confocal microscopy 
and quantification of each stack was determined using ImageJ.  Mean 
fluorescence intensity (MFI) quantification of Z-sections (A) and images of Z-




Figure 31. CCL2 and CCL5 expression in WNV-infected HBCAs. Culture 
supernatants were recovered from mock-infected HBCAs or HBCAs infected with 
WNV-NY or WNV-MAD78 (MOI=0.01) and levels of secreted CCL2 (A) or CCL5 
(B) were determined by ELISA. Values represent an average (+/- standard error) 
from at least 3 independent experiments.  One-way Anova was performed to 




were likely due to the enhanced ability of WNV-NY to spread from cell to cell 
within the HBCA monolayer compared to WNV-MAD78. Indeed, WNV-MAD78 
and WNV-NY-infected HBCAs secreted similar levels of CCL5 per infected cell 
(~0.146pg/infected cell for WNV-NY, ~0.547pg/infected cell for WNV-MAD78). 
These data suggest that the expression of chemokines in astrocytes may play a 
role in WNV-mediated neuroinflammation.   
 
Chemokine expression in a co-culture model of the BBB. Endothelial 
cells bind and internalize chemokines produced by cells within the extravascular 
space (183). As such, the chemokine response to WNV infection in astrocytes 
may alter the expression of chemokines within the endothelial cell monolayer.  
Thus, we examined CCL2 and CCL5 localization within HBMECs cultured on a 
transwell support containing HBCAs cultured in the bottom chamber (Figures 32 
& 33).  In contrast to HBMEC monolayers alone, CCL2 and CCL5 appeared to 
accumulate to higher levels WNV-NY-infected HBMEC monolayers compared to 
mock and WNV-MAD78-infected HBMEC monolayers.  Thus, astrocytes alter 
chemokine gradient profiles established in endothelial cell monolayers in 
response WNV infection. 
 
 Effect of WNV infection on the integrity of an in vitro model of the 
BBB. In addition to attracting leukocytes, chemokines can directly disrupt the 
cell-to-cell junctions necessary for maintaining the integrity of the endothelial 
monolayer (219).  Therefore, we compared the permeability of WNV-NY- and  
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 Figure 32. CCL2 localization within the HBMEC monolayer of an in vitro 
model of the BBB. HBMECs cultured on transwell inserts containing HBCAs 
plated in the abluminal chamber were mock-infected or infected with either WNV-
NY or WNV-MAD78 (MOI=0.1). HBMEC monolayers were fixed at 72 h post-
infection and CCL2 detected using polyclonal antisera to CCL2 followed by a 
Dylight-488 conjugated secondary antibody (green). Nuclei were visualized using 
Hoechst stain (blue) and were used as a reference point for location within the 
stack.   Z-stacks were captured using confocal microscopy and quantification of 
each stack was determined using ImageJ. Mean fluorescence intensity (MFI) 
quantification of Z-sections (A) and images of Z-sections (B) are representative 




Figure 33. CCL5 localization within the HBMEC monolayer of an in vitro 
model of the BBB. Fixed HBMECs from Figure 6 were also probed with CCL5 
polyclonal antisera followed by an Alexafluor-633 conjugated secondary antibody 
(orange). Nuclei were visualized using Hoechst stain (blue) and were used as a 
reference point for location within the stack. Z-stacks were captured using 
confocal microscopy and quantification of each stack was determined using 
ImageJ.   Mean fluorescence intensity (MFI) quantification of Z-sections (A) and 
images of Z-sections (B) are representative of 3 independent experiments.  
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WNV-MAD78-infected HBMEC monolayers in the presence and absence of 
HBCAs. The integrity of the HBMEC monolayer was monitored by quantitating 
the level of FITC-labeled dextran translocation in mock-, WNV-NY- and WNV-
MAD78- infected cultures (Figure 34 A & B).  As expected, ~70% of the FITC-
dextran was detected in the lower chamber of control wells lacking cells and 
HBMEC monolayers treated with EDTA to disrupt tight junctions. In contrast, only 
5-10% of the FITC-dextran was detected in the lower chamber of mock-, WNV-
NY- and WNV-MAD78-infected cultures, indicating that the HBMEC monolayer 
remained intact during infection and the presence of HBCAs did not alter FITC-
dextran transmigration. These data suggest that the endothelial monolayer 
remains intact throughout the initial course of WNV infection, despite the 
establishment of CCL2 and CCL5 gradients. 
 
WNV-NY-infected HBCAs express higher levels of CAMs compared to WNV-
MAD78-infected HBCAs 
Since both WNV-infected HBMECs and HBCAs upregulated expression of 
chemokines, we examined the expression of the next set of molecules to play a 
role in diapedisis, cell adhesion molecules (CAMs) in both cell lines. HBMECs 
constitutively expressed ICAM and VCAM at low levels, but expression of either 
did not increase during WNV infection (Figure 35 A). In contrast, WNV-infected 
HBCAs expressed higher levels of VCAM than mock treated HBCAs, and ICAM 





 Figure 34. Effect of WNV infection on the permeability of the HBMEC 
monolayer. HBMECs grown in the absence (A) or presence (B) of HBCAs were 
infected with WNV-NY or WNV-MAD78 (MOI=0.1) or mock-infected and  FITC-
dextran (100 μM) was added to the upper, luminal chamber at the indicated times 
(h).  Cultures were incubated for 1 h and the amount of FITC-dextran present in 
the lower, abluminal, chamber was determined. Translocation of FITC-dextran 
across control inserts lacking cells and monolayers treated with 5mM EDTA was 
also determined. Values are an average (+/- standard error) from at least 2 





Figure 35. Expression of cell adhesion molecules (CAMs) in HBMECs and 
HBCAs. (A) HBMECs were either mock-treated, or inoculated with WNV-NY or 
WNV-MAD78 (MOI=0.1). At time indicated, cells were washed 2x with PBS, 
lysed in RIPA buffer, and run on SDS PAGE gels. Blots were then probed with 
the indicated antibodies. (B) HBCAs were either mock-treated, or inoculated with 
WNV-NY or WNV-MAD78 (MOI=0.01). At time indicated, cells were washed 2x 
with PBS, lysed in RIPA buffer, and run on SDS PAGE gels. Blots were then 
probed with the indicated antibodies. All blots presented are representative of at 
least 2 independent experiments.  
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that HBCAs may play an active role in extravasation events during WNV infection 
at the BBB.   
 
WNV-NY and WNV-MAD78 replicate to low levels in THP1 cells  
In addition to replication in endothelial cells, replication in hematopoietic 
cells and traversal of infected hematopoetic cells through the BBB into the CNS 
is a proposed model for the initial incursion of WNV into the CNS (15, 57, 268, 
291, 292, 295). Thus, we examined replication kinetics for both WNV-NY and 
WNV-MAD78 in THP1s, a human monocyte cell line. WNV-NY and WNV-MAD78 
replicated to low levels in THP1s  (Figure 36). However, infectious particle 
production never increased compared to the initial amount of virus introduced 
into the cells. Thus, WNV is either replicating to low levels to maintain a basal 
level of infectious particle production, or stabilizing the virus and preventing viral 
clearance.  In addition, the peak viral titers for both strains were lower compared 
to multiple cell lines of the BBB (117). WNV-infected mouse macrophages also 
display low levels of replication (253). Together, these data suggest that initial 
replication in hematopoetic cells is unlikely to account for observed differences in 






Figure 36. WNV-NY and WNV-MAD78 replication in THP-1 cells. THP-1s 
were inoculated with either WNV-NY or WNV-MAD78 (MOI=0.1). At indicated 
time points, cell supernatants were clarified and plaque assays performed on 
Vero cells. Data presented is an average (+/- standard error) of at least 2 





In vitro models of WNV infection and neuroinflammation at the BBB 
represent functional model systems 
 
The extravasation process of leukocytes from the blood into infected 
tissue is a multistep process, including attachment, rolling, and diapedisis 
through the endothelial cell layer. WNV-MAD78-infected HBMECs express 
higher levels of CCL5 compared to WNV-NY-infected HBMECs. To assess if the 
upregulation of CCL5 is functional, fluorescently labeled THP-1 monocytes were 
incubated with mock-infected, WNV-infected, or TNFα-treated (100ng/mL) 
HBMEC monolayers (Figure 37 A). WNV-MAD78-infected HBMEC monolayers 
exhibited increased attachment of labeled monocytes compared to WNV-NY-
infected or mock-infected monolayers. TNFα-treated HBMEC monolayers 
exhibited the highest level of attachment, as these levels of treatment have been 
shown to activate endothelium in several in vitro model systems (167). Since 
WNV-NY-infected HBCAs secrete higher levels of CCL5 than WNV-MAD78-
infected HBCAs, and VCAM expression was increased during WNV infection, we 
assessed the effect of HBCAs on the extravasation process. When fluorescently 
labeled THP-1 cells were added to cocultures containing WNV-infected HBMECs 
in a suspended transwell chamber with HBCAs plated in the bottom chamber, we 
observed that WNV-NY infected co-cultures exhibited increased fluorescence in 
the bottom chamber compared to mock- or WNV-MAD78-infected co-cultures, 




Figure 37. Attachment and diapedisis of monocytes in BBB models.  
(A) Adherence of monocytes to HBMECs.  HBMECs were infected with WNV-NY 
or WNV-MAD78 (MOI=0.1).  At 48 hr post-infection, HBMECs were incubated 
with fluorescently labeled monocytes for 1 hr at 37oC.  HBMECs were washed 
extensively and bound monocytes were visualized and counted using an 
Olympus fluorescent microscope.  Results are an average of three independent 
experiments. (B) Diapedisis of monocytes through HBMEC monolayer in 
coculture model of the BBB. HBMECs were cultured on transwell inserts with 
HBCAs cultured in the bottom well as indicated in the materials and methods. 
HBMECs were inoculated (MOI=0.1) and 72h post inoculation, fluorescently-
labeled THP1 cells were added to the luminal compartment. 6 hours post 
incubation, 2% Triton-X was added to the abluminal chamber, collected, and the 
absorbance read. All readings were then normalized to the total fluorescence 
152 
  
present in the mock wells. Data presented are an average (+/- standard error) of 





Together, these data suggest that initially, monocytes may attach to WNV-
MAD78-infected endothelium more efficiently than WNV-NY-infected 
endothelium. Yet as infection progresses through the BBB into astrocytes, 
infection of astrocytes may influence monocyte extravasation and cause an 




While necessary for viral clearance within the CNS, infiltrating immune 
cells at the BBB also contribute to the severe pathologies observed during WNV 
infection. Several proinflammatory cytokines and chemokines have been 
detected within brains of WNV-infected mice (15, 131, 152, 246, 253, 280), yet 
little is known about how distinct cell types other than neurons within the CNS 
contribute to the kinetics of WNV neuroinflammation.  Because endothelial cells 
and astrocytes comprise the interface between the circulatory system and the 
CNS, and likely constitute one of the sites of WNV neuroinvasion (117, 284, 
285), understanding how these cell types respond to WNV infection may provide 
insight into the regulation of the initial neuroinflammatory response. In this study, 
we demonstrate the effects of proinflammatory cytokines on viral replication in 
endothelial cells and assess the roles different cell types at the BBB may play in 
attachment and extravasation of leukocytes across the BBB during WNV 
infection. Additionally, we describe the innate intracellular antiviral response to 
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both pathogenic and nonpathogenic strains at the BBB, and observed that both 
strains are equivalent in their capacities to initiate the antiviral response in 
HBMECs and HBCAs. We also examined the expression profiles of CCL2 and 
CCL5 in brain microvascular endothelial cells and astrocytes to describe the role 
of the BBB in WNV-mediated neuroinflammation. Although WNV-NY and WNV-
MAD78 induced similar upregulation of CCL5 mRNA in HBMECs, WNV-MAD78-
infected HBMECs secreted higher levels of CCL5 compared to WNV-NY-infected 
HBMECs.  In contrast, higher levels of secreted CCL5 were detected in WNV-
NY-infected HBCAs compared to WNV-MAD78-infected HBCAs. Moreover, 
HBCAs produced substantially higher levels of CCL5 overall compared to 
HBMECs.  This expression pattern for CCL5 is consistent with a previous report 
that detected similar levels of CCL5 mRNA in the brains of mice infected with 
nonneuropathogenic and neuropathogenic strains of WNV at an early time post-
infection; however, significantly higher levels of CCL5 mRNA were detected in 
mice infected with the neuropathogenic strain at a later time point (246). In 
contrast to CCL5 expression, WNV infection did not upregulate CCL2 expression 
in either brain microvascular endothelial cells or astrocytes, suggesting that the 
increased levels of CCL2 in the brains of WNV infected mice is due to 
upregulation of expression in other cell types within the CNS, such as neurons, 
and/or infiltrating leukocytes themselves.  
While soluble chemokine gradients control the recruitment of leukocytes 
into the parenchyma of the CNS, immobilized chemokine fields mediate the initial 
migration of immune cells across the BBB (40, 183).  Therefore, we also 
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assessed CCL2 and CCL5 expression patterns within WNV-infected HBMEC 
monolayers in both the presence and absence of HBCAs. WNV-MAD78 infection 
of HBMEC monolayers alone expressed higher levels of CCL5 compared to 
WNV-NY infection, suggesting that brain endothelial cells infected with WNV-
MAD78 may be more efficient at attracting circulating immune cells to the BBB 
after initial infection. However, inclusion of HBCAs within the culture system 
substantially altered the chemokine expression profile within HBMECs.  As 
endothelial cells are highly efficient at binding and internalizing chemokines 
produced by extravascular cells (68), secreted CCL5 produced by WNV-NY-
infected astrocytes likely contributed to the enhanced chemokine gradient 
induced in the co-culture model system. Since chemokine gradient establishment 
leads to binding and traversal of leukocytes, the progression of WNV infection 
from endothelial cells into astrocytes may influence the kinetics and amplitude 
leukocytes infiltration into the CNS.  Thus, to assess functionality of chemokine 
expression in both the HBMEC monolayer and coculture models, we examined 
attachment and extravasation of monocytes during WNV infection. While WNV-
MAD78 infected HBMECs promoted increased adhesion of monocytes to the 
HBMEC monolayer, when HBCAs were added to the model system, 
extravasation was more pronounced in WNV-NY-infected monolayers compared 
to WNV-MAD78-infected monolayers. Taken together, these data suggest that 
WNV-induced neuroinflammation within the BBB is modulated as infection 
progresses throughout the CNS. 
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In addition to establishing gradients to attract circulating leukocytes, 
chemokines have been shown to disrupt the cell-to-cell junctions necessary for 
the maintenance of the BBB (219). Thus, chemokine secretion during WNV 
infection could contribute to the disruption of the BBB, resulting in the 
unregulated infiltration of leukocytes into the CNS.  However, our data suggests 
that WNV replication in an in vitro model of the BBB does not affect the integrity 
of the endothelial monolayer. Thus, the initial infiltration of leukocytes into the 
CNS is likely due to active recruitment of immune cells by chemokines 
immobilized on the endothelial surface rather than passive migration due to loss 
of integrity of the BBB. Furthermore, the maintenance of the integrity of the 
endothelial cell monolayer suggests that leukocytes utilize transcellular traversal 
as opposed to paracellular traversal during the initial diapedesis of leukocytes 
across the WNV-infected endothelial monolayer. However, other factors, such as 
the secretion of matrix metalloproteases (MMPs) by astrocytes (284) and/or 
infiltrating leukocytes or direct damage caused by infiltrating leukocytes, likely 
contribute to disruption of the BBB that is observed at later times post-infection 
(57, 222, 292). However, it is not likely that infected leukocytes precede 
replication in endothelial cells at the BBB, since WNV replicates to lower levels in 
leukocytes than in endothelial cells. Infected leukocytes may exacerbate 
neuropathogenesis as they are actively recruited to the CNS from the periphery. 
Thus, the breakdown of the BBB at this later stage of infection may serve to 
facilitate a second round of viral entry into the brain by allowing the unrestricted 
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entry of free virus from the blood steam and/or the recruitment of infected 
leukocytes to the CNS.  
Our data suggests that pathogenic and nonpathogenic strains of WNV 
differentially induce chemokine expression and gradient profiles at the BBB, 
which may result in altered kinetics of leukocyte infiltration.  During the initial 
infection of the brain endothelial cells, the enhanced chemokine gradient 
produced in response to WNV-MAD78 may stimulate the rapid recruitment of 
circulating leukocytes to the BBB, thereby restricting viral replication within the 
brain endothelium.  Additionally, reduced replication (117) and a blunted 
inflammatory response to WNV-MAD78 in astrocytes would result in limited 
leukocyte infiltration later during infection, thereby minimizing the potential for 
leukocyte-mediated neuropathology. In contrast, pathogenic strains of WNV, 
such as WNV-NY, may delay the active recruitment of leukocytes to infected 
endothelium until WNV-NY has replicated to high levels within astrocytes, 
providing a window of opportunity for pathogenic strains to spread to highly 
susceptible neurons prior to the en masse infiltration of leukocytes. Together, 
these data suggest that the establishment of chemokine gradients at the BBB in 
response to WNV infection is a complex process that evolves as the infection 
progresses through the various layers of the CNS and is differentially regulated 
by strains that vary in their capacity to cause neuropathogenicity. Therefore, a 
greater understanding of how various chemokines are involved in this process 
may aide in developing therapies to limit WNV-mediated neuroinflammation and 
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Chapter 6- Antiviral responses and detection of virus in mice inoculated 
with a nonneuropathogenic strain of WNV compared to a neuropathogenic 
strain of WNV 
 
Abstract 
 West Nile virus (WNV) neuropathogenesis results from neuronal death by 
both viral replication in neurons and bystander effects of the immune response 
during infection. The degree of WNV neuropathogenesis is highly strain 
dependent. Although the level of viremia may influence neuropathogenesis, 
additional obstacles for nonneuropathogenic strains may be present at the blood-
brain barrier (BBB). Therefore, we monitored the kinetics of virus infection and 
the host antiviral response in a mouse model of WNV infection that simulated 
viremia using a neuropathogenic (WNV-NY) and a nonneuropathogenic (WNV-
MAD78) strain of WNV.  Mice intravenously inoculated with WNV-MAD78 
exhibited increased survival compared to mice inoculated with WNV-NY, 
suggesting that high levels of virus alone does not dictate neuropathogenesis. 
WNV-NY was readily detected in the spleen and brain as early as 48 hours post 
inoculation, reaching peak levels at 120 hours post inoculation. In contrast, WNV-
MAD78 was only detected in the spleen and only at 8 and 24 hours post 
inoculation.  Despite being unable to detect virus consistently, chemokines were 
upregulated in the brains of mice infected with either strain of WNV at 120 hours 
post infection. However, greater chemokine upregulation was observed in mice 
inoculated with WNV-NY compared to WNV-MAD78. Together, these data 
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suggest that an additional barrier exists for nonneuropathogenic strains of WNV 
at the BBB, and that chemokine responses occur after WNV initiates infection in 
the CNS.  
 
 Introduction 
 Since its introduction into the Western hemisphere in 1999, the flavivirus, 
West Nile virus (WNV), has become the most common cause of arthropod-borne 
severe neurological disease {webpage,  #7067}. Historically, WNV has been 
associated with a mild febrile illness, though extremely rare cases noted severe 
neurological disease. With the emergence of newer strains of WNV in the 
Western hemisphere in the late 1990s, severe neurological disease has become 
widespread. Symptoms of WNV-induced neurological disease include acute 
flaccid paralysis, encephalitis, and meningitis, with some patients never fully 
recovering from these symptoms.  The mechanisms underlying this increase in 
neuropathogenesis caused by certain strains are unclear. In vitro identification of 
factors contributing to differential replication in model systems must be validated 
in vivo to apply to disease models.  
 Disease pathology in the CNS during WNV infection is a result of 
neuronal death. Nevertheless, prior replication of WNV in other cell types 
comprising the CNS, especially at the BBB, is necessary prior to exposure of 
neurons to virus in the natural course of infection. WNV replication in the mouse 
model occurs at several sites, including the skin, blood, spleen, kidney, lymph 
nodes, heart, and lungs, with the highest levels identified in the CNS (63-65) . 
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While several studies with neuropathogenic WNV have been performed in mice, 
replication kinetics of infections with nonneuropathogenic strains of WNV is not 
as well documented.  
 In addition to virus replication-induced neuronal death, the inflammatory 
response to infection in the CNS contributes to WNV neuropathogenesis. Thus, 
many chemokines, chemokine receptors, and cytokines play a role in WNV 
neuropathogenesis, including TNFα, IL-22, IL-23, type-1 IFN, CCR2, CCR5, 
CXCL10, and CXCL1/2 (15, 93, 127, 152, 253, 280, 291). During WNV infection, 
the innate immune response induces production of type-1 IFN and 
proinflammatory cytokines in both the serum and several organs, including the 
CNS (227).  Therefore, the blood-brain barrier (BBB) may be exposed to 
proinflammatory cytokines prior to the virus. While other pathogens have been 
shown to induce cytokine secretion, which disrupts the BBB via antiviral 
responses from infected peripheral cells, this does not appear to be the case for 
WNV.  However, secretion of cytokines in response to WNV replication functions 
to attract leukocytes to the site of infection for viral clearance (280). The process 
of leukocyte attraction and viral clearance is a multi-step event, and it is unclear 
how different immune factors contribute to a balanced immune response within 
the CNS.  Likewise, the kinetics of the innate immune response during WNV 
infection in vivo and which cell types are involved is unclear. 
 A prominent hypothesis in the field is that nonneuropathogenic strains of 
WNV do not reach high enough levels of viremia to initiate replication in distal 
organs. In this model, nonpathogenic strains are restricted to the initial site of 
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infection and therefore are unable to access the CNS and cause 
neuropathogenesis.  To test this hypothesis, we designed in vivo experiments in 
which the initial peripheral infection of WNV was bypassed by introducing 
equivalent levels of a neuropathogenic strain, WNV-NY, or a 
nonneuropathogenic strain, WNV-MAD78, directly into the blood stream.  In our 
mouse model, survival was higher in WNV-MAD78-inoculated mice compared to 
WNV-NY inoculated mice, suggesting an additional barrier for 
nonneuropathogenic strains of WNV exists beyond viremia. High levels of WNV-
NY and increased CCL2 expression were detected in the brains of mice 5 days 
after inoculation. In contrast, CCL2 expression in the brain was only modestly 
increased in mice 5 days after WNV-MAD78 inoculation. Together, our data 
suggests that WNV-MAD78 is restricted in its ability to replicate in the CNS and 
induce a robust chemokine response, which limits its capacity to induce 




WNV-NY causes greater lethality that WNV-MAD78 in intravenously-
inoculate mice.  
 Most, if not all, strains of WNV are neurovirulent in mice when inoculated 
via an intracranial route. However, many strains rarely cause neuropathogenesis 
following peripheral inoculation, possibly due to an inability of these strains to 
reach high levels in the blood (23). To determine if the level of viremia is the only 
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determining factor in WNV-induced neuropathology, mice were inoculated via the 
tail vein with either WNV-NY or WNV-MAD78 at levels representative of viremia 
in a mammalian model (104 PFU) (Figure 38). Fewer mice survived when 
inoculated with WNV-NY than with WNV-MAD78, suggesting additional factors 
restrict WNV-MAD78 neuropathogenesis in the animal model. Considering that 
WNV-MAD78 survival is decreased when directly inoculated into the CNS 
compared to inoculation into the bloodstream, these factors likely represent a 
barrier of entry into the CNS.  
 
Detection of WNV in intravenously-inoculated mice 
 Because WNV neuropathogenesis is a result of neuronal death, we 
determined presence of replicating virus within the CNS in the viremic mouse 
model (Table 4, Figure 39).   Viral RNA was detected in the brains of WNV-NY-
infected mice as early as 48 hours post infection, with maximum viral replication 
detected in the brain at 120 hours post inoculation (Figure 39). In contrast, viral 
RNA was not detected in the brains of WNV-MAD78-infected mice. We also 
examined replication in the blood and spleen, since some models suggest that 
viral replication in leukocytes initiates CNS infection.  We detected viral RNA in 
the spleens at early times post infection for both WNV-NY- and WNV-MAD78-
infected mice. Infectious WNV-MAD78 was not detected in the blood via plaque 





Figure 38. Survival analysis of mice infected with WNV-NY and WNV-
MAD78.  Four week old Swiss Webster mice were intravenously infected with 104 
pfu of either WNV-NY (n=10) or WNV-MAD78 (n=10) via the tail vein, or sham 
inoculated with PBS (n=7). Survival was assessed twice daily as described in 




Table 4. Virus location in mice infected via tail vein injection. 
 
†Value determined using plaque assay 
††Value determined using nested PCR 
†††Value determined using integrated PCR using RT-PCR and plaque 
assay 
*Samples were assayed using plaque assays 
‡ Samples were assayed using nested PCR 
∆ Samples assayed using integrated RT-PCR and plaque assays   
Viral strain Location 8 hpi 24 hpi 48 hpi 96 hpi 120 hpi 
WNV-NY Serum* 0/3 6/6† 6/6† 0/3 0/6 
 Spleen‡∆ 0/3∆‡ 0/3∆‡ 3/3†* 3/3†* 3/3†*∆ 
 Brain*‡∆ 0/3‡ 0/6∆‡ 2/6†††∆‡ 1/3†‡ 3/3†*∆ 
       
WNV-
MAD78 
Serum* 0/2 0/5 0/5 0/2 0/2 
 Spleen*‡∆ 2/2††∆‡ 2/2††‡ 0/2∆‡ 1/2††∆ 0/2∆‡ 
 Brain*‡∆ 0/2∆‡ 0/5∆‡ 0/5∆‡ 0/2‡ 0/2∆‡ 
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Figure 39.  Detection of infectious WNV-NY in intravenously-inoculated 
mice. Mice inoculated with WNV-NY were sacrificed at the indicated times and 
serum, spleen, and brain were collected as described in materials and methods. 
Homogenates of tissues were then subject to plaque assay. Data represented is 
the median titer of the total number of animals assayed (ranging from n=2 to n=6 





together, our findings suggest that WNV-NY propagates more frequently in the 
blood and brain than WNV-MAD78. Thus, WNV-MAD78 may be cleared more 
efficiently from the blood and less likely to enter the brain than WNV-NY during 
intravenous inoculation.  
 In addition to viral replication, differential immune responses to WNV 
infection may contribute to the strain-specific pathologies observed during WNV 
infection. Because we did not detect WNV-MAD78 in the blood via plaque assay, 
we hypothesized that this virus may not induce the adaptive immune response 
due to insufficient levels of stimulating pathogen. However, when we measured 
the levels of neutralizing antibodies present in the serum at day 4 post-
inoculation, similar levels of neutralizing antibodies were present in serum of 
WNV-MAD78- and WNV-NY-infected mice (Figure 40). Thus, both strains 
stimulated an initial antibody response early after infection, despite different 
levels of WNV present in the blood. Thus, detection of viral replication methods 
may not be sensitive enough to explain observed neuropathologies, since virus 
must be present for a response to occur.  
 
Cytokine and chemokine levels in blood and brains of WNV-inoculated 
mice 
  
 To determine if differential cytokine production in the blood prior to 





Figure 40. Plaque reduction Neutralization test. Serum from WNV-infected 
mice at 96h post inoculation was mixed with WNV and titrated on Vero cells. 
Plaque reduction was considered when >50% of plaques were reduced 





levels of several proinflammatory cytokines in the serum of mice infected with 
WNV-NY or WNV-MAD78 (Figure 41 A) early during infection. Neither strain 
significantly induced IL-6 or TNFα, at 8, 24 or 48 hours after infection (data not 
shown). However, similar levels of IL-12 were detected in the serum of WNV-NY- 
and WNV-MAD78-inoculated mice at 8, 24, and 48 hours post infection.  Thus, 
proinflammatory cytokine levels were not differentially expressed in the blood of 
WNV-NY and WNV-MAD78 infected mice. Therefore, the proinflammatory 
responses in the blood did not correspond to the differential neuropathology of 
these strains.  
 In addition to proinflammatory cytokines in the serum, we also examined 
expression of chemokines CXCL2, CCL2, and CCL5 in the brain and spleen 
(Figure 41 B). While there was moderately higher chemokine expression in the 
spleens of WNV-MAD78-infected mice compared to WNV-NY-infected mice, the 
increases were very slight and not reach significance (data not shown). Likewise, 
chemokine expression was not induced in the brain at 48 h post infection. In 
contrast, all three chemokines were upregulated in WNV-infected brains at 120 
hpi. Similar levels of CCL5 were detected in the brains of WNV-MAD78 and 
WNV-NY infected mice.  However, CCL2 levels were increased in WNV-NY-
infected mice compared to WNV-MAD78-infected mice.   Thus, upregulation of 






Figure 40- Cytokine and chemokine responses in the blood and brain of 
WNV-infected mice. (A) Serum from inoculated mice was collected and 
subjected to ELISA as described in materials and methods. Values presented are 
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an average (+/- standard error) of at least 2 independent experiments. (B) Brain 
homogenates were collected at the time indicated and viral RNA was collected 
and subjected to real time qRT-PCR with primers specific to (i, iv) CCL5, (ii, v) 
CCL2, or (iii, vi) CXCL2 as described in materials and methods. Data presented 
is relative to GAPDH expression of the same samples normalized to mock-





 Nonneuropathogenic strains of WNV are restricted when mice are 
inoculated in the periphery, but if virus is directly inoculated into the CNS, 
neuropathological symptoms are observed. One current hypothesis addressing 
the differential capabilities of strains of WNV to induce neuropathology suggests 
that nonneuropathogenic strains of WNV are restricted in the periphery and do 
not reach high enough levels in the blood to enter the CNS. Therefore, we 
hypothesized that neuropathogenesis may occur regardless of strain inoculated if 
equivalent, high levels of virus were introduced intravenously. Thus, we 
introduced viremic levels of either a neuropathogenic strain (WNV-NY) or a 
nonneuropathogenic strain (WNV-MAD78) directly into the blood of mice. Still, 
mice inoculated with WNV-NY exhibited lower survival than mice inoculated with 
WNV-MAD78. Thus, there is another factor that contributes to WNV 
neuropathogenesis in addition to achieving a high level of viremia during 
infection.  
To describe the restriction for neuropathogenesis of WNV-MAD78 in vivo, 
we assessed presence of virus and cytokine expression in several sites 
permissive to WNV infection.  In mice inoculated intravenously, WNV-MAD78 
was only detected in the spleen at early times post inoculation. However, at 5 
days post inoculation, increased levels of CCL2 and CCL5 were observed in the 
brains of mice inoculated with WNV-MAD78. In mice inoculated intravenously 
with WNV-NY, virus was detected in all locations examined, including the CNS at 
low levels as early as day 2 after infection, and consistently at day 5 post 
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inoculation. Despite upregulation of CCL2 and CCL5 in brains of mice inoculated 
with either WNV-NY and WNV-MAD78 at five days post inoculation, no 
significant increase in chemokines was detected for either virus in the spleens. A 
slight increase in IL-12 was observed in the blood of mice inoculated with either 
WNV-NY and WNV-MAD78. The lack of other proinflammatory cytokines and the 
similar levels of cytokines expressed for both strains suggests that 
proinflammatory cytokine expression in the blood may not account for the 
differential capability to induce neuropathology.  Together, these data suggest 
that viral replication precedes high levels of expression of proinflammatory 
chemokines in the brain, indicating that WNV may enter the brain before initiation 
of the proinflammatory response. The specific chemokines examined, CXCL2, 
CCL2, and CCL5, are expressed in early stages during WNV infection in the 
CNS, and are necessary for the initial infiltration of leukocytes into infected 
tissues (7, 15, 88, 92, 152, 246).  Therefore, determining which tissues initially 
express these chemokines demonstrates the cell types responsible for 
supporting early viral replication and the activation of the antiviral response to 
WNV infection.  
 Mice inoculated intravenously with WNV-MAD78 expressed increased 
levels of chemokines in the CNS despite being unable to detect infectious virus. 
Although less robust than the response in mice inoculated with WNV-NY, the 
chemokine response in the brain of mice inoculated with WNV-MAD78 suggests 
that virus may enter into the CNS and initiate infection. Likewise, a detectable 
response in the blood with the PRNT (Figure 39) suggests that active infection, 
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albeit to low levels, may be present in mice inoculated with WNV-MAD78. We 
consistently observed ~90% survival in mice inoculated intravenously with WNV-
MAD78.  Other studies performed with WNV-MAD78 inoculation in the periphery 
consistently observe 100% survival, regardless of mouse strain or dose of virus 
used (127, 253, 269). Thus, our assays may not be sensitive enough to detect 
the low levels of viral replication occurring in mice inoculated with WNV-MAD78.   
Alternatively, the kinetics of replication of WNV-MAD78 may be delayed 
compared to that of WNV-NY in the sites of replication examined. Therefore, 
virus for WNV-MAD78-infected mice may not be detectable until later times 
during infection, which were not assessed in the experiments performed.    
Our observations in chemokine expression for WNV-MAD78, a 
nonpathogenic, lineage 2 strain, are similar to observations for a moderately 
pathogenic lineage 1 strain (246). Thus most, if not all, strains of WNV may 
initiate replication in the CNS, but replication for nonneuropathogenic strains may 
be limited within the CNS. Further, we detected an upregulation of chemokine 
expression for nonneuropathogenic strains in the CNS; however, the response 
may be more tightly regulated than chemokines expressed in mice inoculated 
with neuropathogenic WNV.  WNV-MAD78 restriction in inducing 
neuropathologies may therefore be attributed to the limitation of viral replication 
and spread through successfully controlled infiltration of inflammatory leukocytes. 
In addition to the restriction for cell-to-cell spread within cell types of the CNS 
(117) , a controlled inflammatory process may promote a successfully regulated 
immune response for mice inoculated with WNV-MAD78. In contrast, mice 
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inoculated with WNV-NY experience a more robust, less regulated response due 
to higher levels of viral replication (117) and chemokine expression (Chapter 5) 
within cell types of the CNS compared to nonneuropathogenic strains. The 
capacity for strains of Semliki Forest virus to induce neuropathology also lies 
beyond the BBB. Neuroinvasion occurs in all SFV infections through the 
hematogenous route, and nonpathogenic strains are further limited within the 
CNS itself (77, 260), illustrating that restriction in the CNS of viral infection and 
spread is a likely cause of restriction for nonpathogenic viral infections in the 
CNS. 
  Because neither WNV-NY nor WNV-MAD78 induced a proinflammatory 
cytokine response in the blood prior to virus detection in the brain, it is unlikely 
that the disruption of the BBB by proinflammmatory cytokines is responsible for 
the incursion of WNV into the CNS. Others (267) and we can detect pathogenic 
WNV in the CNS as early as 48h after inoculation in the periphery. The ability to 
detect neuropathogenic WNV at 48h in the CNS is consistent with the kinetics of 
viral replication in a coculture model of the BBB (117). Thus, it is likely that WNV 
traversal of the BBB via replication in endothelial cells is nondiscriminant, and 
neuropathogenicity is not determined simply by access to the CNS. Further 
replication in astrocytes and neurons, and the immune responses responsible for 
limiting infection and initiating the innate immune response in these cell types, 
may then contribute to neuropathogenicity. Herein, we observed that, although 
rare, mice inoculated via the tail vein with WNV-MAD78 exhibited symptoms of 
neuropathogenesis, supporting data suggesting that many or all strains of WNV 
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may initially invade the CNS. However, nonneuropathogenic strains of WNV are 
restricted in their replication in cell types of the CNS. Once accessing astrocytes 
and neurons, increased replication of neuropathogenic strains of WNV in either 
of these cell types may induce a more robust proinflammatory response, leading 
to increased neuropathology.  Additional in vivo studies with detailed analyses 
identifying individual cell types that are infected are necessary to assess if this is 
the mechanism of incursion. In addition, more extensive experiments are 
necessary for distinguishing between the kinetics of neuropathogenic and 
nonneuropathogenic strains within the CNS. Together, these data support a 
model where WNV-MAD78 may initiate replication in the CNS. After replicating to 
low levels, an immune response may then be initiated in the CNS that is tightly 
regulated and may restrict viral replication and spread prior to massive neuronal 
cell death and uncontrolled infiltration of immune cells. Further characterization of 
this model system may provide insight into how controlled immune responses to 
viral infection develop within the CNS, and how to manipulate immune responses 







Discussion of Dissertation research 
Neurotropic viruses are responsible for encephalitis, neurological 
disorders, and chronic illnesses worldwide (27, 277). Traditionally, neuroscience 
has focused on examination of pathogen triggered actions and reactions within 
neurons. Yet recent studies indicate that non-neuronal cell types in the CNS, 
including trafficking immune cells, glia, and endothelial cells, play an essential 
role in the physiological and immunological responses to viral infection within 
the CNS (254). As a virus with the potential to cause neuropathogenesis, West 
Nile virus (WNV) continues to be a public health threat. Naturally occurring 
strains of WNV vary greatly in their capability to cause neuropathogenesis. 
Thus, comparing replication of these strains within the CNS provides an 
excellent model for determining factors, both host and viral, that contribute to 
neuropathogenesis cause by viral infection. In addition, several labs have 
established mouse models for WNV infection, allowing for observations made in 
cell culture models to be examined in vivo.   
Here, we analyzed WNV replication and the innate antiviral immune 
responses to infection in several cell types representing the various components 
of the CNS. Initially, we observed that a nonneuropathogenic strain of WNV, 
WNV-MAD78, was delayed at initiating replication and restricted in cell-to-cell 
spread in astrocytes compared to a neuropathogenic strain, WNV-NY, 
identifying astrocytes as a possible site of regulation for viral infection in the 
CNS (Chapter 3). Further, this restriction was independent of type-1 IFN. 
However, inhibition of enzymes that play a role in viral particle maturation led to 
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increased particle production for nonneuropathogenic WNV in astrocytes. In 
addition, replication of a recombinant virus with the structural components from 
nonneuropathogenic WNV was restricted to similar levels as 
nonneuropathogenic WNV in astrocytes (Chapter 4). Thus, we suggest that all 
strains of WNV may replicate well in the endothelium and enter into the CNS, 
but are limited in astrocytes by the strain-specific differences in the structural 
proteins that comprise the virion.    
Replication of other viruses in endothelial cells, including high and low 
pathogenic Semliki Forest virus displayed similar results (77, 260), suggesting 
that traversal from the blood into the CNS may not always correlate with 
neuropathogenesis. Indeed, mice inoculated intracranially with WNV-MAD78 
experience delayed and reduced mortality compared to mice inoculated with 
WNV-NY (253), suggesting that a component within the CNS restricts WNV-
MAD78-induced neuropathology. Our data demonstrates that this restriction is 
not at the level of replication within neurons. Therefore, we examined additional 
cells types within the CNS. Since WNV may enter into the CNS via the 
hematogenous route, cell types of the BBB were plausible candidates for limiting 
nonneuropathogenic WNV infection. Thus, we examined replication of WNV-NY 
and WNV-MAD78 in endothelial cells and astrocytes, which are cell types that 
comprise the BBB. Both strains replicated to equivalent levels in endothelial cells, 
and initially infected astrocytes at equivalent levels. However, in astrocytes, 
WNV-MAD78 was restricted in both initiating viral replication as well as cell-to-
cell spread compared to WNV-NY. These data suggest that astrocytes may be a 
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unique physiological site of restriction for WNV infection. Since astrocytes reside 
within the CNS, all strains of WNV may be neuroinvasive, and a restriction for 
neuropathogenesis may reside within the CNS.  
The restriction for WNV-MAD78 replication and cell-to-cell spread in 
astrocytes was independent of type-1 IFN. Moreover, type-1 IFN levels were 
significantly higher in WNV-NY-infected astrocytes compared to WNV-MAD78-
infected astrocytes. While secretion of type-I IFN did restrict WNV-NY replication 
in astrocytes to some degree, it is well documented that neurons are highly 
responsive to type-1 IFN (289) and prolonged exposure to type-1 IFN induces 
apoptosis (61).  Therefore, in the context of the CNS, secretion of type-I IFN by 
astrocytes may be neurotoxic and contribute to neuropathogenesis. This 
hypothesis is consistent with the observation that bystander neuronal cell death 
occurs in mice infected with a highly pathogenic strain of WNV (32) and in vitro 
studies demonstrating that WNV-infected astrocytes secrete neurotoxic factors 
(282). Further in vitro and in vivo analyses are necessary to determine what cells 
within the CNS secrete type-1 IFN in response to WNV infection, and the role of 
secreted IFN in bystander cell death during WNV infection within the CNS.  
Our data suggests that viral and host factors other than IFN were 
responsible for restricting WNV-MAD78 cell-to-cell spread in astrocytes. Other 
viruses that replicate in astrocytes are limited by several factors, including 
astrocyte activation and reactive nitrogen species (RNS) (209). Likewise, a 
recent study demonstrated that exosomes may transport antiviral effector 
proteins to neighboring cells (281). However, we demonstrated that WNV-
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MAD78-infected astrocytes did not secrete an inhibitory factor.  In addition, cell-
to-cell spread was not the result of increased activation of astrocytes as 
assessed by GFAP expression (data not shown), a classical indicator of 
neurological distress and ischemia (72). Since classical antiviral pathways did not 
appear to be responsible for the restriction in cell-to-cell spread, we compared 
the quantity and quality of particles produced by WNV-NY-infected and WNV-
MAD78-infected astrocytes. Both the particle:PFU ratio in astrocytes as well as 
the ratio of infectivity on Vero cells compared to astrocytes were significantly 
higher for WNV-MAD78 compared to WNV-NY, suggesting that WNV-MAD78 
produces higher levels of defective particles in astrocytes compared to WNV-NY.  
  Others have shown that partially mature particles are still infectious, but 
at a lower degree compared to more highly processed particles (53). Therefore, 
we explored the roles of cellular enzymes that contribute to the maturation 
process of WNV particles. Maturation of WNV particles involves the host 
protease furin (262). However, furin activity in astrocytes was higher compared to 
more permissive cell types, such as endothelial cells (Chapter 4). Furthermore, 
WNV-MAD78-infected astrocytes produced increased levels of infectious 
particles in astrocytes in the presence of furin inhibitor. Therefore, the infectivity 
of WNV-MAD78 particles produced in astrocytes inversely correlated with furin 
activity, suggesting that complete maturation is detrimental for WNV-MAD78 in 
astrocytes. 
To address the viral-specific factors that contribute to cell-to-cell spread in 
astrocytes, we examined the replication kinetics of chimeric viruses that 
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exchanged the structural and nonstructural proteins of WNV-NY and WNV-
MAD78 in astrocytes. Consistent with our infectivity data, the structural 
components of WNV-MAD78 limited infectious viral particle production, even 
when the chimeric virus encoded the nonstructural proteins of WNV-NY. 
Similarly, chimeric virus consisting of WNV-NY structural proteins replicated to 
equivalent levels as WNV-NY even with all of the nonstructural proteins from 
WNV-MAD78.  Viral replication for both chimeric viruses was delayed compared 
to WNV-NY; however, peak viral titers of chimeric viruses closely followed that of 
the parental strain of the structural proteins they contained. Therefore, we 
hypothesize that strain-specific variation in the structural proteins that comprise 
the viral particle is a factor in the restriction in cell-to-cell spread for 
nonneuropathogenic strains of WNV in astrocytes. Thus, examination of moieties 
within structural proteins known to contribute to neuropathogenicity was carried 
out. The glycosylation motif at residues 154-156 of the envelope protein is 
essential for WNV neuropathogenesis (13, 24, 237). In addition, sugar moieties 
of several viruses, such as HIV, are essential for attachment and entry into cells 
(30). However, disruption of the glycosylation site for WNV-NY or addition of the 
glycosylation site for WNV-MAD78 did not alter the replication kinetics of these 
chimeric viruses in astrocytes. Further studies performed in astrocytes with the 
WNV-MAD78 structural: WNV-NY nonstructural chimeric virus will determine 
whether the lower level of viral replication is due to a restriction in cell-to-cell 
spread or by another mechanism. Additional chimeric viruses exchanging the 
structural proteins individually will be used to determine which proteins and 
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residues play a role in restricting infectious particle production for WNV-MAD78 
in astrocytes. These constructs provide novel tools for studying WNV replication 
at the BBB.  
In addition to the viral factors that contribute to cell-to-cell spread, a 
cellular factor within astrocytes contributes to the delay in infectious particle 
production for WNV-MAD78-infected astrocytes. We observed a delay in the 
production of negative strand genomic RNA, suggesting that there may be a 
delay in the switch from translation of the incoming virus to initiation of negative 
strand synthesis.  The cellular and viral factors involved in regulating this 
transition remain to be determined.  
In order to initiate and maintain constant translation or replication, WNV 
genomes must circularize. Circularization of the WNV genome involves the 
interaction between two regions within the 5’ and 3’ portions of the genome 
(319).  One of these cyclization sites resides within the coding region of the 
capsid protein, and is necessary for efficient initiation of viral replication (319). 
Stem-loop structures in the 3’UTR of WNV bind to TIA-1 and TIAR, aiding in 
circularization for genomic replication (70, 71, 149, 244). Presence of these 
factors within astrocytes has yet to be examined, and additional astrocyte-
specific factors may play a role in binding to the 3’UTR and promoting negative 
strand synthesis. Since the 3’UTRs of WNV-NY and WNV-MAD78 are 
significantly different in sequence and possibly structure, binding affinities of 
these regions to the viral replication complex (VRC) and host factors associated 
with it may be altered within astrocytes. A chimeric virus consisting of the 5’ and 
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3’UTRs from WNV-NY and the ORF of WNV-MAD78 replicated at a similar rate 
and to similar levels as WNV-MAD78 in astrocytes (data not shown). However, 
other proteins in the VRC, including the nonstructural proteins, may bridge the 
viral UTRs with host transcription factors, and may play a role in initiating viral 
replication. In addition to cellular proteins, several enzymatic cofactors, such as 
cations, are necessary for efficient viral propagation and intracellular levels of 
these cations may vary in different cell types (235). Assessing viral components 
that contribute to initiating replication and identifying cell-type specific host 
components that promote assembly of the VRC and the switch from translation to 
replication is a necessary approach to determine the mechanistic basis for the 
delay in WNV-MAD78 replication in astrocytes.  
In addition to viral replication, neuronal death may occur during WNV 
infection from the activity of infiltrating immune cells from the periphery. It is well 
documented that WNV-infected neurons secrete CXCL10 to attract CD8+ T cells 
to the CNS (131). However, little is known about how other cell types within the 
CNS contribute to neuroinflammation during WNV infection. To determine the 
contribution of the BBB to neuroinflammation during WNV infection, innate 
immune responses during WNV infection in cell types of the BBB were assessed. 
Surprisingly, the antiviral response to WNV in HBMECs and HBMVEs was not 
sufficient to inhibit viral replication, since peak viral titers remained high 
throughout infection in both cell types. In both WNV-NY- and WNV-MAD78-
infected HBMECs, CCL5 mRNA was elevated at equivalent levels compared to 
mock-infected cells. However, WNV-MAD78-infected HBMECs expressed higher 
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levels of intracellular CCL5 and secreted higher levels of CCL5 compared to 
WNV-NY-infected cultures. This suggests that regulation of CCL5 protein 
expression may occur post-transcriptionally during WNV infection, possibly by 
microRNA pathways. Regulation is also possible via protein stability and 
degradation of CCL5. Since we observed higher levels of CCL5 in WNV-MAD78-
infected HBMECs, it is possible that one of the strain-specific differences in the 
proteins for WNV-NY promotes degradation of antiviral molecules such as CCL5. 
However, extensive studies will need to be performed to explore the possible 
pathways regulating CCL5 expression during WNV infection in HBMECs.  
Chemokine secretion and establishing chemokine gradients is an initial 
step in extravasation. However, expression does not confer functionality. Thus, 
we performed functional assays with both monolayers and transwell cocultures of 
endothelial cells and astrocytes during WNV infection. Indeed, increased levels 
of labeled monocytes adhered to WNV-MAD78-infected endothelial cells 
compared to WNV-NY-infected endothelial cells. Therefore, initiating cellular 
innate immunity before WNV can reach highly permissive neurons may prevent 
progression of nonneuropathogenic strains, and thus limit severe neurological 
disease. As viral replication progressed into astrocytes, higher levels of CCL5 
and VCAM were observed in WNV-NY-infected astrocytes compared to WNV-
MAD78-infected astrocytes, which correlated with the enhanced levels of WNV-
NY replication within the monolayer. We hypothesize that the chemokine 
induction by WNV-NY-infected astrocytes may lead to increased leukocyte 
infiltration into the CNS during WNV-NY infection in mice compared to WNV-
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MAD78. Although a regulated cellular response, both innate and adaptive, in the 
CNS is necessary for survival of WNV infection (63-65, 248), there is increasing 
evidence that it can also contribute to WNV-mediated neuropathology. For 
example, ICAM is a cellular adhesion molecule necessary for extravasation of 
leukocytes from the blood into the brain. Mice deficient in ICAM exhibit 
decreased morbidity and viral load in the CNS compared to wild type mice, 
suggesting that trafficking of leukocytes may be important for establishing a 
sustained infection in the CNS (57). Matrix metalloproteinases (MMPs) are 
expressed by activated leukocytes and contribute to the disruption of cell:cell 
junctions at the BBB. Mice deficient in MMP9 also exhibit decreased morbidity 
and viral loads in the CNS compared to wild type mice, suggesting that leukocyte 
trafficking and disruption of the BBB contributes to WNV-induced neuropathology 
(292). Finally, mice deficient in DRAK2, an apoptosis-inducing enzyme 
specifically expressed by activated B and T cells, exhibit decreased morbidity 
and viral loads in the CNS compared to wild type mice, suggesting that infected T 
cell trafficking into the CNS may contribute to WNV-induced neuropathology 
(295).  Further, aberrant or overactive immune responses to infection often cause 
pathology, most notably filoviruses (170). Unregulated immune responses to 
infection may also contribute to chronic illnesses within the CNS, including 
multiple sclerosis (27).  
Although it has been hypothesized that the cellular response is 
responsible for the initial neuroinvasion of WNV, (15, 291, 292, 295), replication 
in monocytes (Chapter 5) as well as other leukocytes and macrophages (253, 
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295) is not as robust as more permissive cell types, including endothelial cells 
(117, 285). In addition, viral replication in the CNS is detected (day2-4) prior to 
the presence of infiltrating leukocytes (day6-8) (212, 250). Thus, WNV 
neuroinvasion likely occurs prior to the initial attachment and extravastion of 
leukocytes into the CNS. Since endothelial cells comprise the vasculature, virus 
detected in the serum may be a result of infected endothelial cells in the 
periphery in addition to replication in hematopoetic cells. Moreover, viral 
persistence in the CNS and the inability to clear cytolytic T cells during the late 
stages of WNV infection leads to increased morbidity. In CD4-/- mice, viral loads 
in the CNS were persistently high compared to wild type mice despite early high 
levels of CD8+ T cells. However, after acute infection, CD8+ T cells were not 
sustained in CD4-/- mice, suggesting that CD4 T cells are also necessary for 
clearance of virus in the CNS and survival during WNV infection (257). It is also 
likely that modulation of the cellular innate response may result from the immune 
response initiated once viral replication occurs within neurons. Yet in order to 
replicate within neurons, WNV must traverse endothelial cells and astrocytes. 
Thus, limitation of nonneuropathogenic strains in astrocytes may provide an 
essential site for regulating WNV infection, further emphasizing the need to 
understand the nature of infection within these cells more completely.  
 In order to support our in vitro hypotheses, we examined WNV infection in 
a mouse model. By simulating viremia, the peripheral responses were bypassed, 
exposing the brain endothelium to virus without the requirement for replication in 
the periphery. Kinetics studies of intravenous inoculation display that inoculation 
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into the blood is sufficient for delivery of small molecules to the CNS within 
minutes (140), suggesting that virus inoculated via this route will reach the BBB 
directly after inoculation. Despite inoculation with high levels of virus in the blood, 
WNV-MAD78-infected mice exhibited increased survival compared to WNV-NY-
infected mice. Although we detected virus only in the spleen for WNV-MAD78-
infected mice, the methods we used were not sensitive enough to detect low 
levels of replication that are likely to occur with WNV-MAD78 infection. Indeed, 
WNV-MAD78-infected mice displayed neurological pathologies in ~10% of mice, 
including seizures and paralysis, albeit at delayed kinetics compared to WNV-
NY. Thus, WNV-MAD78 may enter into the CNS during intravenous inoculation, 
but additional factors limit WNV-MAD78-induced neuropathologies. WNV-MAD78 
may either be cleared quickly by an early activation of the cellular innate immune 
response during infection, or limited at sites within the CNS, such as astrocytes. 
In examining cytokine profiles in the blood, spleen, and brain of both WNV-NY 
and WNV-MAD78-infected mice, elevated levels were not observed in the spleen 
or the blood. However, CCL5 was notably higher in the brains of both WNV-NY 
and WNV-MAD78-infected mice at late times (day 5) post inoculation, and 
substantially higher levels of CCL2 were observed for WNV-NY. Although CCL2 
levels were also elevated for WNV-MAD78-infected mice, WNV-NY-infected mice 
exhibited a greater increase than WNV-MAD78-infected mice.  Virus was 
detected as early as 48 hours post inoculation in WNV-NY-infected mice, and 
others have likewise detected virus at early times post infection in other studies 
(267). Despite the detection of viral replication at early timepoints, increased 
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cytokine expression was only observed at later time points, suggesting that viral 
replication in the CNS occurs prior to attraction and infiltration of immune cells. In 
vivo analysis of viral replication in specific cell types of the CNS may describe a 
physiological role for astrocytes and other non-neuronal cells during WNV 
neuropathogenesis. Examination of replication in the CNS of mice inoculated 
with viral chimeras may further detail viral components necessary for WNV 
neuropathogenesis. 
 Taken together, our data contribute to the following model of WNV 
neuropathogenesis. Mosquitoes introduce WNV either directly into the blood, 
which is likely to occur in 76% of cases (266), or WNV reaches the blood after 
trafficking from the epidermal and dermal layers of the skin into the spleen where 
a second round of replication occurs. Upon entering the blood stream, WNV has 
access to brain endothelial cells as well as peripheral organs. Both 
neuropathogenic and nonneuropathogenic strains replicate to equivalent levels in 
the brain endothelium and progress into astrocytes, which are in direct contact 
with endothelial cells in vivo. During infection of endothelial cells, 
nonneuropathogenic strains express high levels of monocyte- chemoattractant 
chemokines, leading to the activation of the extravasation process. In vivo, the 
attachment and activation of leukocytes may initiate clearance of virus from the 
endothelium, further restricting nonneuropathogenic strains of WNV. As 
replication progresses into the CNS and into astrocytes, nonneuropathogenic 
strains are delayed in initiating replication and restricted in cell-to-cell spread. 
High levels of replication in astrocytes of neuropathogenic strains of WNV 
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induces high levels of proinflammatory cytokines, such as type-1 IFNs, and 
chemokines, such as CCL5, leading to a robust response from resident 
leukocytes and leukocytes in the blood. The robust expression of CCL5 by WNV-
infected astrocytes may lead to extravasation of more leukocytes than necessary 
to clear infection. Therefore, the traversal of leukocytes in response to infection 
initiated in astrocytes may exacerbate pathology, and may include traversal of 
infected leukocytes, thereby enhancing infection in the CNS. 
Nonneuropathogenic strains, however, are restricted in infectious particle 
production in astrocytes, limiting their capability to spread to neurons. Since 
neurons also express molecules that contribute to the trafficking of leukocytes to 
the CNS (131), limiting their exposure to nonneuropathogenic strains may limit 
the antiviral response in neurons and therefore leukocyte trafficking into the CNS.   
While low levels of leukocyte homing to the infected CNS may promote viral 
clearance, high levels of immunoreactive cells may lead to unregulated immune 
responses and neuronal death, or bystander cell death of glial cells. The high 
levels of replication in astrocytes for neuropathogenic strains of WNV permit 
further transfer and propagation into neurons. Although additional in vivo data will 
be necessary to validate this model, our initial studies utilizing intravenous 
inoculations of high levels of both neuropathogenic and nonneuropathogenic 
WNV suggest that an additional restriction exists for nonneuropathogenic strains 
of WNV at the BBB. Observations in neutrophil-depleted mice prior to or directly 
after infect ion support this hypothesis; if neutrophils are depleted prior to 
infection, an increase in pathogenesis is observed, suggesting that early on in 
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infection, neutrophils are beneficial to the host. However, if depleted after 
infection, survival of mice increases, suggesting that if infection is established in 
the CNS, activity of these cells may contribute to pathogenesis, or may lead to a 
secondary infection of the CNS (15). Further, in macrophage-depleted mice 
infected with a nonneuropathogenic strain of WNV, mice had a lower survival 
rate and higher viral loads in the CNS and the periphery compared to controls, 
demonstrating the active role for macrophages in restricting nonneuropathogenic 
WNV (26). Finally, IFNAR-/- mice inoculated with nonneuropathogenic WNV have 
a longer mean time to death (127), suggesting an additional factor to the type-1 
IFN response restricts nonneuropathogenic strains. Thus, we propose that all 
strains of WNV may enter into the CNS. However, the immune responses 
initiated at the BBB and the restriction in cell-to-cell spread by the structural 
proteins of nonneuropathogenic strains of WNV limit the transfer of virus to 
neurons and promote a controlled immune response to infection in the CNS. 
However, neuropathogenic strains are not restricted at the level of astrocyte 
replication, and the increased initiation of the cellular immune response in 
astrocytes may initiate an excessive immune response in the CNS, leading to 
bystander cell death. Indeed, WNV-NY-infected astrocytes secrete high levels of 
type-1 IFN, as do infected neurons (144). This model displays a novel role for 
astrocytes at modulating WNV neuropathogenicity.  
  Several additional experiments may expand on the presented model.  In 
vivo data supporting and expanding on the immune response during tail vein 
inoculations of both WNV-NY and WNV-MAD78 will provide a more complete 
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model of the kinetics of the response to infection at the CNS. Detection of viral 
antigen present in astrocytes and endothelial cells would provide physiological 
evidence of replication in both endothelial cells and astrocytes. More detailed 
analysis on residues and motifs present within the structural proteins of WNV that 
limit infectious particle production in astrocytes may provide a mechanism of the 
restriction of nonneuropathogenic WNV in astrocytes. While infectious viral 
particle production was examined with chimeric viruses, a restriction in cell-to-cell 
spread still must be confirmed. Thus, there may not be an inherent deficiency in 
astrocytes for entry by either strain, but in the production of infectious particles. It 
is possible that the inability to synthesize infectious particles is the cause for the 
restriction in cell-to-cell spread. In addition, the factors that contribute to the delay 
in initiating replication was not determined. Both chimeric viruses with structural 
and nonstructural portions were delayed at initiating infectious particle 
production. Thus, these viruses may be utilized in further examination of the 
delay of WNV replication in astrocytes. Overall, the data presented provide novel 
tools and insights into the varying degrees of neuropathologies induced among 
strains of WNV. The data presented provides sites within cell types, such as the 
maturation pathway within astrocytes, as well as within the CNS, where 
nonpathogenic strains may be restricted, offering possible mechanisms that 
underlie WNV neuropathology. This knowledge provides novel targets for the 
development of vaccines through synthesis of chimeric viruses and antiviral drug 
targets, such as pathways of viral maturation in astrocytes, within the CNS that 
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